ࡱ> QSJKLMNOP` R0Ibjbjss6hbfffffffz}}}}Trz0BPPPP+E Q٧ۧۧۧۧۧۧ$h(fY++YYffPP8YfPfPipY٧ffP6 :Z}T<0ȯȯȯf4YYYYYYYYYY0YYYYzzzv}zzz}zzzffffff Integration the biologic factors into the staging of breast cancer patients with ipsilateral supraclavicular lymph node metastasis Running title: AJCC staging in ISLN metastasis patients Chen-Lu Lian1, Xiao-Yang Cai2, Ping Zhou1, Jun Wang1, Xiu-Bei Chen1,*, San-Gang Wu1,* 1 Department of Radiation Oncology, the First Affiliated Hospital of Xiamen University, Xiamen 361003, Peoples Republic of China 2 Department of Intensive Care Unit, the First Affiliated Hospital of Xiamen University, Xiamen 361003, Peoples Republic of China Chen-Lu Lian and Xiao-Yang Cai contributed equally to this work. *Corresponding author: Xiu-Bei Chen and San-Gang Wu Xiu-Bei Chen Department of Radiation Oncology, the First Affiliated Hospital of Xiamen University, Xiamen 361003, Peoples Republic of China; Tel. +86 592 2139531; Fax. +86 592 2137322; E-mail. linqingjiangxmu@163.com San-Gang Wu Department of Radiation Oncology, the First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, Xiamen 361003, Peoples Republic of China; Tel. +86 592 2139531; Fax. +86 592 2137322; E-mail. wusg@xmu.edu.cn Abstract Purpose: To investigate the accuracy and the discriminatory performance in the prognostic prediction in breast cancer (BC) patients with ipsilateral supraclavicular lymph node (ISLN) metastasis using the between the American Joint Committee on Cancer (AJCC) 7th and 8th edition staging system. Methods: Female patients diagnosed as BC were retrieved from the Surveillance, Epidemiology, and End Results database between 2010 and 2014. Chi-squared test, Kaplan-Meier method, Cox proportional hazard analysis, and the receiver operating characteristics were used to conduct statistical analysis. Results: We included 1097 BC patients with ISLN metastasis (N3c disease), including 29.4% (n=322) and 70.6% (n=775) of patients with non-metastatic and metastatic stage at diagnosis, respectively. In non-metastatic stage patients, 64.9% of the patients categorized as having stage IIIC disease in the 7th edition AJCC staging system were downstaged to stage IIIA or IIIB according to the 8th AJCC staging criteria. The AJCC 8th edition staging system had better discriminatory prognostic value than the 7th AJCC staging (area under the curve: 0.586 vs. 0.577, P=0.0006), with a 5-year breast cancer-specific survival (BCSS) rate of 71.3%, 62.2%, 45.2% and 39.1% in stage IIIA, IIIB, IIIC, and IV cohorts, respectively (P<0.0001). The multivariate prognostic analysis revealed that the AJCC 8th edition staging system was an independent prognostic factor for BCSS, while no statistical difference in BCSS was found between the 8th AJCC stage IIIC and IV patients (P=0.188). Conclusion: The AJCC 8th edition pathological prognostic staging showed a better discriminatory prognostic value in ISLN-metastasized breast cancer patients. An additional clarification strategy in stage IIIC disease based on the 8th AJCC staging should be developed to differentiate patients who are curable with multimodality therapy and patients who have less benefit from curative treatment. Keywords: Breast cancer; Ipsilateral supraclavicular lymph nodes; Staging; Prognosis; AJCC. Introduction Breast cancer (BC), the most commonly diagnosed female cancer, is also the leading cause of women cancer-related death in most regions and countries of the globe (1). The incidence of ipsilateral supraclavicular lymph node (ISLN) metastasis in BC patients without distant metastasis accounted for a small proportion of 1-4.3% (2). Historically, it was generally believed that ISLN-metastasized BC was a locoregional disease and should be assigned to stage IIIB (3). It was not until 1988 that ISLN-metastasized BC was defined as stage M1 disease in the 3rd American Joint Committee on Cancer (AJCC) Tumor-Node-Metastasis (TNM) staging system for BC due to its poor prognosis and high incidence of distant metastasis within one year (2). However, in 2002, Brito et al. (3) reported significantly statistical differences in prognosis between ISLN-metastasized and de novo stage IV disease. They believed ISLN-metastasized patients without distant metastasis should be reclassified into stage IIIB instead of stage IV. Therefore, ISLN-metastasized patients without distant metastasis have been identified as stage IIIC (N3c) disease since the 6th AJCC staging system was published (4). In the 8th AJCC staging manual, ISLN metastasis was still categorized as N3c. This newly proposed BC pathological prognostic staging system combined several biological factors and traditional TNM factors (5). The ISLN-metastasized BC without distant metastasis, was reclassified into stage IIIA, IIIB, or IIIC according to its biological characteristics in 8th AJCC criteria. However, to our knowledge, the available literature regarding the validation of prognostic prediction of the 8th AJCC staging system for ISLN-metastasized patients is rather scarce. Therefore, this retrospective study was intended to compare the accuracy and the discriminatory performance in the prognostic prediction among ISLN-metastasized patients between the 7th and 8th AJCC staging system using the Surveillance, Epidemiology, and End Results (SEER) database. Materials and methods Patients Female BC patients diagnosed between 2010 and 2014 were retrieved from the SEER database established by the National Cancer Institute of the United States, which collected data on demographics, clinical characteristics, the first course of treatments, and follow up for vital status (6). We included patients with T1-4N3cM0-1 breast cancer (according to the 7th AJCC-TNM staging manual). In non-metastatic stage disease (M0), the information regarding age, race/ethnicity, histology, tumor grade, T category, estrogen receptor (ER) status, progesterone receptor (PR) status, human epidermal growth factor receptor 2 (HER2) status, surgical procedure, radiotherapy, and chemotherapy were available. Patients aged <18 years without positive pathological diagnoses were excluded. Since the identifiable patient information in the SEER database is de-identified, there is no need for approval from the Institutional Review Board of the First Affiliated Hospital of Xiamen University. Variables The variables of this study included: age, race/ethnicity, histology, tumor grade, T category, M category, ER status, PR status, HER2 status, surgery methods, the receipt of chemotherapy and radiotherapy. The pathological prognostic stages were allocated by the AJCC 8th edition pathological prognostic staging manual, and the 7th AJCC-TNM staging manual allocated the T and M categories. Statistical analysis The chi-square test or Fisher's exacttest was used to compare patients' characteristics after stratification by stage change, and to perform the comparison of the characteristics among stage migration between the two editions of AJCC stages. The area under the curve (AUC) was calculated to show the discriminatory ability of the 8th AJCC staging in predicting outcomes using the receiver operating characteristics (ROC). Survival curves were drawn using the KaplanMeier method, and the statistical differences among stages were compared using the log-rank test. Multivariate Cox regression analysis was performed to determine the independent prognostic factors associated with breast cancer-specific survival (BCSS). All statistical analyses were performed by the IBM SPSS 26.0 software package (IBM Corp., Armonk, NY). P values <0.05 were considered statistical significance. Results Patient characteristics A total of 1097 BC patients with ISLN metastasis were identified for the analysis, including 29.4% (n=322) and 70.6% (n=775) of patients with M0 stage and metastatic stage (M1), respectively. Among the stage M0 patients, 78.9% of them (n=254) had infiltrating ductal carcinoma, 50.6% (n=163) had T3-4 disease, 68.3% (n=220) had poorly/undifferentiated disease, 66.1% (n=213) had HER2-negative disease, 57.8% (n=186) had ER-positive tumors, and 42.5% (n=137) had PR-positive tumors. The majority of the stage M0 patients received multimodality treatments including surgery (n=322, 100.0%), chemotherapy (n=301, 93.5%), and radiotherapy (n=237, 73.6%). The details on patients and tumor characteristics are summarized in Table 1. Restaging of the AJCC 7th stage IIIC patients Significantly statistical differences were found in the stage migration from the 7th to 8th AJCC stages (P<0.001). In the stage M0 cohort, 209 (64.9%) patients with stage IIIC diseases in the 7th staging had their stages reassigned and were downstaged into stage IIIA (n=65, 20.2%) and stage IIIB (n=144, 44.7%) according to the 8th edition criteria. Demographic and tumor characteristics of stage migration are presented in Table 2. All patients with well-differentiated (G1) diseases and 87.2% of patients with moderately differentiated (G2) diseases were downstaged, while among the poorly/undifferentiated (G3) diseases, only 54.1% were downstaged (P<0.001). Moreover, 86.6% and 97.1% of the ER-positive and PR-positive patients were downstaged, respectively, while only 35.3% and 41.1% of the ER-negative and PR-negative were downstaged, respectively. In addition, all patients with HER2-positive diseases were downstaged. However, only 46.9% of the HER2-negative patients were downstaged (P <0.001) (Table 2). Survival With a median follow up of 41.5 (range, 0-83) months, the 5-years BCSS rate of the 7th AJCC stage IIIC and IV patients was 58.4% and 39.1%, respectively (Figure 1). The new pathological prognostic staging system has re-stratified these ISLN-metastasized BC patients, with a 5-year BCSS rate of 71.3%, 62.2%, 45.2% and 39.1% in stage IIIA, IIIB, IIIC, and IV cohorts, respectively (P<0.0001) (Figure 2). The ROC analysis demonstrated that the AJCC 8th edition pathological prognostic staging had superior discriminative ability than the 7th AJCC-TNM staging in predicting the BCSS (AUC: 0.586 vs. 0.577, P=0.0006) (Figure 3). Multivariate prognostic analysis Two prognostic models were conducted to assess the independent prognostic factors associated with BCSS. The first Cox proportional hazard model was incorporating ER, PR, HER2 status, and tumor grade with other demographic and clinical characteristics, the results that age, race/ethnicity, tumor grade, T category, M stage, ER, PR, and HER2 status were the independent prognostic factors related to BCSS (Table 3). In the second model, the 8th AJCC pathological prognostic staging was included in the multivariate prognostic analysis. The results indicated that the AJCC 8th edition pathological prognostic stage was the independent prognostic factor for BCSS. However, the stage IIIC disease showed comparable BCSS compared with the stage IV disease (hazard ratio [HR]=0.820, 95% confidence interval [CI]: 0.611-1.102, P=0.188) (Table 4). Discussion Unlike those previous staging systems for breast cancer, the newly revised 8th AJCC staging included not only TNM factors but also four important biological factors (ER status, PR status, HER2 status, and tumor grade) (5). Several studies have confirmed that the 8th AJCC staging could more accurately predict the prognosis of BC patients (7-16). However, to our knowledge, no studies assessed the prognosis accuracy of the new AJCC staging for patients with ISLN metastasis (7-16). Our study was the first study to evaluate the role of the AJCC 8th edition of pathological prognostic staging systems in ISLN-metastasized BC patients. In the newly revised staging system, the ISLN-metastasized BC without distant metastasis was no longer generally assigned into stage IIIC but would be stratified into stage IIIA, IIIB, or IIIC according to the biological characteristics. In our study, 64.9% of the ISLN-metastasized patients (7th AJCC-TNM stage IIIC) were reassigned and downstaged to stage IIIA or IIIB using the 8th AJCC criteria. Overall, the discriminatory performance of the AJCC 8th edition of pathological prognostic staging in ISLN-metastasized BC patients was superior to the 7th AJCC-TNM staging. The multivariate prognostic analysis revealed that the AJCC 8th edition of the pathological prognostic stage was an independent prognostic factor for BCSS, but there was no statistical difference in BCSS between the 8th AJCC stage IIIC and IV patients. With the evolving knowledge of breast cancer biology, biological factors are gradually elevated to similar importance in the determination of AJCC staging. It was well acknowledged that ER, PR, and HER2 status were associated with the prognosis of BC patients and were regarded as predictive indicators of benefit from endocrine or anti-HER2 therapy (17). In our study, ISLN-metastasized patients with ER-positive or PR-positive diseases were associated with better survival outcomes. Moreover, we found that 86.6% and 97.1% of patients with ER-positive and PR-positive were downstaged, demonstrating that those ER-positive or PR-positive patients tend to be associated with lower stage and have a better prognosis in comparison with ER-negative and PR-negative tumors (18-21). Another study from Lee et al. (22) found that the prognosis of stage III patients with hormone receptor (HR)+/HER2- disease was better than those of stage II patients with HR-/HER2- diseases. In our study, the rate of downstaging in HER2-positive patients was higher than that in HER2-negative patients (100.0% vs. 46.9%) after using the novel staging system, and the multivariate analysis also showed that HER2-positive disease was a favorable prognostic factor for BCSS compared to those with HER2-negative disease. Thus, HER2-positive status instead of HER2-negative status should be deemed as a better prognostic factor in patients who received anti-HER2 therapy. Howlader et al. (23) also reported that HR+/HER2+ subtype had better survival than HR+/HER2-in advanced-stage BC in the era of anti-HER2 targeted therapy. The role of ISLN metastasis in the BC staging system has undergone two significant changes. The first change occurred in 1988, ISLN-metastasized BC without distant metastasis was allocated into stage M1 from stage IIIB. The second change occurred in 2002, ISLN-metastasized BC was reclassified into stage IIIC from stage M1 in the 6th AJCC staging system. Different studies on the prognosis of ISLM-metastasized BC patients have raised conflict results (3, 24-32). Several studies showed that BC with ISLN metastasis had a better survival outcome than that with distant metastasis disease, and was potentially curable (3, 4, 24-28). However, a study reported that the prognosis of ISLN-metastasized BC was better than stage IV but worse than stage IIIB and IIIC (29). With the development of BC molecular biology, researchers revealed that ISLN-metastasized BC was a disease of significant heterogeneity with significantly different long-term prognosis. In the 8th AJCC staging, most of the patients diagnosed with stage IIIC disease were with G3 and triple-negative disease (ER-negative, PR-negative, and HER2-negative), which were relevant to a significantly higher risk of distant metastasis and worse survival. Our results showed comparable BCSS in patients with stage IIIC disease and M1 disease, which revealed that the 8th AJCC stage IIIC ISLN-metastasized BC might be reclassified into stage M1. In our study, we found that 70.6% of the ISLN-metastasized BC patients developed distant metastasis at the time of diagnosis. ISLN metastasis might be a potentially high-risk factor for distant metastasis. The 5-year distant metastasis rates of BC patients with ISLN metastasis were reported to be 77.8-85.5% (25, 32, 33). The 2-year distant metastasis rate of ISLN-metastasized patients in the study from Fan et al. (32) was 60.4%, which meant that patients with ISLN metastasis had a significantly high risk of distant metastasis. Furthermore, there was a higher proportion of triple-negative breast cancer (TNBC) in BC patients with ISLN metastasis, compared with other stage N3 patients without ISLN metastasis (34, 35). TNBC was a unique subtype in BC that was unable to benefit from endocrine therapy and anti-HER2 therapy. These factors stated above may explain why although most stage M0 patients received a comprehensive treatment including surgery (100.0%), chemotherapy (93.5%) and radiotherapy (73.6%) in our study, there was still no significant statistical difference in the 5-year BCSS rates between the 8th AJCC stage IIIC patients and stage M1 patients. In recent years, multimodality treatment including surgery, radiotherapy, chemotherapy, endocrine therapy, and targeted therapy with curative intent has been strongly recommended for BC patients with ISLN metastasis (3, 24, 27, 29, 36, 37). Taken together, we need to explore more new therapeutic targets to improve the survival of ISLN-metastasized patients. We acknowledged that several limitations were exiting in this study. Firstly, as a retrospective study, the inherent defects are inevitable in our study. Secondly, the local relapse and metastatic pattern of the ISLN-metastasized patients were unknown in our study. Thirdly, there was no record on endocrine and anti-HER2 therapy in the SEER database. However, our study was in the context of contemporary treatment, and most patients received chemotherapy. Therefore, we could assume that most patients in our study also received corresponding multidisciplinary therapy. Finally, the duration of follow up in our study was relatively short; studies with a more extended period of follow up are needed to confirm our results. Conclusion In conclusion, our study suggests that ISLN-metastasized BC is a disease entity of significant heterogeneity. Compared with the 7th AJCC staging, the 8th AJCC pathological prognostic staging showed a better discriminatory value of prognosis among ISLN-metastasized BC patients. An additional clarification strategy in stage IIIC disease based on the 8th AJCC staging should be developed to differentiate patients who are curable with multimodality therapy and patients who have less benefit from curative treatment. Large sample, multi-center, and long-term follow up studies are required to verify our results. Conflict of interests The authors declare that there are no conflicts of interest. Acknowledgments This work was partly supported by the Commission Young and Middle-aged Talents Training Project of Fujian Health Commission(No. 2019-ZQNB-25). References: 1. Bray F, Ferlay J, Soerjomataram I, et al. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: Cancer J Clin 2018;68:394-424. 2. Chen SC, Chen MF, Hwang TL, et al. Prediction of Supraclavicular Lymph Node Metastasis in Breast Carcinoma. Int J Radiat Oncol Biol Phys 2002;52:614-619. 3. Brito RA, Valero V, Buzdar AU, et al. Long-term Results of Combined-Modality Therapy for Locally Advanced Breast Cancer With Ipsilateral Supraclavicular Metastases: The University of Texas M.D. Anderson Cancer Center Experience. J Clin Oncol 2001;19:628-633. 4. Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer Staging System for Breast Cancer. J Clin Oncol 2002;20:3628-3636. 5. AJCC cancer staging manual. New York: Springer International Publishing, 2018. 6. The Surveillance, Epidemiology, and End Results (SEER) Program. Available at HYPERLINK https://seer.cancer.gov/ https://seer.cancer.gov/. 7. Weiss A, Chavez MacGregor M, Lichtensztajn DY, et al. Validation study of the American Joint Committee on Cancer eighth edition prognostic stage compared with the anatomic stage in breast cancer. JAMA Oncol 2018;4:203-209. 8. Abdel Rahman O. Validation of the 8th AJCC prognostic staging system for breast cancer in a population-based setting. Breast Cancer Res Treat 2018;168:269-275. 9. Wang M, Chen H, Wu K, et al. Evaluation of the prognostic stage in the 8th edition of the American Joint Committee on Cancer in locally advanced breast cancer: an analysis based on SEER 18 database. Breast 2018;37:56-63. 10. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/?term=Joo%20JH%5bAuthor%5d&cauthor=true&cauthor_uid=30194189"Joo JH,HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/?term=Kim%20SS%5bAuthor%5d&cauthor=true&cauthor_uid=30194189"Kim SS,HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/?term=Son%20BH%5bAuthor%5d&cauthor=true&cauthor_uid=30194189"Son BH,et al. Evaluation of the Prognostic Stage in the 8th Edition of the American Joint Committee on Cancer in Patients with Breast Cancer and Internal Mammary Lymph Node Metastasis. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/?term=Evaluation+of+the+Prognostic+Stage+in+the+8th+Edition+of+the+American+Joint+Committee+on+Cancer+in+Patients+with+Breast+Cancer+and+Internal+Mammary+Lymph+Node+Metastasis"Anticancer Res2018;38:5357-5361. 11. Zhang J, Zhao B, Jin F. The assessment of 8th edition AJCC prognostic staging system and a simplified staging system for breast cancer: The analytic results from the SEER database. Breast J 2019;25:838-847. 12. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/?term=He%20J%5bAuthor%5d&cauthor=true&cauthor_uid=31906874"He J,HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/?term=Tsang%20JY%5bAuthor%5d&cauthor=true&cauthor_uid=31906874"Tsang JY,HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/?term=Xu%20X%5bAuthor%5d&cauthor=true&cauthor_uid=31906874"Xu X,et al. AJCC 8th edition prognostic staging provides no better discriminatory ability in prognosis than anatomical staging in triple negative breast cancer. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/?term=AJCC+8th+edition+prognostic+staging+provides+no+better+discriminatory+ability+in+prognosis+than+anatomical+staging+in+triple+negative+breast+cancer"BMC Cancer 2020;20:18. 13. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/?term=Liu%20YY%5bAuthor%5d&cauthor=true&cauthor_uid=30620221"Liu YY,HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/?term=Yu%20TJ%5bAuthor%5d&cauthor=true&cauthor_uid=30620221"Yu TJ,HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/?term=Liu%20GY%5bAuthor%5d&cauthor=true&cauthor_uid=30620221"Liu GY. The predictive value of the prognostic staging system in the8thedition of the American Joint Committee on Cancer for triple-negative breast cancer: a SEER population-based analysis. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/30620221"Future Oncol2019;15:391-400. 14. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/?term=Shao%20N%5bAuthor%5d&cauthor=true&cauthor_uid=30863154"Shao N,Xie C,HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/?term=Shi%20Y%5bAuthor%5d&cauthor=true&cauthor_uid=30863154"Shi Y,et al. Comparison of the 7th and 8th edition of American Joint Committee on Cancer (AJCC) staging systems for breast cancer patients: a Surveillance, Epidemiology and End Results (SEER) Analysis. Cancer Manag Res 2 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/?term=%22Cancer+Manag+Res%22%5Bjour%5D" 019;11:1433-1442. 15. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/?term=Kim%20I%5bAuthor%5d&cauthor=true&cauthor_uid=29963113"Kim I,HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/?term=Choi%20HJ%5bAuthor%5d&cauthor=true&cauthor_uid=29963113"Choi HJ,HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/?term=Ryu%20JM%5bAuthor%5d&cauthor=true&cauthor_uid=29963113"Ryu JM,et al. Prognostic Validation of the American Joint Committee on Cancer 8th Staging System in 24,014 Korean Patients with Breast Cancer. J Breast Cancer2018;21:173-181. 16. Jang N, Choi JE, Kang SH, et al. Validation of the pathological prognostic staging system proposed in the revised eighth edition of the AJCC staging manual in different molecular subtypes of breast cancer. Virchows Arch 2019;474:193-200. 17. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-5312. 18. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/?term=Stolnicu%20S%5bAuthor%5d&cauthor=true&cauthor_uid=30509058"Stolnicu S,HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/?term=Bauer%20O%5bAuthor%5d&cauthor=true&cauthor_uid=30509058"Bauer O,Naznean A,et al. ER/PR+ subset of invasive breast carcinoma (IBC): a distinct phenotype with good prognosis. Pol JHYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/?term=ER%E2%80%93/PR++subset+of+invasive+breast+carcinoma+(IBC):+a+distinct+phenotype+with+good+prognosis" Pathol2018;69:311-313. 19. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/?term=Khoshnoud%20MR%5bAuthor%5d&cauthor=true&cauthor_uid=18043896"Khoshnoud MR,Fornander T,HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/?term=Johansson%20H%5bAuthor%5d&cauthor=true&cauthor_uid=18043896"Johansson H,et al Long-termpatternofdiseaserecurrenceamongpatientswithearly-stagebreast cancer accordingtoestrogen receptorstatusand use ofadjuvanttamoxifen. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/?term=%EF%BC%AC%EF%BD%8F%EF%BD%8E%EF%BD%87%E2%81%83%EF%BD%94%EF%BD%85%EF%BD%92%EF%BD%8D+%EF%BD%90%EF%BD%81%EF%BD%94%EF%BD%94%EF%BD%85%EF%BD%92%EF%BD%8E+%EF%BD%8F%EF%BD%86+%EF%BD%84%EF%BD%89%EF%BD%93%EF%BD%85%EF%BD%81%EF%BD%93%EF%BD%85+%EF%BD%92%EF%BD%85%EF%BD%83%EF%BD%95%EF%BD%92%EF%BD%92%EF%BD%85%EF%BD%8E%EF%BD%83%EF%BD%85+%EF%BD%81%EF%BD%8D%EF%BD%8F%EF%BD%8E%EF%BD%87+%EF%BD%90%EF%BD%81%EF%BD%94%EF%BD%89%EF%BD%85%EF%BD%8E%EF%BD%94%EF%BD%93+%EF%BD%97%EF%BD%89%EF%BD%94%EF%BD%88+%EF%BD%85%EF%BD%81%EF%BD%92%EF%BD%8C%EF%BD%99%E2%81%83%EF%BD%93%EF%BD%94%EF%BD%81%EF%BD%87%EF%BD%85+%EF%BD%82%EF%BD%92%EF%BD%85%EF%BD%81%EF%BD%93%EF%BD%94+%EF%BD%83%EF%BD%81%EF%BD%8E%EF%BD%83%EF%BD%85%EF%BD%92+%EF%BD%81%EF%BD%83%EF%BD%83%EF%BD%8F%EF%BD%92%EF%BD%84%EF%BD%89%EF%BD%8E%EF%BD%87+%EF%BD%94%EF%BD%8F+%EF%BD%85%EF%BD%93%EF%BD%94%EF%BD%92%EF%BD%8F%EF%BD%87%EF%BD%85%EF%BD%8E+%EF%BD%92%EF%BD%85%EF%BD%83%EF%BD%85%EF%BD%90%EF%BD%94%EF%BD%8F%EF%BD%92+%EF%BD%93%EF%BD%94%EF%BD%81%EF%BD%94%EF%BD%95%EF%BD%93+%EF%BD%81%EF%BD%8E%EF%BD%84+%EF%BD%95%EF%BD%93%EF%BD%85+%EF%BD%8F%EF%BD%86+%EF%BD%81%EF%BD%84%EF%BD%8A%EF%BD%95%EF%BD%96%EF%BD%81%EF%BD%8E%EF%BD%94+%EF%BD%94%EF%BD%81%EF%BD%8D%EF%BD%8F%EF%BD%98%EF%BD%89%EF%BD%86%EF%BD%85%EF%BD%8E"Breast Cancer 2008;107:71-78. 20. Ouyang Y, Li D, Pater JL, et al. TheimportanceoftemporaleffectsinevaluatingtheprognosticimpactofjointERPRexpressioninpremenopausalwomenwithnode-positivebreast cancer. Breast Cancer Res Treat 2005;92:115-123. 21. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/?term=Bonnefoi%20H%5bAuthor%5d&cauthor=true&cauthor_uid=12598346"Bonnefoi H,HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/?term=Diebold-Berger%20S%5bAuthor%5d&cauthor=true&cauthor_uid=12598346"Diebold-Berger S,Therasse P,et al. Locally advanced/inflflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome? HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/?term=Locally+advanced/inflflammatory+breast+cancers+treated+with+intensive+epirubicin-based+neoadjuvant+chemotherapy:+are+there+molecular+markers+in+the+primary+tumour+that+predict+for+5-year+clinical+outcome?"Ann Oncol 2003;14:406-413. 22. Lee SB, Sohn G, Kim J, et al. A Retrospective Prognostic Evaluation Analysis Using the 8th Edition of the American Joint Committee on Cancer Staging System for Breast Cancer. Breast Cancer Res Treat 2018;169:257-266. 23. Howlader N, Cronin KA, Kurian AW, et al. Differences in Breast Cancer Survival by Molecular Subtypes in the United States. Cancer Epidemiol Biomarkers Prev 2018;27:619-626. 24. Chang XZ, Yin J, Sun J, et al. A retrospective study of different local treatments in breast cancer patients with synchronous ipsilateral supraclavicular lymph node metastasis. J Cancer Res Ther 2013;9 Suppl:S158-61. 25. Chen SC, Chang HK, Lin YC, et al. Prognosis of Breast Cancer After Supraclavicular Lymph Node Metastasis: Not a Distant Metastasis. Ann Surg Oncol 2006;13:1457-1465. 26. Olivotto IA, Chua B, Allan SJ, et al. Long-Term Survival of Patients With Supraclavicular Metastases at Diagnosis of Breast Cancer. J Clin Oncol 2003;21:851-854. 27. Grotenhuis BA, Klem TM, Vrijland WW. Treatment Outcome in Breast Cancer Patients With Ipsilateral Supraclavicular Lymph Node Metastasis at Time of Diagnosis: A Review of the Literature. Eur J Surg Oncol 2013;39:207-212. 28. Ogino T, Komoike Y, Ishitobi M, et al. Breast Cancer With Ipsilateral Supraclavicular Metastases. Breast J 2011;17:555-557. 29. Liu XH, Zhang L, Chen B. A meta-analysis of the prognosis in patients with breast cancer with ipsilateral supraclavicular lymph node metastasis versus patients with stage IIIb/c or IV breast cancer. Chronic Dis Transl Med 2016;1:236-242. 30. Kiricuta IC, Willner J, Klbl O, et al. The Prognostic Significance of the Supraclavicular Lymph Node Metastases in Breast Cancer Patients. Int J Radiat Oncol Biol Phys 1994;28:387-393. 31. Debois JM. The Significance of a Supraclavicular Node Metastasis in Patients With Breast Cancer. A Literature Review. Strahlenther Onkol 1997;173:1-12. 32. Fan Y, Xu B, Liao Y, et al. A retrospective study of metachronous and synchronous ipsilateral supraclavicular lymph node metastases in breast cancer patients. Breast 2010;19:365-369. 33. van der Sangen MJ, Coebergh JW, Roumen RM, et al.  HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/12833449/" Detection, treatment, and outcome of isolated supraclavicular recurrence in 42 patients with invasive breast carcinoma. Cancer 2003;98:11-17. 34. Jin R, Hu X, Luo J. Clinical characteristics and prognostic analysis of ipsilateral supraclavicular lymph node metastases in breast cancer patients: a retrospective study. Int J Clin Exp Pathol 2019;12:3526-3534. 35. Koca E, Kuzan TY, Dizdar O, et al. Outcomes of locally advanced breast cancer patients with e"10 positive axillary lymph nodes. Med Oncol 2013;30:615. 36. Dellapasqua S, Bagnardi V, Balduzzi A, et al. Outcomes of Patients With Breast Cancer Who Present With Ipsilateral Supraclavicular or Internal Mammary Lymph Node Metastases. Clin Breast Cancer 2014;14:53-60. 37. Jung J, Kim SS, Ahn SD, et al.Treatment Outcome of Breast Cancer with Pathologically Proven Synchronous Ipsilateral Supraclavicular Lymph Node Metastases. J Breast Cancer 2015;18:167-172. Figure legends  Figure 1. Kaplan-Meier survival curves of the AJCC 7th anatomic stage IIIC and IV patients.  Figure 2. Survival curves according to different stages using the AJCC 8th pathological prognostic staging system.  Figure 3. Receiver operating characteristics analyses for predicting the breast cancer-specific survival between the 7th and 8th AJCC staging system. Table 1. Patient and tumor characteristics. Variablesn (%)M0 (%)M1 (%)Age (years)<50270 (24.6)108 (33.5)162 (20.9)e"50827 (75.4)214 (66.5)613 (79.1)Race/ethnicity Non-Hispanic White626 (57.1)190 (59.0)436 (56.2) Non-Hispanic Black225 (20.5)56 (17.4)169 (21.8) Hispanic (All Races)157 (14.3)55 (17.1)102 (13.2) Other89 (8.1)21 (6.5)68 (8.8)Histological subtype Infiltrating ductal carcinoma 796 (72.6)254 (78.9)542 (69.9) Invasive lobular carcinoma 70 (6.4)19 (5.9)51 (6.6) Other231 (21.0)49 (15.2)182 (23.5)T category T191 (8.3)39 (12.1)52 (6.7) T2262 (23.9)120 (37.3)142 (18.3) T3177 (16.1)62 (19.2)115 (14.8) T4502 (45.8)101 (31.4)401 (51.7) Tx65 (5.9)0 (0)65 (8.4)Grade Well differentiated32 (2.9)8 (2.5)24 (3.1) Moderately differentiated292 (26.6)94 (29.2)198 (25.5) Poorly/undifferentiated625 (57.0)220 (68.3)405 (52.3) Unknown148 (13.5)0 (0)148 (19.1)ER status Negative409 (37.3)136 (42.2)273 (35.2) Positive657 (59.9)186 (57.8)471 (60.8) Unknown31 (2.8)0 (0)31 (4.0)PR statusNegative559 (51.0)185 (57.5)374 (48.3)Positive496 (45.2)137 (42.5)359 (46.3)Unknown42 (3.8)0 (0)42 (5.4)HER2 statusNegative721 (65.7)213 (66.1)508 (65.6)Positive313 (28.5)109 (33.9)204 (26.3)Unknown63 (5.7)0 (0)63 (8.1)SurgeryNo surgery469 (42.8)0 (0)469 (60.5)BCS145 (13.2)69 (21.4)76 (9.8)MAST483 (44.0)253 (78.6)230 (29.7)RadiotherapyNo581 (53.0)85 (26.4)496 (64.0)Yes516 (47.0)237 (73.6)279 (36.0)ChemotherapyNo305 (27.8)21 (6.5)284 (36.6)Yes792 (72.2 )301 (93.5)491 (63.4)T, tumor; M, distant metastasis; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; BCS, breast-conservation surgery; MAST, mastectomy. Table 2. Comparisons of demographic and tumor characteristics among stage change from the 7th to the 8th edition of the AJCC breast cancer staging system (stage M0 patients). VariablesDownstageNo changeP(%)(%)Age (years)<5058 (53.7)50 (46.3)0.003e"50151 (70.6)63 (29.4)Race/ethnicity Non-Hispanic White130 (68.4)60 (31.6)0.016 Non-Hispanic Black29 (51.8)27 (48.2) Hispanic (All Races)32 (58.2)23(41.8) Other18 (85.7)3 (14.3)Histological subtype Infiltrating ductal carcinoma 160 (63.0)94 (37.0)0.162 Invasive lobular carcinoma 16 (84.2)3 (15.8) Other33 (67.3)16 (32.7)T category  T123 (59.0)16 (41.0)0.874 T279 (65.8)41 (34.2) T341 (66.1)21 (33.9) T466 (65.3)35(34.7)Grade Well differentiated8 (100.0)0 (0)<0.001 Moderately differentiated82 (87.2)12 (12.8) Poorly/undifferentiated119 (54.1)101 (45.9)ER status Negative48 (35.3)88 (64.7) Positive161 (86.6)25 (13.4)<0.001PR status Negative76 (41.1)109 (58.9) Positive133 (97.1)4 (2.9)<0.001HER2 status Negative100(46.9)113 (53.1) Positive109(100.0)0 (0)<0.001T, tumor; M, distant metastasis; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2. Table 3. Multivariate analysis of prognostic factors using the Cox- regression model (including biologic factors). VariablesHR95%CIPAge (years)<501e"501.3451.087-1.6650.006Race/ethnicity Non-Hispanic White1 Non-Hispanic Black1.4191.140-1.7660.002 Hispanic (All Races)1.0750.813-1.4210.613 Other0.9170.656-1.2830.613Histological subtype Infiltrating ductal carcinoma 1 Invasive lobular carcinoma 1.3420.931-1.9350.115 Other1.0480.833-1.3190.688T category T11 T20.9840.670-1.4450.933 T31.1060.741-1.6520.621 T41.5741.097-2.2580.014 Tx1.9171.134-3.2420.015M category  M01 M12.570 2.055-3.214<0.001Histological grade5PQwʱfS@/S!h[h>B*CJOJQJph$h[h>B*CJH*OJQJph$h[h>B*CJOJQJo(ph3h[h>B*CJKHOJPJQJ\aJo(ph6h[h>5B*CJKHOJPJQJ\aJo(ph(h[h>5B*CJ OJQJaJ ph0h[h>B*CJ KHOJPJQJ\aJ ph3h[h>5B*CJ KHOJPJQJ\aJ ph6h[h>5B*CJ KHOJPJQJ\aJ o(ph     [ \ k dUD ]gdi d9D^` dUD]d7$8$H$UD ]^dh7$8$H$UD ]^dhUD ]^gd) d d7$8$H$I        ' 8 s  ڴڴڊn[@5h[h>B*CJOJQJfHo(phq %h[h>B*CJOJQJaJph6h[h>B*CJOJQJaJfHphq +h[h>B*CJH*OJQJ\aJph'h[h>B*CJH*OJQJ\ph$h[h>B*CJH*OJQJph$h[h>B*CJOJQJo(ph!h[h>B*CJOJQJph'h[h>B*CJH*OJQJo(ph S j k l w x ] a b l m p }  νkO60h o5B*CJKHOJPJQJ\aJo(ph6h[h>5B*CJ KHOJPJQJ\aJ o(ph+h[h>5B*CJOJQJ\aJ$phh[h>5B*CJphh)B*CJOJQJo(phhi @B*CJOJQJo(phh[h>0JB*ph!h[h)B*CJOJQJphh>B*CJOJQJo(phhiB*CJOJQJo(ph!h[h>B*CJOJQJphk l x m n o p q r s t u v w x y z { | } ~  d7$8$H$dh dUD ]gdi @ dUD ] dUD ]gd)    8 a %ͽpV?p?p??p-h[h>B*CJKHOJPJQJaJph3h[h>5B*CJKHOJPJQJ\aJph0h[h>B*CJKHOJPJQJaJo(ph%h[h>B*CJOJQJaJph(h[h>B*CJOJQJaJo(phh,0JCJOJQJh,5B*CJOJQJph3h[h>5B*CJKHOJPJQJ\aJph0hi @5B*CJKHOJPJQJ\aJo(ph 45d d9D^` d9D^`gdkF d7$8$H$dgd "%_oxz|ռռռռռռռtռtcPcPcPռ$h[h>B*CJOJQJo(ph!h[h>B*CJOJQJph,h[h>B*CJKHOJQJ_Ho(ph-h[h>B*KHOJPJQJ^JaJph3h[h>5B*CJKHOJPJQJ\aJph0h[h>B*CJKHOJPJQJaJo(ph-h[h>B*CJKHOJPJQJaJph%h[h>B*CJOJQJaJph   $KPSWZ^agkop罨Бv]v]v]v]1h[h>B*CJKHOJPJQJ_HaJph4h[h>B*CJKHOJPJQJ_HaJo(ph-h[h>B*CJKHOJQJ_HaJph(h[h>B*CJOJQJaJo(ph%h[h>B*CJOJQJaJph-h[h>B*CJKHOJPJQJaJph0h[h>B*CJKHOJPJQJaJo(ph@[myзФpY@Y@pppp0h[h>B*CJKHOJPJQJaJo(ph-h[h>B*CJKHOJPJQJaJph1h[h>B*CJKHOJPJQJ_HaJph4h[h>B*CJKHOJPJQJ_HaJo(ph%h[h>B*CJOJQJaJph1h[h>B*CJKHOJPJQJ_HaJph-h[h>B*CJKHOJQJ_HaJph0h[h>B*CJKHOJQJ_HaJo(ph˱~e~eJ02h[hqB*CJOJQJfHphq 5h[h>B*CJOJQJfHo(phq 0h[h>B*CJKHOJPJQJaJo(ph-h[h>B*CJKHOJPJQJaJph6h[h>5B*CJKHOJPJQJ\aJo(ph3h[h>5B*CJKHOJPJQJ\aJph4h[h>B*CJKHOJPJQJ_HaJo(ph1h[h>B*CJKHOJPJQJ_HaJph .;FI35?NO϶ϟvdddJ5(h[h>B*CJOJQJaJo(ph3h[h>5B*CJKHOJPJQJ\aJph"hkFB*CJOJQJaJo(ph*hkFB*CJKHOJPJQJaJo(ph%hi @hkFB*CJOJQJaJph-hi @hkFB*CJKHOJPJQJaJph0h[h>B*CJKHOJPJQJaJo(ph-h[h>B*CJKHOJPJQJaJph2h[h TB*CJOJQJfHphq OtuMNOPQRT )*2369@z{|}ב~llllll"h,B*CJOJQJaJo(ph$h h 5B*CJOJQJph+h[h>5B*CJOJQJaJo(ph0h[h>B*CJKHOJPJQJaJo(ph-h[h>B*CJKHOJPJQJaJph(h[h>B*CJOJQJaJo(ph%h[h>B*CJOJQJaJph*M ""2"%%%%(((,,, d1$WD`d1$$d[$\$a$d dWD`gd dgd gd   35Of  27DNioرؚر+h[h>6B*CJOJQJaJo(ph-h[h>B*CJKHOJPJQJaJph(h[h>6B*CJOJQJaJph"h,B*CJOJQJaJo(ph%h[h>B*CJOJQJaJph(h[h>B*CJOJQJaJo(ph4o!GHIJQRyz * $AE띇سk6h[h>B*CJOJQJaJfHphq +h[h>5B*CJOJQJaJo(ph+h[h>5B*CJOJQJaJo(ph%h[h TB*CJOJQJaJph"h,B*CJOJQJaJo(ph%h[h>B*CJOJQJaJph(h[h>B*CJOJQJaJo(ph* ;<CT|-/Cap ƚƚƚƚ⚇vcv$h[h>B*OJQJ^Jo(ph!h[h>B*OJQJ^Jph%h[h>0JB*OJQJ^Jph(h[h>B*CJOJQJaJo(ph,h[h>B*CJKHOJQJ_Ho(ph6h[h>B*CJOJQJaJfHphq 9h[h>B*CJOJQJaJfHo(phq & !!!!!!!!!!!!!"""1"2"7"I"J"\"]""""""""#!###G#R#V#Z###$&$ܳ܍| h[h>B*OJQJo(ph$h[h>B*OJQJ_Ho(ph%h[h>0JB*OJQJ^Jph!h[h TB*OJQJ^Jph.h[h>B*OJQJfHphq !h[h>B*OJQJ^Jph$h[h>B*OJQJ^Jo(ph0&$$$ %)%j%k%%%%%%%%%%%s\E-h[h>B*CJKHOJPJQJ_Hph-h[h>B*CJKHOJPJQJ_Hph+h[h>5B*CJOJQJaJo(ph(h[h>5B*CJOJQJaJph(h[h>5B*CJOJQJaJph(h[h>B*CJOJQJaJo(ph%h[h>0JB*OJQJ^Jph$h[h>B*OJQJ^Jo(ph!h[h>B*OJQJ^Jph%%%%%&&&&&&''''(+(=(N(R(X(з砉p]p]pDp1h[h>B*CJKHOJPJQJ_HaJph%h[h>B*CJOJQJaJph1h[h>B*CJKHOJPJQJ_HaJph-h[h>B*CJKHOJPJQJ_Hph,h[h>B*CJKHOJQJ_Ho(ph0h[h>B*CJKHOJPJQJ_Ho(ph-h[h>B*CJKHOJPJQJ_Hph0h[h>B*CJKHOJPJQJ_Ho(phX(\(](d(e(((((((((( )))))&)'),)0)1)E)M)V)_)`)b)k)o)̳̳̤yfQfQfQfQfQfQfQfQfQfQ(h[h>B*CJOJQJaJo(ph%h[h>B*CJOJQJaJph+h[h>5B*CJOJQJaJo(ph(h[h>5B*CJOJQJaJphh[h>B*OJQJph1h[h>B*CJKHOJPJQJ_HaJph1h[h>B*CJKHOJPJQJ_HaJph4h[h>B*CJKHOJPJQJ_HaJo(pho)t)))))))))))))))))))))))))))****(***@*{h%h[h>B*CJKHOJQJph)h[h>B*CJKHOJQJ_Hph,h[h>B*CJKHOJQJ_Ho(ph0h[h>B*CJKHOJPJQJ_Ho(ph-h[h>B*CJKHOJPJQJ_Hph(h[h>B*CJOJQJaJo(ph%h[h>B*CJOJQJaJph"@*P*R*Y*b*c*f*z*{*|*******++,+Y+_+j+k+l+1,ϡϡϡ{_F1h[h>B*CJKHOJPJQJ_HaJph6h[h>B*CJOJQJaJfHphq !h[h>B*CJOJQJph)h[h>B*CJKHOJQJaJph,h[h>B*CJKHOJQJaJo(ph,h[h>B*CJKHOJQJ_Ho(ph0h[h>B*CJKHOJPJQJ_Ho(ph-h[h>B*CJKHOJPJQJ_Hph1,5,=,>,C,Q,Z,i,l,,,,,,,,,,,,,,,,,,,, - --ddddM-h[h>B*CJKHOJQJ_HaJph4h[h>B*CJKHOJPJQJ_HaJo(ph1h[h>B*CJKHOJPJQJ_HaJph(h[h>5B*CJOJQJaJph+h[h>5B*CJOJQJaJo(ph0h[h>B*CJKHOJPJQJ_Ho(ph!h[h>B*CJOJQJph$h[h>B*CJOJQJo(ph---"-%-&-E-F-J-N-P-h-r-t-{-|------------------.. .εΜΜΜεεpppppΉ[(h[h>B*CJOJQJaJo(ph1h[h>B*CJKHOJPJQJ_HaJph%h[h>B*CJOJQJaJph0h[h>B*CJKHOJQJ_HaJo(ph1h[h>B*CJKHOJPJQJ_HaJph-h[h>B*CJKHOJQJ_HaJph4h[h>B*CJKHOJPJQJ_HaJo(ph# . ...&.(.,.-...<.J.L.M.N.U.`.s..........////%/(/+/,/0/2/A/B/洛洈曈ssssssssssdh[h>B*OJQJph(h[h>B*CJOJQJaJo(ph%h[h>B*CJOJQJaJph0h[h>B*CJKHOJQJ_HaJo(ph-h[h>B*CJKHOJQJ_HaJph4h[h>B*CJKHOJPJQJ_HaJo(ph1h[h>B*CJKHOJPJQJ_HaJph%,A/B/d/22265q8>nB1D-JMMMtOuO d7$8$H$gd d7$8$H$ d7$8$H$` dWD`gd d7$8$H$WD`d7$8$H$WD`gd dWD`dgd dB/d////000$0^0_0`000000000001111&1>1B1G1ҿ|c|c|c|c|c|cLL-h[h>B*CJKHOJQJ_HaJph1h[h>B*CJKHOJPJQJ_HaJph4h[h>B*CJKHOJPJQJ_HaJo(ph(h[h>B*CJOJQJaJo(ph%h[h TB*CJOJQJaJph%h[h>B*CJOJQJaJph0h[h>B*CJKHOJQJ_HaJo(ph(h[h>5B*CJOJQJaJphG1I1[1r11111112c2g2l2q2r2s2222222222϶ϝmZmOmZmZmZmZmh[h>B*ph%h[h>B*CJOJQJaJph(h[h>B*CJOJQJaJo(ph4h[h>B*CJKHOJPJQJ_HaJo(ph1h[h>B*CJKHOJPJQJ_HaJph1h[h>B*CJKHOJPJQJ_HaJph0h[h>B*CJKHOJQJ_HaJo(ph-h[h>B*CJKHOJQJ_HaJph2222222233333^3`3c3k3m3v3y3z3{3333333333333344 4 44444I4ƱƱƱƱƱƱooƱƱƱƱƱoo"h,B*CJOJQJaJo(ph-h[h>B*CJKHOJPJQJaJph0h[h>B*CJKHOJPJQJaJo(ph(h[h>B*CJOJQJaJo(ph%h[h>B*CJOJQJaJph+h[h>5B*CJOJQJaJo(ph h[h>B*OJQJo(ph+I4Z44444444444445545[5_5c5s5t5555555555666Ͼϕ~iViViViViViViViV%h[h>B*CJOJQJaJph(h[h>B*CJOJQJaJo(ph-h[h TB*CJKHOJPJQJaJph*h,B*CJKHOJPJQJaJo(ph$h[h>B*CJOJQJo(ph!h[h>B*CJOJQJph0h[h>B*CJKHOJPJQJaJo(ph-h[h>B*CJKHOJPJQJaJph!6$63666;6Q6Z6t6y666666666 7>7@7f7j7s7t7u7777778ԻԻԻԻԤԻԑeԻԻN-h[h TB*CJKHOJPJQJaJph4h[h>B*CJKHOJPJQJ_HaJo(ph!h[h>B*CJOJQJph$h[h>B*CJOJQJo(ph-h[h>B*KHOJPJQJ^JaJph0h[h>B*CJKHOJPJQJaJo(ph-h[h>B*CJKHOJPJQJaJph(h[h>B*CJOJQJaJo(ph88888@8L8Z8^8_8`8g8o8p8q8888888889%9<9C9H9W9c9d9f9u9y9999999˶sa"h,B*CJOJQJaJo(ph0h[h>B*CJKHOJPJQJaJo(ph-h[h>B*CJKHOJPJQJaJph%h[h>B*CJOJQJaJph(h[h>B*CJOJQJaJo(ph4h[h>B*CJKHOJPJQJ_HaJo(ph1h[h>B*CJKHOJPJQJ_HaJph&99999999::::%:&:n::::::::::::::::::;;O;s;x;{;;;;Ưƀj+h,h,B*CJOJQJ]aJo(ph+h[h>6B*CJOJQJ]aJph0h[h>B*CJKHOJPJQJaJo(ph-h[h>B*CJKHOJPJQJaJph%h[h>B*CJOJQJaJph(h[h>B*CJOJQJaJo(ph"h,B*CJOJQJaJo(ph';;;;;;;;;;;;;;; <<!<'<)<*</<1<9<:<;<U<Y<h<i<{<~<<<<<<<<<== = =='=(=+=S=j=îîîîîîîîîî~~~~~~~~~~~~-h[h>B*CJKHOJPJQJaJph0h[h>B*CJKHOJPJQJaJo(ph(h[h>B*CJOJQJaJo(ph%h[h>B*CJOJQJaJph%h,B*CJOJQJ]aJo(ph+h[h>B*CJOJQJ]aJo(ph1j=n=====>>>&>'>(>)>*>+>>>@>A>B>G>H>I>Q>T>l>m>r>s>賞ydyGdG9h[h>B*CJOJQJaJfHo(phq (h[h>B*CJOJQJaJo(ph"h,B*CJOJQJaJo(ph%h[h>B*CJOJQJaJph(h[h>6B*CJOJQJaJph6h[h>B*CJOJQJaJfHphq 0h[h>B*CJKHOJPJQJaJo(ph-h[h>B*CJKHOJPJQJaJphs>>>>>>>>>>>>>>>>>> ?@!@)@7@8@O@Q@]@_@g@x@y@@@@@@@@@Ǽǜtbb"h,B*CJOJQJaJo(ph%h[h TB*CJOJQJaJph(h[h>B*CJOJQJaJo(ph%h[h>B*CJOJQJaJphh[h>B*o(phh[h>B*ph9h[h>B*CJOJQJaJfHo(phq 6h[h>B*CJOJQJaJfHphq &@@@@AAAA)A*A;AD쮕앮0h[h>B*CJKHOJPJQJaJo(ph-h[h>B*CJKHOJPJQJaJph"h,B*CJOJQJaJo(ph(h[h>B*CJOJQJaJo(ph%h[h>B*CJOJQJaJph:>D?DADLDMDODQDUDYD^D_DgDDDDDDDDDD EEEEEGETEUE[EdEeEfEgEiEjEkEqE컞׌{j h[h>0JCJOJQJaJ!h[h>0JB*CJaJph"h,B*CJOJQJaJo(ph9h[h>B*CJOJQJaJfHo(phq 6h[h>B*CJOJQJaJfHphq (h[h>B*CJOJQJaJo(ph%h[h>B*CJOJQJaJph%qErEuEwExEEEEEEEEEEEEEEEEEEEEFFFFF%F2F:FEFTFYF\FFFFFFȬyggȏ"h,B*CJOJQJaJo(ph+h[h>6B*CJOJQJaJo(ph9h[h>B*CJOJQJaJfHo(phq 6h[h>B*CJOJQJaJfHphq %h[h>B*CJOJQJaJph(h[h>B*CJOJQJaJo(phh,0JCJOJQJaJo((FFGG&G+G8G\GaGbGdGmGGGGGGGGG4H;H>H?HEH_H`HkHmHyH}HHHHHHHHHHHIII%I-IDI{I}IIIIIIIIIIIIIIIIJ!J+J,J-Jƹh[h>0JB*ph%h[h>B*CJOJQJaJph(h[h>B*CJOJQJaJo(ph"h,B*CJOJQJaJo(phD-J{J}J~JJJJJJJJJ6KWK`KeKjKnKvKKKKKKKKLL L2L7LNLOLhLLLLLLLLLLLLMMMM6M8M:MbMcMmMoM~MMMMMMMMMMMϵ3h[h>5B*CJKHOJPJQJ\aJph0h[h>B*CJKHOJPJQJaJo(ph-h[h>B*CJKHOJPJQJaJphBMMMMNN NNN$N&N)NnNNNNNNNNNNѺwawO=w=w"hCB*CJOJQJaJo(ph"hB*CJOJQJaJo(ph*hCB*CJKHOJPJQJaJo(ph%hi @hi @B*CJOJQJaJph-hi @hi @B*CJKHOJPJQJaJph0h[h>B*CJKHOJPJQJaJo(ph-h[h>B*CJKHOJPJQJaJph-h[h TB*CJKHOJPJQJaJph-h[hqB*CJKHOJPJQJaJphNNOOO'O(O.O/OGOPOsOtOuOOOOįpZI*<h[h>5B*CJOJQJ\aJfHphq !h[h>B*CJOJQJph+h[h>5B*CJOJQJ\aJph0h[h>B*CJKHOJPJQJaJo(ph%h[h TB*CJOJQJaJph%h[h>B*CJOJQJaJph(h[h>B*CJOJQJaJo(ph-hi @h>B*CJKHOJPJQJaJph%hi @hi @B*CJOJQJaJph"hB*CJOJQJaJo(phuOOOOOiPjPvP>QQRSSTVWX[\_b$dh7$8$H$a$gd dh7$8$H$dhgd dh7$8$H$gd  d7$8$H$ d2gdkFdOOCPTPUPiPjPvPxPyPPPPmV? ?=h~:!h,B*CJOJQJfHmHo(phq sH, *h,h>B*CJKHOJQJaJph, *h[h>B*CJKHOJQJaJph%h[h>B*CJOJQJaJph+h[h>5B*CJOJQJaJo(ph0h[h>B*CJKHOJPJQJaJo(ph!h[h>B*CJOJQJph%h[h>0JB*CJOJQJph%h[h>0JB*CJOJQJph2h[h>B*CJOJQJfHphq PQ,Q>QAQ]QbQdQQQQQQRRRRRRRS S SSjjSB!h,h>0JB*CJaJph-h,h>B*CJKHOJPJQJaJph9h,h>B*CJOJQJ]aJfHphq 9h,h B*CJOJQJaJfHo(phq 6h,h>B*CJOJQJaJfHphq %h,h>B*CJOJQJaJph,h,h>B*CJKHOJQJ]aJph)h,h>B*CJKHOJQJaJphSbScSpSSJTLTTTTTTT.Uα~^~^~^D+~0h,h>B*CJKHOJPJQJaJo(ph2hkFB*CJKHOJPJQJaJmHo(phsH>jh,h>B*CJKHOJPJQJUaJmHphsH-h,h>B*CJKHOJPJQJaJph6h,h>B*CJOJQJaJfHphq 9h,h>B*CJOJQJ]aJfHphq 9h,h>B*CJ OJQJ]aJ fHphq (h,h>B*CJOJQJ\aJph .U8UPVXVlV|VVWWX XXXXX˴˂iJi03h,h>B*CJKHOJPJQJ]aJo(ph=h~:!h,B*CJOJQJfHmHo(phq sH0h,h>B*CJKHOJPJQJ]aJph0 *h,h>B*CJKHOJPJQJaJph0h,h B*CJKHOJPJQJ]aJph-h,h B*CJKHOJPJQJaJph-h,h>B*CJKHOJPJQJaJph9h,h B*CJOJQJaJfHo(phq XX=Y>YDYEYGYHYYYYYYY+Z,Z2Z3Z5Z:Z;ZZZZ[Ũő|Y?3 *h,h>B*CJKHOJPJQJ]aJphDj *h,h>B*CJKHOJPJQJU]aJmHphsH)h,h>B*KHOJPJQJaJph-h,h>B*CJKHOJPJQJaJph9h,h B*CJOJQJaJfHo(phq 0 *h,h>B*CJKHOJPJQJaJphAj *h,h>B*CJKHOJPJQJUaJmHphsH[[[[[[\\\\-].]2]3]5]6]]]]]]]^^ ^!^#^êzYYYYYYYYYAj *h,h>B*CJKHOJPJQJUaJmHphsH0h,h>B*CJKHOJPJQJ]aJph-h,h>B*CJKHOJPJQJaJph0 *h,h>B*CJKHOJPJQJaJph3 *h,h>B*CJKHOJPJQJ]aJphDj *h,h>B*CJKHOJPJQJU]aJmHphsH#^(^)^^^_______`````````````aaaaaaabɲuuɲTTTTTTTTTɏuuAj *h,h>B*CJKHOJPJQJUaJmHphsH3 *h,h>B*CJKHOJPJQJ]aJphDj *h,h>B*CJKHOJPJQJU]aJmHphsH-h,h>B*CJKHOJPJQJaJph0 *h,h>B*CJKHOJPJQJaJph9h,h B*CJOJQJaJfHo(phq bb bbbbbbbbbc cccccccêlU@(h,h B*CJOJQJ]aJph-h,h>B*CJKHOJPJQJaJph9h,h B*CJOJQJaJfHo(phq Aj *h,h>B*CJKHOJPJQJUaJmHphsH0 *h,h>B*CJKHOJPJQJaJph3 *h,h>B*CJKHOJPJQJ]aJphDj *h,h>B*CJKHOJPJQJU]aJmHphsHccccdOdPdTdUddddddd7e8e?e@eBeCeeeeee}\\\\\\\\\Aj *h,h>B*CJKHOJPJQJUaJmHphsH-h,h>B*CJKHOJPJQJaJph%h,h>B*CJOJQJaJph0 *h,h>B*CJKHOJPJQJaJph.jh,h>B*CJOJQJUaJph%h,h>B*CJOJQJaJph(h,h>B*CJOJQJ]aJphbPdbfUgh;j qqtuvhwxxyz {{h|%}#~~ dh7$8$H$ d7$8$H$gd dh-D1$M gd dh7$8$H$gd dh-DM gd eeAfQfaffffff3g4gBgUg˱|]|J|-|9h,h>B*CJOJQJ]aJfHphq %h,h>B*CJOJQJaJph=h~:!h,B*CJOJQJfHmHo(phq sH6h,h>B*CJOJQJaJfHphq 0 *h,h>B*CJKHOJPJQJaJph3 *h,h>B*CJKHOJPJQJ]aJph-h,h>B*CJKHOJPJQJaJph9h,h B*CJOJQJaJfHo(phq UgYgyg~gggghhhhɨɕmX<6h,h>B*CJOJQJaJfHphq (h,h>B*CJOJQJ]aJph(h,h B*CJOJQJ]aJph%h,h B*CJOJQJaJph%h,h>B*CJOJQJaJphAh,h B*CJOJQJaJfHmHo(phq sH-h,h>B*CJOJQJaJmHphsH>h,h>B*CJOJQJaJfHmHphq sH hhhhhhhhii iii i!i"i#iiiŦōv_F0h,h>B*CJKHOJPJQJaJo(ph-h,h>B*CJKHOJPJQJaJph-h,h>B*CJ KHOJPJQJaJ ph0 *h,h>B*CJ KHOJPJQJaJ ph=h~:!h,B*CJOJQJfHmHo(phq sH0 *h,h>B*CJKHOJPJQJaJphAj *h,h>B*CJKHOJPJQJUaJmHphsHiiij j!j'j(j:j;j?j@jjjjjjjAkBkMkNkPk¦t]<<<<<<Aj *h,h>B*CJKHOJPJQJUaJmHphsH-h,h>B*CJKHOJPJQJaJph0h,h>B*CJKHOJPJQJaJo(ph0 *h,h>B*CJKHOJPJQJaJph6 *h,h>B*CJKHOJPJQJ]aJo(phDj *h,h>B*CJKHOJPJQJU]aJmHphsH3 *h,h>B*CJKHOJPJQJ]aJphPkUkkkppppp q'q,qqqqqǤnRR5R9h,h>B*CJOJQJ]aJfHphq 6h,h>B*CJOJQJaJfHphq 6 *h,h B*CJKHOJPJQJ]aJo(ph3 *h,h>B*CJKHOJPJQJ]aJphDj *h,h>B*CJKHOJPJQJU]aJmHphsH0 *h,h>B*CJKHOJPJQJaJph=h~:!h,B*CJOJQJfHmHo(phq sHqqqqcrdrnrorqrrrrrrrs ssstt̫̫̫̫̫̫̎wT:T3 *h,h>B*CJKHOJPJQJ]aJphDj *h,h>B*CJKHOJPJQJU]aJmHphsH-h,h>B*CJKHOJPJQJaJph9h,h B*CJOJQJaJfHo(phq Aj *h,h>B*CJKHOJPJQJUaJmHphsH0 *h,h>B*CJKHOJPJQJaJph3 *h,h>B*CJKHOJPJQJaJo(phtttuuuuuuᾣbO29h,h>B*CJOJQJ]aJfHphq %h,h>B*CJOJQJaJphAh,h B*CJOJQJaJfHmHo(phq sH>h,h>B*CJOJQJaJfHmHphq sH5h,h>B*CJKHOJPJQJaJmHphsHDj *h,h>B*CJKHOJPJQJU]aJmHphsH; *h,h>B*CJKHOJPJQJ]aJmHphsHuuuuuuvvXvyvvvvvv@wRwgwhwiwjwwʹeHeHH9h,h>B*CJOJQJaJfHo(phq 9h,h>B*CJOJQJ]aJfHphq %h,h>B*CJOJQJaJph=h~:!h,B*CJOJQJfHmHo(phq sH0h,h>B*CJKHOJPJQJaJo(ph-h,h>B*CJKHOJPJQJaJph6h,h>B*CJOJQJaJfHphq wwwwwwxx6x;x=xxxƳdE0(h,h>B*CJOJQJ\aJph=h~:!h,B*CJOJQJfHmHo(phq sH9h,h>B*CJOJQJaJfHo(phq 9h,h>B*CJOJQJ]aJfHphq (h,h>B*CJOJQJ]aJph%h,h>B*CJOJQJaJph6h,h>B*CJOJQJaJfHphq 9h,h B*CJOJQJaJfHo(phq xxxxxxxxxxxxħqT?)?+h,h>B*CJOJQJ\aJo(ph(h,h>B*CJOJQJ\aJph9h,h>B*CJOJQJaJfHo(phq 3h,B*CJOJQJaJfHo(phq 6h,h>B*CJOJQJaJfHphq 9h,h>B*CJOJQJ]aJfHphq 9h,h B*CJOJQJ]aJfHphq <h,h>B*CJOJQJ]aJfHo(phq xwyxyyyyyyyzzzz6zzz{{2{7{9{{{{{׺bE캞b캞9h,h B*CJOJQJ]aJfHphq =h~:!h,B*CJOJQJfHmHo(phq sH9h,h>B*CJOJQJaJfHo(phq 6h,h>B*CJOJQJaJfHphq 9h,h>B*CJOJQJ]aJfHphq (h,h>B*CJOJQJ]aJph%h,h>B*CJOJQJaJph{{{{F|Y|i|j|||| }}$})}T}Y}[}\}}}ؼ؟c؟cKK.jh,h>B*CJOJQJUaJph=h~:!h,B*CJOJQJfHmHo(phq sH9h,h>B*CJOJQJaJfHo(phq 9h,h>B*CJOJQJ]aJfHphq 6h,h>B*CJOJQJaJfHphq %h,h>B*CJOJQJaJph(h,h>B*CJOJQJaJo(ph} ~ ~ ~~~ ~"~&~;~n~o~~~~~~ȳz]z]zJ5J5Jz]z(h,h>B*CJOJQJaJo(ph%h,h>B*CJOJQJaJph9h,h>B*CJOJQJaJfHo(phq 6h,h>B*CJOJQJaJfHphq 9h,h>B*CJOJQJ]aJfHphq (h,h>B*CJOJQJ]aJph.jh,h>B*CJOJQJUaJph=h,h>0J>*B*CJOJQJaJfHphq "#ĀƀȀıfI2-h,h>B*CJKHOJPJQJaJph9h,h>B*CJOJQJaJfHo(phq 0h,B*CJOJQJaJfHphq 9h,h>B*CJOJQJ]aJfHphq (h,h>B*CJOJQJ]aJph%h,h>B*CJOJQJaJph6h,h>B*CJOJQJaJfHphq =h~:!h,B*CJOJQJfHmHo(phq sH ~ƀ8pqCEƀ]'$a$gd,dhgd dh7$8$H$ dh7$8$H$gd Ȁʀ΀&*'78<TYZׂдeH+9h,h>B*CJOJQJ]aJfHphq 9h,h>B*CJOJQJaJfHo(phq 9h,h B*CJOJQJ]aJfHphq %h,h>B*CJOJQJaJph=h~:!h,B*CJOJQJfHmHo(phq sH6h,h>B*CJOJQJaJfHphq -h,h>B*CJKHOJPJQJaJph0h,h>B*CJKHOJPJQJaJo(phƱ➋ubI3+h[h,5B*CJOJQJaJo(ph1jh,h,5B*CJOJQJUaJph%h>5B*CJOJQJaJo(ph+h[h>5B*CJOJQJaJo(ph%h,5B*CJOJQJaJo(ph%h 5B*CJOJQJaJo(ph(h,h>5B*CJOJQJaJph6h,h>B*CJOJQJaJfHphq 9h,h>B*CJOJQJaJfHo(phq pqrŃ{cL5-h[h>B*CJKHOJPJQJ_Hph-h[h>B*CJKHOJPJQJ_Hph/h[h>5B*CJKHOJQJ_Ho(ph0h[h>5B*CJKHOJPJQJ_Hph1jh,h,5B*CJOJQJUaJph%h,5B*CJOJQJaJo(ph%h>5B*CJOJQJaJo(ph+h[h>B*CJOJQJ\aJo(ph+h[h>5B*CJOJQJaJo(ph qrstuvwxyz{|}~$a$gd,Ńʃσ܃ 8Nл磐}d}N4#!h[h>B*CJOJQJph2h[h>B*CJOJQJfHphq +h[h>5B*CJOJQJaJo(ph1jh,h,5B*CJOJQJUaJph%h,5B*CJOJQJaJo(ph%h>5B*CJOJQJaJo(ph/h[h>5B*CJOJPJQJaJo(ph)h[h>B*CJKHOJQJ_Hph-h[h>B*CJKHOJPJQJ_Hph0h[h>B*CJKHOJPJQJ_Ho(ph  ܄ $$1$Ifa$dhNPUV[\tȱjTA.%hrM5B*CJOJQJaJo(ph%h>5B*CJOJQJaJo(ph+h[h>5B*CJOJQJaJo(ph,h[h>B*CJOJPJQJaJo(ph,h[h>B*CJKHOJQJ_Ho(ph0h[h>B*CJKHOJPJQJ_Ho(ph-h[h>B*CJKHOJPJQJ_Hph)h[h>B*CJKHOJQJ_Hph!h[h>B*CJOJQJph!h[h TB*CJOJQJph ۄ܄ÈˈNQ*ȍӾө}l}U}U}U}U}U}U}D!h[h>B*CJOJQJph,h[h>B*CJKHOJQJaJo(ph!h[h>B*CJKH^Jph)h[h>B*CJKHOJQJaJph,h[h>B*CJKHOJPJQJo(ph)h[h>B*CJKHOJPJQJph(h[h>5B*CJOJQJaJph+h[h>5B*CJOJQJaJo(ph+h[hrM5B*CJOJQJaJo(ph }vkdk$$IfJ\  4 &  &P  &(  &(  4 644 lal $$1$Ifa$ %0wlll $$1$Ifa$$$1$IfWDd`a$vkd$$IfJ\  4 & &P&(&(4 644 lal014Jwlll $$1$Ifa$$$1$IfWDd`a$vkd$$If6\  4 & &P&(&(4 644 lalJLjlnp}}}} $$1$Ifa$vkd>$$If6\  4 & &P&(&(4 644 lalprȆކ}}}} $$1$Ifa$vkd$$If6\  4 & &P&(&(4 644 lalކ 4J}}}} $$1$Ifa$vkdl$$If6\  4 & &P&(&(4 644 lalJLz}}}} $$1$Ifa$vkd$$If6\  4 & &P&(&(4 644 lal̇އuuu $$1$Ifa$$1$Ifvkd$$If6\  4 & &P&(&(4 644 lal}}}} $$1$Ifa$vkd1$$If,\  4 & &P&(&(4 644 lal<GR]}}}} $$1$Ifa$vkd$$If6\  4 & &P&(&(4 644 lal]^|}}}} $$1$Ifa$vkd_$$If6\  4 & &P&(&(4 644 lal}}}} $$1$Ifa$vkd$$If6\  4 & &P&(&(4 644 lal͈̈Έψ}}}} $$1$Ifa$vkd$$If6\  4 & &P&(&(4 644 lalψЈՈވ}}}} $$1$Ifa$vkd$$$If6\  4 & &P&(&(4 644 lal }}}} $$1$Ifa$vkd$$If6\  4 & &P&(&(4 644 lal)3>}}}} $$1$Ifa$vkdR$$If6\  4 & &P&(&(4 644 lal>?DOZe}}}} $$1$Ifa$vkd$$If6\  4 & &P&(&(4 644 lalefktz}}}} $$1$Ifa$vkd$$If6\  4 & &P&(&(4 644 lal}}}} $$1$Ifa$vkd$$If6\  4 & &P&(&(4 644 lal}}}} $$1$Ifa$vkd$$If6\  4 & &P&(&(4 644 lalۉ}}}} $$1$Ifa$vkdE$$If6\  4 & &P&(&(4 644 lal!,7}}}} $$1$Ifa$vkd$$If6\  4 & &P&(&(4 644 lal78BMS^}}}} $$1$Ifa$vkds$$If6\  4 & &P&(&(4 644 lal^_ijkl}}}} $$1$Ifa$vkd $$If6\  4 & &P&(&(4 644 lallmx}}}} $$1$Ifa$vkd$$If6\  4 & &P&(&(4 644 lalƊ}}}} $$1$Ifa$vkd8$$If6\  4 & &P&(&(4 644 lalƊNJъڊ}}}} $$1$Ifa$vkd$$If6\  4 & &P&(&(4 644 lal}}}} $$1$Ifa$vkdf$$If6\  4 & &P&(&(4 644 lal "wlll $$1$Ifa$$$1$IfWDd`a$vkd$$If6\  4 & &P&(&(4 644 lal"#,7BMwlll $$1$Ifa$$$1$IfWDd`a$vkd$$If6\  4 & &P&(&(4 644 lalMNV_enwlll $$1$Ifa$$$1$IfWDd`a$vkd+$$If6\  4 & &P&(&(4 644 lalno{|}~}}}} $$1$Ifa$vkd$$If6\  4 & &P&(&(4 644 lal~wlll $$1$Ifa$$$1$IfWDd`a$vkdY$$If6\  4 & &P&(&(4 644 lalɋԋwlll $$1$Ifa$$$1$IfWDd`a$vkd$$If6\  4 & &P&(&(4 644 lalԋՋ݋wlll $$1$Ifa$$$1$IfWDd`a$vkd$$If6\  4 & &P&(&(4 644 lal}}}} $$1$Ifa$vkd$$If6\  4 & &P&(&(4 644 lal )wlll $$1$Ifa$$$1$IfWDd`a$vkd$$If6\  4 & &P&(&(4 644 lal)*.9CLwlll $$1$Ifa$$$1$IfWDd`a$vkdL$$If6\  4 & &P&(&(4 644 lalLMR]hswlll $$1$Ifa$$$1$IfWDd`a$vkd$$If6\  4 & &P&(&(4 644 lalst}}}} $$1$Ifa$vkdz$$If6\  4 & &P&(&(4 644 lalwlll $$1$Ifa$$$1$IfWDd`a$vkd$$If6\  4 & &P&(&(4 644 lalÌΌwlll $$1$Ifa$$$1$IfWDd`a$vkd$$If6\  4 & &P&(&(4 644 lalΌό܌݌ތߌ}}}} $$1$Ifa$vkd?$$If6\  4 & &P&(&(4 644 lalߌwlll $$1$Ifa$$$1$IfWDd`a$vkd$$If6\  4 & &P&(&(4 644 lal)wlll $$1$Ifa$$$1$IfWDd`a$vkdm$$If6\  4 & &P&(&(4 644 lal)*wwwwwwwwwww d7$8$H$iUD2]ivkd$$If6\  4 & &P &( &( 4 644 lal ȍɍЍӍՍ8DFH{ܰnnYF%h[h>B*CJOJQJaJph)h[h>B*CJKHOJQJ_Hph-h[h>B*CJKHOJPJQJ_Hph+h[h>5B*CJOJQJaJo(ph(h[h>5B*CJOJQJaJph0h[h>B*CJKHOJPJQJaJo(ph%h[h>B*CJKHOJQJph!h[h>B*CJOJQJph$h[h>B*CJOJQJo(phH\p$If v1$UD,]v d7$8$H$ $Ifrkd$$If4@\ H<&  & &T &  4a$Ifrkd$$If4@\ H<  & &T   4aȏ܏|||$If $IfWDd`pkd $$If@\ H<& &&T&4a|||$If $IfWDd`pkd $$If6\ H<& &&T&4a)*+,$Ifpkd3 $$If6\ H<& &&T&4a,-BMW]$Ifpkd $$If6\ H<& &&T&4a]^s}$Ifpkd $$If6\ H<& &&T&4a$Ifpkd4 $$If6\ H<& &&T&4aǐАѐ$Ifpkd $$If6\ H<& &&T&4aѐҐ$Ifpkd$$If6\ H<& &&T&4a !'$Ifpkd5$$If6\ H<& &&T&4a'(FPYZ$Ifpkd$$If6\ H<& &&T&4aZ[cmwx$Ifpkd$$If6\ H<& &&T&4axy$Ifpkd6$$If6\ H<& &&T&4a{2468>JLPǴǡs]sF-0h[h>B*CJKHOJPJQJ_Ho(ph-h[h>B*CJKHOJPJQJ_Hph+h[h>5B*CJOJQJaJo(ph(h[h>5B*CJOJQJaJph0h[h>B*CJKHOJPJQJaJo(ph$h[h>B*CJOJQJo(ph%h[h>B*CJKHOJQJph!h[h>B*CJOJQJph%h[h>B*CJOJQJaJph(h[h>B*CJOJQJaJo(ph$Ifpkd$$If6\ H<& &&T&4a‘Ñ$Ifpkd$$If6\ H<& &&T&4aÑđɑӑݑޑ$Ifpkd7$$If6\ H<& &&T&4aޑߑ$Ifpkd$$If6\ H<& &&T&4a$Ifpkd$$If6\ H<& &&T&4a#)0$Ifpkd8$$If6\ H<& &&T&4a01MWab$Ifpkd$$If6\ H<& &&T&4abc}$Ifpkd$$If6\ H<& &&T&4a$Ifpkd9$$If6\ H<& &&T&4a’Ò$Ifpkd$$If6\ H<& &&T&4aÒĒϒڒ$Ifpkd$$If6\ H<& &&T&4a$Ifpkd:$$If6\ H<& &&T&4a$Ifpkd$$If6\ H<& &&T&4a'2:A$Ifpkd$$If6\ H<& &&T&4aABNOPQ$Ifpkd;$$If6\ H<& &&T&4aQR]grs$Ifpkd$$If6\ H<& &&T&4ast$Ifpkd$$If6\ H<& &&T&4a8:<>$8>JN}}}wllll $$1$Ifa$$1$a$ d7$8$H$UD^]pkd<$$If6\ H<& & &T & 4a $jp~ܕ ǖɖ˖Ԗ#+-08:—ʗ̗ зttttrU,h[h>B*CJKHOJQJaJo(ph-h[h>B*CJKHOJPJQJaJph)h[h>B*CJKHOJQJaJph0h[h>B*CJKHOJPJQJ_Ho(ph0h[h>B*CJKHOJPJQJ_Ho(ph,h[h>B*CJKHOJQJ_Ho(ph#NPhjln}}}} $$1$Ifa$vkd$$IfJ\l &l  &  &O  &  644 lalnpx|~wooo$1$If$$1$IfWDd`a$vkd$$If@\l &l &&O&644 lalwooo$1$If$$1$IfWDd`a$vkdM$$If6\l &l &&O&644 lalڕܕޕ}}uu$1$If $$1$Ifa$vkd$$If@\l &l &&O&644 lal }uuu$1$If $$1$Ifa$vkd $$If6\l &l &&O&644 lal &28}uuu$1$If $$1$Ifa$vkd5B*CJOJQJaJo(ph(h[h>5B*CJOJQJaJph!h[h>B*CJOJQJph$h[h>B*CJOJQJo(ph,h[h>B*CJKHOJQJaJo(ph-h[h>B*CJKHOJPJQJaJph)h[h>B*CJKHOJQJaJph,h[h TB*CJKHOJQJaJo(ph:@LR}uuu$1$If $$1$Ifa$vkd,$$If6\l &l &&O&644 lalRSms}uuu$1$If $$1$Ifa$vkd{-$$If6\l &l &&O&644 lal}uuu$1$If $$1$Ifa$vkd .$$If6\l &l &&O&644 lal}}uu$1$If $$1$Ifa$vkd.$$If6\l &l &&O&644 lal}uuu$1$If $$1$Ifa$vkdj/$$If6\l &l &&O&644 lal}uuu$1$If $$1$Ifa$vkd0$$If6\l &l &&O&644 lal  }uuu$1$If $$1$Ifa$vkd0$$If6\l &l &&O&644 lal      }}uu$1$If $$1$Ifa$vkdY1$$If6\l &l &&O&644 lal  & ( ) * wooo$1$If$$1$IfWDd`a$vkd1$$If6\l &l &&O&644 lal* + 4 : F L wooo$1$If$$1$IfWDd`a$vkd2$$If6\l &l &&O&644 lalL M W ] i o }uuu$1$If $$1$Ifa$vkdH3$$If6\l &l &&O&644 lalo p | } ~  }}uu$1$If $$1$Ifa$vkd3$$If6\l &l &&O&644 lal      wooo$1$If$$1$IfWDd`a$vkd4$$If6\l &l &&O&644 lal      wooo$1$If$$1$IfWDd`a$vkd75$$If6\l &l &&O&644 lal      wooo$1$If$$1$IfWDd`a$vkd5$$If6\l &l &&O&644 lal         zztttt$If$1$a$;UD];vkd6$$If@\l &l & &O & 644 lal         HDIJIgImIIIIѼ{y{d{d{QBh[h>B*OJQJph$h[h>B*CJOJQJo(ph)h[h>B*CJKHOJQJaJphU%h[h>B*CJOJQJaJph,h[h>B*CJKHOJQJ_Ho(ph,h[h>B*CJH*KHOJPJQJph)h[h>B*CJKHOJPJQJph-h[h>B*CJKHOJPJQJ_Hph-h[h>B*CJKHOJPJQJ_Hph ! - . / 0 $Ifrkd47$$IfJ\&  &   &  &   64a0 1 5 7 8 9 {{{$If $IfWDd`rkd7$$If@\""""64a9 :   , : {{{$If $IfWDd`rkd8$$If6\""""64a: < Z \ ^ ` $Ifrkd9$$If6\""""64a` b     $Ifrkd9$$If6\""""64a      $IfrkdH:$$If6\""""64a  " . F T $Ifrkd:$$If6\""""64aT V f r   $Ifrkdt;$$If6\""""64a      $Ifrkd <$$If6\""""64a  H H H H$Ifrkd<$$If6\""""64ainoma 1 Invasive lobular carcinoma1.1550.815-1.6370.417 Other0.7950.795-0.6370.044T category T11 T21.0740.732-1.5760.716 T31.2620.848-1.8810.254 T41.6631.162-2.3810.005 Tx1.2460.746-2.0820.4018th AJCC pathological prognostic stages IV1 IIIA0.312 0.186-0.525<0.001  IIIB0.415 0.300-0.573<0.001  IIIC0.820 0.611-1.1020.188 HR, hazard ratio; CI, confidence interval. H H)H/H;HAH$Ifrkd6=$$If6\""""64aAHBHJHPH\HbH$Ifrkd=$$If6\""""64abHcHnHoHpHqH\VVVV$Ifkdb>$$If6\"""" (64ap(qHrHwHyHzH{H$IfrkdY?$$If6\""""64a{H|HHHHH$Ifrkd?$$If6\""""64aHHHHHH$Ifrkd@$$If6\""""64aHHHHHH$IfrkdA$$If6\""""64aHHHHHH$IfrkdA$$If6\""""64aHHIIII$IfrkdGB$$If6\""""64aI I%I'I(I)I$IfrkdB$$If6\""""64a)I*I1I8IDILI$IfrkdsC$$If6\""""64aLIMITI[IgIoI$Ifrkd D$$If6\""""64aoIpIwI~III$IfrkdD$$If6\""""64aIIIIIIIIw dWD` d7$8$H$rkd5E$$If@\" " " " 64aIIIh[h>B*PJo(ph0h[h>B*CJKHOJPJQJaJo(ph4182P/R . A!"#$%S DdjN  C *AFigure 1bXMGEϽٯ:DnXMGEϽٯ:PNG  IHDR/ 8sRGBgAMA a pHYs.#.#x?v6IDATx^ݍڶ7 IȀ HaR  r*9͞ucIe#?CG8j&˿n]^&k81^s .VM]+' οZczǿ' WMuֻ_}.& 5y~6@?oռc2:;<p9oS⯼;yd~}z=\+']>_@_[_YWM_?Z_YW!UP.㕓r~nc|5~=O{{)u2_^$I$I:bzd~MLK$I$I|I$I$id脥m-I$Io~=|%I$I^5_T&Ҷ$I$IzC:d;X^#Rzd~_׽=1G'쟭 :5+'~m?xݒ;GmkJG_Z_Y߭ޭ,}eQ[ZR)r2V{>ȶ_Gƛء@ZWH땓eg:wO-iٱCk8}Q5׫'lHW]n%-;Ƌ';NhYj^!WO}nVg]X-i1^=q"~F*U )c2wGſ{4vKZviOvgCR1_uL/[ίWWֱ%-;Ƌ';NU)yMDS۾>v:4_ڲ^:=G߳/Ҟ8Ζ\W w-nwפ{?|:]nIˎ"Ɏlyhu@ `{! -i1vm8?eu@ ZݒcF3ZV\W -i1vm8[] -i1vm8[] -i1Nm8 ?e55~ ZݒƍZV[] -i1Nm8 C] -i1Nm8C] -i1Nm8C] -i1Nm8C] -i1Nm8C] -i1cĉ-SlꖴG1DUP)6HkuKZv q"~F*}k%-;v8ΖU)6HkuKZv i;TѲ `NAX[Ҳc0MۡDUs5w Zݒi'gSlꖴLv8?e\u͝`4Ve`Cʼn-k%-;Ӵ*NhY0W]s -i1Pq"~F*;i`nIˎ4m3ZVU)6HkuKZv ޮqoYSlꖴ]~߲(0W]s -i1x# eQ`NAX[ҲcvmG}ˢ\u͝`4VegӴ*N-s5w ZݒLv8߷, U)6HkuKZvV0MۡUY]; -iY4m3ZVdu`4VegӴ*NhYյs ZݒLv8?e@V)6HkuKZvV0MۡDUY]; -iY4m3ZVdu`4VegӴ*NhYյs Z͖1Ӵ*NhYյs Z͖1Ӵ*NhYյs Z͖1ov8߷, du`4Vu۵1N-Y]; licvmG3ZVgW)6Hk5[Z]DU5p Z͖1ov8?epvu `4Vu۵1NhY]] licvmG3ZVgW)6Hk5[Z]DU5p Z͖1ov8?epvu `4Vu۵1NĿul Z͖1ov8GPױ)6Hk5[ZVہ$ul Z͖1v8 ?e5pu`4Vua8NjY A]Ǧ licpXmZVGPױ)6Hk5[ZVہ$ul Z͖1v8 ?e5pu`4Vua8NjY A]Ǧ licpIm}ˢpu`4Vu qoYcSlja8N-ul Z͖138 -W-cfpXm3ZVTף)6Hk5[Z'g^GSlja8NhYR] li3j;pѲ xMAX:fv8?eJu=`4Vu q"~F*z4i`$=18lj-Wړ'g^GSljOi;~[Wړrڎ'Ez4i`$=1 eQxMAX=Io .qoY^GSljOi;~[Wړrڎ'Ez4i`$=1 -ړrڎ'g+SljOi;~Ѳ LAX=Io .q"~F*+2i`$=Ya8NhY|E]W ՞7+8lj-ړfv8?eu]`4V{߬'g+SljOVہDUWue ZIz|i;~[ړfv8߷, _Qו)6Hk' .qoY+SljO\N~߲(|E]W \N~߲(|E]W \N~߲(|E]W \N~߲(|E]W \N~߲(|E]W \N~߲(|E]W \N~߲(|E]W \N~߲(|E]W ׬'E+2i` fv8߷, _Qו)6Hku5+8 eQLAX3HYa8N-Wue ZA{ qoY+Sl kVpXm}ˢu]`4Vg^j;p[:VہUpmu}`4Vg^j;pѲ Sl1v8?e\[] Օc q"~F*>LAX+KVہDUpmu}`4VW18lj-0i`,=cpXm3ZVa Z]Yz>'gk|a8NhYVׇ)6Hkuei;~[0i`,=cp9mǏ}ˢ\[] Օc .qoYk|?N-pmu}`4VW1 eQSl1v8߷, a Z]Yz>fv8߷, a Z]Yz>fv8߷, a Z]Yz>fv8߷, a Z]Yz>fv8߷, a Z]Yz>fv8߷, a Z]Yz>fv8߷, a Z]Yz>fv8߷, a Z]Yz>fv8߷, a Z]Yz>fv8߷, a Z+IY-8IAX+-mY?NjY QuL Zqni .q~VjcRl֊sK|Vp9mǏZVpu`4V[泂i;~ղ6\N$E]Ǥ 疶rڎ'g(:&i`8gv8 ?e5GQ1)6HkŹm>+}ˢGQ1)6HkIWƀ&N-E]Ǥ $i_8߷, pu`4V}e x@;h~߲(QuL ZA1}ˢGQ1)6HkIWfv8߷, pu`4V}efp9mǏ}ˢGQ1)6HkIWfv8߷, pu`4V}efp9mǏ}ˢGQ1)6HkIWfv8߷, pu׷֯ߖzZ/z k?* $i_\N~߲(QuL I?[5(|o˯_1_cNY=Y$i_\NUZ]wBMj֟?._'kQ$+3i;~Ѳ Wpa$z .I~0߹w诏} .q"~F*^GREխsցj|]n$z;>1-gcp9mǏ3ZVju=.j}{Uvz{_=O̖1lj-xIԿýnnzw~t~3fK٬'gz$\Gv8լw~qJ~6+8lj-xI3Nׄ=|tGu?{WWO̖Ya8NhYH 7}?A{5c"}u;?>-gj;pѲ Wp1Vf{?#}C {N{̖Y?N-Z]a|M_7-Ϸ֨{̖Y?N-Z]{>NϺx۟~B{/c~6+ eQWp1 2g[?_ٛli?\NU|U]W '0_nMWns=̖Y?NhYWuE L[[o糃H\NDU|U]W d~5WW`/9v8?e_U)B>{S_N>"cp9mǏ3ZVUu].f0C_}:.z7~εG'xvii;~Ѳ p1 z 5Nڏ? ?.G&?;؋?NhYWuE N揓5?=}ZH\NDU|U]W'iݣt~nmU^z{[҄Ǵ{1lj-Hk}Vw Y٢<}i8߷, Uu].neN_37u{sB{Y?N-|U]W oS'[}=w/ ޭ,}i\N~߲(WuE q"Ϯ{W3nwCpCE?gv8߷, Uu].wg$߫{ߣeνfO^fcHrڎ'E+RE[]r 2Q cHrڎ'E+RnsS~_ܣWw?/,Ng[E?gv8߷, Uu].nNf|:_vD~Mg︯ ~B֙_2{/Hrڎ'E+Rzܯ uޙk 1k8Rm>؋ .qoY"8UM?2{w׺Qcy{Y?N-|U]W{G .cp9mǏ}ˢ_U)6HkG1 w<<?i`~=v8C ]گrڎ'ssK\Nd[pu`4Vptii;~LwΡSl .cp9mǏnyx99~ Zѥz .q2-8:OAX+8_?NP)6HkG1w<<?i`~=@;~߲(pu`4Vptiv eQ?i`~=+}ˢ99~ ZѥzVA'EssK&NhY/u`4Vptivĉ-Sl .׳8?eԹz ZѥzVA'gؗ:WOAX+8_ x@;hDUR)l5kptivĉ-S}k}o9kT0<4q"~F*}s\B_甶uW13ZVK8+t<hMѲ `_\=vW9m]Ua xv w<4cuKH;Ҷ0@;;[:wN%qNi[WpUx^lqB- X;8+t</8Ζ|ΝSp iuS\U:ƀh[PgC>V)ٿUuW?Ua xv w<4cuKx`;~@탫J`lyh9i`0@;;[:wNO_+ \U:ƀh[PgC>V)n_qFi`0P;~߲(:wNOK?g4kpUxNqoYX;|kՄo_ޙl}8~@탫JpB}ˢ9?j8+t<'8߷, |ΝS&2#'m *c ;NhY\EA>,3|v0P;DUU9p XO\U:ƀjwѲ :N?Z@Q} .瓶uWY;8?epu:tl{sJۻJìkiѲ :N{׻{?[ZyL\U:fX;HD;[M˦z`ԽoUϯn[oc2}f *vqB- eS@zgϯP)\U:fX;H;[M˦NMzzz:_խw8uUaV4NԹl ԭq]zW}M̏?,7rgoڏ-Χ}pUxpB3ZVGS)_]}˜kz!}gϸ0+'geS@=u`Y'o-^O\U:fP;DUԹl _O܊I۹1'geSw~jz~Z.\IpB3ZVGS) X{c8+18W[lQ)op{L|ҶǤh _mPnyxEWOԤ~ޭпuϾJۻ1A!Nu^&{ڪלWX+18Wd[lQ)6Hk<&G3Nq2-0po{ xL:fL;d[lQ)`PF[HAu xL:fL;d[lQ)`PF}-cT׀Ǥhfɴ;Nu^g-wL?ÌivLw-2 ƃ&nA2/kcq43`'E`:LtT~iA/+t `6 -R)`PƯ|n+4뤾ɥt `6ĉ-R)`pZ5@k׶ ccq43`'gJAMޙOj:ج &q"~F*a V}@z@xL_K?1`'gJ U5۽xt l8?eP0lPߙ?VfRvIfm03ZVS~VM?瓶wN:6kIѲ (u~z}>g<I۹^'WDU@0_]ZH._[O:fm0}ˢP0 փꏖ{[:fm03ZVy^ ~oI6kIѲ ΥR (T[ԭy/TcpV$NhYRy)`u+JDN:gYLDUp.u@Ir+ҾQYl8?eK祀A:Pjխt` xt `6ĉ-\5`ұ;6m}ˢK祀{4Vcw m 'g}5`ұ;6m3ZV>Z xo]yx6ʼn-`|-s>vkV 3ҶK6kIѲ Rpz5vOiqNi[WcwV$NhYTk)8[i~ir3ҶK6kIѲ Rpzi_5J͈sJۺ/ج &q"-sG5J͈sJۺ/ج &q2-s{Li[WcwV$N>1?pHm3ZV) ncRKp^队[(NhYs0H__Z0JKW:gVm 3ZV) Z/=`nԧcyc~Vo8?e|ΝRUIŵp^队[(NhYs0zg~MIk[11?+jQѲ >WN)jR> w=ws~W:gVm 3ZV)lS&׃ʤjp^队[(NhYsQMz~6n51?+jQѲ >WN) ҽoeR6J `qoYչS RϪ'm `Ɗ1CjX[suu`;{?jO(c8߷, ) N [|8+Q+ `qoYչS +}o}kqniW4VR~߲(s0Hʽջmz8T4VR~߲(s0Hgub 'E\;A:PnUub 'E\;A:PV:J `Ɗ1CjXZUWA:P-}b 'tlU)`0$nGe `Ɗ1CjXܾZUWzp0Jc!,Nn_ت+R'>cTFi۴A(Nn_ت+RJk0Jcަ Bqrj-OVu^ukzgo_Z?4V4V m 'tlU)s+(Zbfo8}`:H[@I_*Q+f6mWky:I$i_FiO8߷, UWέwނ$/(3@'EЩ=e_FiO8߷, UW_|>}4V 'jm[ت+R:_Li@'g`U) ?Zu|ȭzkTfJO8?e:?HUʟ7ǖ`4ΌDm3ZV0w;&Ru[>836NhYR (3ҶfJO8?e:?HẗsJۺ)3c83+ q"~F*0w>)3@'g8zOAX+83+ q"--57i`fJ̬x6I)3`'583+v q2-xzMO`;qP]؃4>Cmnyxskn eFSi jtLw^sS (3Ҷ OcPd[\@甶ui|`'0Hʌ8+=H;8=HӬ86 eQ57 f{>}{ƧYp2mp}ˢskn x?Zu>4k{ƧYp2mp}ˢskn x[=W?Afɴ=N-U)[TNi|'8߷, i{[^sS (|v,kcL~߲(\@SqmVT~߲(\@Q}.瓶updi\;8߷, ڙ`4VGƵYSm3ZVܧ^;Sl x8NA:NĿk` Z\Qة6H w<4z L|kk! pVTDUk` _Z[pVTDUk` JJիZSpVTDUk` [{'pi{WWYSm3ZVWS)`NIR{m]\QgNA:NhY\MNMׁQ85?DzGyw9۽x8+v q"~F*j50tu`|W5ނ'5N߯|pEi<;8?ep5:uPԄ}ҿV}g5+J86 eQz L:(j}t޺5O1^~pEi<'8߷, WS)mv|֭[y!7k/cL~߲(\MnS[;o­eq>㾰8:ɴ=N-k` t>ֺܭwsl8:ɴ=N-k` 謷Ĺ[[~n])CK'8߷, WS)`p=o}폭?Z㲜S_G86 eQz LAMtϨ&{sJۺ~id'g^Rj>ܶ&﫺uNz7~en~i;8?epTZ`4V/3`'g^Rl qtfPDUQkY Zp4 jtѲ 8z-KAX+љCm3ZVGUe)6Hk8:3v q"~F*,i`_Gg:NhYU Kء6@lj-ײ~i'8߷, GUe)6Hkk1x i{[ײ5<=N-QkY Zi D'E,i`x4p"m`}ˢpTZ`4VF86 eQ8z-KAX+^#cH~߲(U~h5<=N-QkY ϭZ~߸C}M\[5Ϲ1N qoY^R@wk<`Q_-6#kF86 eQ8z-KOKG^l} s5^#`'E,tj=#ֽ<խz/ "qڻGYCm}ˢpTZ:5Y#~QA}{U}ITjR4?>^#`'E,t[jBw__{TIWC[7k1xVP~߲(UNpDz|o~n˽ LĞoS?>^#`'E,t+}{R V Q{WC5 }Kcة6Hlj#8S(ߋqxd~^=ޝ_ط4v jt?b_ sq>Q5٭YjY={88_`U{U"_Ƚ,}[gNA:N98K᫷&fdWk–1CXط4v jt?b_ sq>7N[fqտWpK{d>_Y&$N࿻|5Ҏ&r3ڋ-M V}oc2WJcl^Ld[Wcn N/ki"8-7?D[Nq2=x4&$N|5܌dg1^YϚܿX}GsJcl^Ld[Wcn No4^ $-;=?ևvDuYmw?B`pNiMڋILwjM%u&kwH->{ӿ;l]>v]j,91 6i/&q2-17Qǯ ĮR;w;{HXpNiMڋILwjM%>g_9C[ίǾ>gdU?88cen"=91 6i/&q2-173~lhكoS${߾?O@`ȿr_e}cS`b'xsSpz?Ud:^G},U}{fcҘ?^~߲(Wcn N>j¼8IMWm__޷SwҘ?^Zw(v=s@HUpNii/`qrj-Oxӫnr;.U>3kSp XܾZn5jGV/Re sJcN{Wky:ޭƣ^+i_~zp̯̚ `;uҘ?^Zw(W_w:.[ ;91V6(Nn_xRpzu:)m sJcm QܾZn5]xeSY۴8}j}Kc8IZF5K9uo}LX+׊1ڋm}-O#u̥ kD6NR뾖x:R IkZ1׊1ڋm}-O#u̥eg9m]@/V D{Ժi^[܌8+׊|Y;}ˢk1K;oQZnFSkL eQ5Kd>[m]@/V D[^^Mاf9m]@/V D[^\~U͌sJۺ^z8߷, Fs)Z?nMk/^>׊|Y;}ˢk1u`,l}K{N ~߲(u̥A~g|O! k8߷, Fs)6HkיYIA[^3oþY̬ N|-m>pCor~㠺יwH{q:_&gj[&ֽ_˹H̒^gp"=N|-m5a_逹wr&mG`:i/qWk_m0^u{rfI38'~uMնJ[@YkEo>%μ;Dڋ{Z69W*t=AZ?~קY'^įײٿV)w?@uk_[ףm^fH{q:_&gj[z`V|m^fH{q:_&gj[N|-u;`8+x4+v eQU AQ"#I۹JkcL;I}ˢ_mЩwׁQ~Nlݚg~Oi[WpTum i'iqoYm:&?~h|Ҷ;N~߲(W*t@Q@IۺJkcL;I}ˢ_m0ߝ?ZSUz]`gIZ[ej[&վ8+86+l eQU ~h͚7niWpTumVۚ}nyC58D;i}ˢ_mpC>4ki2ԻKb & O8߷,նJwݚ_ѪWո_դYv'EٿV)`;>̯[}& O8߷,նJ~>/A9~I)N-R@=:}p5pV|4 eQU Zo_[5qN3~&9~դYv'EٿV)Mg˔!8qդYv'EٿV)Sgg2[?8+z8+>N~߲(W*td-M|v1>N~߲(W*tMi2&kcu~'m Oz)N-R@V:PjnS59_ު~Pm]Ic|4 eQU <2AH}`.ǔu'v'EٿV)`pkهr\i{W}. eQU ~iY\F;}ˢ_mpÌ eOӟJ۽^Ggp'NhYSy EN:x>뷖w_p::+h'?q"~F*xzS>pܚe:~PI{P LѲ ^5SWkJk'!Ci'0q"~F*xzSl OzCN`DU: p:ĉ-u9OAX+>uE;3ZVsTɯ­߫?e4Vs=D$NhYSy Zekk9Ts=D$NhYSy iG^ϕ^8߷,st|^W\wJ;}ˢN=)`PI˖{rNi{W~YJ;}ˢN=)c+(3m]^gp(&N-:t̨7瓶uWz8߷,s:ҁg&v9?~ Ҫ?{W_{VN`~߲(Sy HM q>'J;}ˢN=)N9~'J;}ˢN=)&gw;kݶc1Ci'0qoYש<tu`̼u/}ΧPIcN`~߲(Sy _mfjp>5 P L[u9Oį&ᷫz7~}Gޕ_PIxv"'EyzS@UUXoj]c>|kޢ eQ^0wWvik8u^gD$N-:A:P^Ǒ_Oz͟[8߷,s@yuG~p>5VoND~߲(Sy qiUwI;}ˢN=)`WqW^&"N-:A:P^Ǒ_Ozw8߷,s@yuG~p>5lN(~߲(Sy ԁWO/Vׁy,J ؤP eQ^0ߗ:0PV\aV8߷,s.wzyLX+U:W&"N-: *+ `vB'EyzSl `fI;}ˢN=)6HkU:ؤP eQ^я_[.~KkU:ؤP eQ^Y'o5ZWVc `vB'EyzS@߭_ZOˎzym^l1fvb'EyzSށ 5SktD_-)m `t1+8߷,s5_GM'wsi[W[sY eQ^Щ :0Clzxv=ϭzW~ޭɱ~ `t1+8߷,s:-v҇Pj|~uOJG;1}ˢN=)SEM'ok+Y59ƬN 6 A&93mtL׸l1fvb'yO@g=0[Ի&UnS~l2ϱVcVh'q"Yt[$}[z~-s<۸/l1p"=N$oN#?(5~mWC>wI&3Nljdm0w䧃%-w]ҹi/q"Y j"έj~T_[o=9~;K:7p"=N$oҤ|U?Fuq1'm ]ҹi/q"Y|u_Gﮯ?[ ]ҹi/q"Yi`% J`xtn23+U>^X+wI&39X<ȁD/1+UHPQ:9X<ȁD/Ypt.Ur KCpDfV'KUHPQ:ywWΉ*A$zi(׼;ID ?TGkդs x^*#J5G ҹM<ȁD/pTܦ@ yQ8tnSr KCpDU:9t>*THP\I:zwGm*A4V|.G!wJ'sΣ; J-HR㠺>sY̐3*Z-wryjf0C:ϨA~l%;~ w^>%;~ ={i`sY^+6Hk%+ 8_AX+(\qV9 S*֟oQ\CX+"c^+?j><>5w No/`t9SzݯY_?qX-9pNu[5Uϯ8qX-9pNu#EϺl}OΩ'`t9+`wt l2|}H瘳-~W@=:}E:ǜo:փu[VMܯL߫}Χ}E:ǜo:D}MLol1|5:uP|{&mI۹-9/W@gNMd)'m H{x\pkӄ}̯ZX݃Iۺ-9^K+s+(5I_ߩ eoU?(|Ҷ`ty <2AH}`.ǔuMpZZ[^>TJۻwH{_z-V:`-)m !9X7̘Я[;9+xtnzkb|V"'<[;/m &׾;XwwqkזIHAGk\QzM/\SX+8t^kbi`*kb<\GX+t><+XINV^r~㠺W·gW^+ I`9~Hó+J0 O̽0n>|,G JKUv=uns^|,G JG_{-z8~KѺ?+?k;m|,G84W@V}:}g}-G1۸X:p^iܯz`V|m|,G84W@G>xUOt:uPԭvH_|vh&-ЩwׁQ~Nlݚg~Oi[Wy^ ܯwi~{ ZIۺ>Σط4vW@a8+c ZC> ZC> ZC> xy;Yi '`;qP]xt}2+^#p/?ZhGkÈQړ+wH'5\Z&&lIPu'jW;Yi γ&򫽪w&{$gRd} k{2>5#I5cF+SHOʌȯ;&!з'c[8t]3+ <]ԭsw ;_ϭu}{_p$fV<&IɬfG~Uv>6^gmO$] Ǥ: ՞(܎Żw$] Ǥ:uo{̯{2އ3ug]$] Ǥ:փ[kߋqbnsc?HY'c[8t]*?~F A~qg:~՞m Huͻ4&V`Gmu-sƯi:^jOǶp$\U+ X'I6In}-|V{2>5#I5ҘX75[?؋~~jc̟/2ӯړ\AU1@^ka=oݿ_o'c[t=tfJL ҁ2=)0>wO:n[=jWpz̔ƙ eF{PzdGY5~+t=tfJL ҁ2=dz{[=jWpz̔ƙ eF{:5~+tufJL ҁ2׻&}?ӯzuԑ)30Hʌb|\_U^gկzuԑ)30{nU}^{:6 pd~M_wDh=_ow#0Sg*`cO8)Kmq~n}Eo)= uԑ)3p1-n}gZ_a2#I|c3q.Mu~4>5!]̔ƙ 9o|[8ԯړpo `4TդyMx>/[|UjOǶ9k18SO{{?dweq[uk{2>5!] IE<:_}WoSԻ+uk{2>5!] IEP{ʧ{S__}2WֿHX׿'c[5߬4^T@O`l[-=Nן;_w߫~՞m sH|HxQ۫[@[ԯ|m/fǶ9kY$iN3=(ڻ8-r_=cZۓ9kY$iγnSb=,m sH|HxQtY{y%m sH|GؿtV@'$[w?+!]9`ұ[M1L_aۺόpmZq GNׄGk}`+sזحNu;kُy_h9upmZq D='~z~ݦg]9x kK׊{ؿtV@VuVVg~"זحzk_uB&?^OזحA>,k|}mZVOזحA',k=?|vح&SYoY5m]1`ұ[AV:hj~ٻp]'m ^-] @Mүo&{8+xt}:_:v+`[[AV6^WKקcc`4Vjt ؿtVl ^-] n>$sJkOǀKn|>֯=krk5xt}:_:v+ 50Z s5xt}:_:v+`P`hݫ1n>OǀKntj=#ֽ<խz8~WKקcc:ҁVDscqZ>/Yow?z>OحNpﭺEν|o~?Χ}jtVc:Qݒ?*gkjtVc:uPx}Rg<*'m ^-] xt V@g=07nS? >'m ^-] xt V@gKjsZOZ>:N=NA}5?.OZ>:N^'(3OZ>:A2',[[pNi{WjtVct|WW?PKۼWKק^'pC>4d"v(u:zCn&/m "]׎ CG{EϏ-!E^'zߺ~n}kq=i`(u: E^'H׵cc`4Vpv xt Vl "]98_Wl "]98_Wl "]98_Wl "]98_Wl "]98_Wl "]98_Wl "]98_Wl "]98_Wl "]98_Wl /]ѥ`4V|\sRߖ~W_W_/' /]|]]zN*`5ş>?+j_5եu2|o_qF2̗u.='0XV}g/c|\sR1___KY0_Tp)5IQQO~owW9ukpKIO:'m /]|]]zN*z|: 瓶s̗u.='\֫ߥ_|Ҷ42vu9jjcv8++ͣ]]zN*JȬsNi{WWGTY8++ͣ]]zN*`1rq_:?8~@<ե:55!>+ͣ]]zN*`U|1kWGT@s_PX++ͣ]]zN*6HkyKIi`42vu9 >u\CX++ͣ]]zN*NjT_Z[QƮ.='{Wi?Z?8++ͣ]]zN*`0N;l_y]_iesRu2;N◺x O-'m J(cW Ԅ{5nSAwnlmpPQ<7e@{ rB5< {؋%y眽Q:R(dtg>|UQ\]uL_jشϺ|!.g|[꣌$@'/4+(sI~-|UQ\]uLE=_x65OhyWUeU$:OӦɹy7 x>ʘIt$dڜ_/m>>\h૪2cx?y%vk#yos_U}1WW)qfr%v|>ʘI Α?,cx[>S8૪2c4t<49T= _U}1WWؐ}6$ST#m[ * _U}1WWšUGsu1I8* _U}1WWx̓/sU5૪2cے2>i,-|UQ\]uLZ3?y>ʘIiK^Rx%|N꣌$@Qy9૪2c_T/{S= _U}1WWd^ry9૪2cGMd}>OX'|UQ\]uLrS= _U}1WWT/Ɉ|U= _U}1WW_K~ \d~5m/>Y{Ό૪2cǿUk4n˒.>W{Ό૪2c(2o-qniI{|૪2c44$sW#3MOMFc<>ʘIt~[FߜuIkK2N[o|qn૪2c65N{Fݏ/O~V.>OX'|UQ\]uL`QՋom۬S= _U}1WWd:2Ω߇S= _U}1WW(a_`q65ϭ>ʘI2_KM[|.z(c:& !M巕~֑7<UGsu1I;aKYǺ_U}1WWšUGsu1I8* _U}1WWšUGy;$@!M^4-[&@nud>k|^UGy;$ W/1if|9>;$@' RV3?7ܞ?'UGyNWUvӿ8~[m.[~$yǸ_U}w#TIN^/ڽп>ުϘG(n}YfKZ z[vp_m5Xϓ?S= yj; Ic?4Ӥof~ɟX˭NxoUg#TINz#yS= yj; 0cIb9~t?z[v`s˙;U=1Pm' n's<U=1Pm'VKmo%V|cN UaMxoUg#TI8* yj; 0aɯK2e/K|-[šުϘG̋_P̃ϚުϘG|mBc TK{z>cNtI TJ{z>cNtF*%U=1Pm':E{z>cN Z^ FsK_PުϘG,i [Ƣ{z>cNcI^$'sEV|cN =gV|3$ #5T5U=1Pm'&3$PV|cNF~B^]n+.U{{z>cN%Ջ`+Y5-:S{z>cN?o5򛌾;:~]>SU=1Pm'KhO#~t}F.=cxoUg#TI~t٦-gj[v<_ɗܞ}L1V|13$p y?9[;V|:U= \B{d;ٞgk[%˿tٮ j[%|݋s|gV|3p db\}A{z>N k{z>N k3^S UaM`FkJ8* ̨zM 'T5U)&05%PfTšהpBUXQN k3^S UaM`FkJ8* ̨zM 'T5U)&05%PfTšהpBUXQǒ_%3d;K\ÒWUfT_MS%ok-i?덅#}M`FkJH4mo~\J}L`FkJ mI+_I#gZ~O}^i~ ̨zM pQiBF~볞ε7)w^Ÿo-05%E [S#\֤3mNm-2θ_-05%S$G'읶K^_-05%n[=qvt~Fg?ܚY}3^S\L?W})޿GGg}|>QkJuI_NWyܳ笟}}3^S\e{47ySg^AO}`FkJ%i=>~ ~~ה316=M~ߧ>05%ŌE]N ה2nOޥOttT~ ̨zM p!YU).]V3~V`FkJ qX^߿3^S\X^^LYU).f,ߗݣujQMIfGL3j8W}3^SpwFTfTšהpBUXQN k3^S UaM`FkJ8* ̨zM 'T5U)&05%PfTšהpBUXQN k3^S UaM`FkJ8* ̨zM 'T5U)&05%PfTšהpBUXQN k3^S UaM`FkJ8* ̨zM 'T5U)&05%PfTšהpBUXQN k3^S UaM`FkJ8* ̨zM 'T5U)&05%PfTšהpBUXQN k3^S UaM`FkJ8* ̨zM 'T5U)&05%PfTšהpBUXQN k3^S UaM`FkJ8* ̨zM 'T5U)&05%PfTšהpBUXQN k3^S UaMǒsK%KzM 'T5gGeI[iЧy_֒~WU]&P!%/-M}FGF垦w\K]n7:ga> q}٧6 %oP͆Ϳi>P-ݲqFx|{cFlHUUױ 'T5s1#O2{CY?N7 f ^x  UaM;d$\;Fq})rfGxUkN kS~\̈Q3o #}8* |OhKv,% %OxEuq 'T5 lsQm|^x] UaM;{3?8jkN kݛը{̕?rkN k᝛\#dڞWx9q UaM;s3%r,[8* |wnWSwq 'T58˝KPwmgʛq$ST 'T58Z^8+{f~LT 'T58;/Ke|FN8*ifqD3+N kq45wskš||49&G3_3}I49&G3_3'|8FN8*ive.FN8*Y_?/_╽s3KjN k᝛.{ \x} UaM;s3%rɏKJšwxf~dZqGM}jkN kݛkty+8&޽|^2mOǿg.n&>>c4|xU5q 'T5˒xf#id\ϙ~FgGmn&~[2>LQ&|{݇fu1DFgG}.x- UaM~]R=F5G|dj'}՛I6X[g~߷){wx5p 'T5gH:ƩnFfwR~Lۦ޴gae%mZyE]š3=6=M7Q捄O&>墨M8* xGWTN k3^S UaM`FkJ8* ̨zM 'T5U)&05%PfTšהpBUXQN k3^S UaM`FkJ8* ̨zM 'T5U)&05%PfTšהpBUXQN k3^S UaM`FkJ8* ̨zM 'T5U)&05%PfTšהpBUXQN k3^S UaM`FkJ8* ̨zM 'T5U)&05%PfTšהpBUXQN k3^S UaM`FkJ8* ̨zM 'T5U)&05%PfTšהpBUXQN k3^S UaM`FkJ8* ̨zM 'T5U)&05%P'T%)s޽sܗv~^3Yzl+zM 'T5gR=lO-3&')fϷdOc4?)K3YWʶ}}K11n&l9ɪIuҕd%gGyd\oN5zKys>9nIߥ?ioٳ+OM5}3r|߿u{y~=cy۲I>]'8nM%A$H<pBUX3 ی?[fϫh74+iZWƩ>>ݛ}o{x~=cY.{[.﷌ug9pBUX ($'>ur h|}dYiަ?6s06qz}Y{,qn5oו6e[6dqv9{o{>;z}{7Mc߫?}8* |t'NΜW&w,fFߧk~^_FX5.Q34WpBUXgռɌv7{y u\69r~4rQ9O?kܫ z6y}'fk}N kl3?<}췑$9:s~ۍ&{||\> # 5\CUqq3Y&˶D >PKrqK^ݙHѓُs'8s~^}խˏ5K>6ѓ#.h&-U?{_̔d{UO3{~^-}b68@~;m[{ez}9B33Ǿ'T5D^'z2g69?O~Pi濾5Ğ綋E$Gs]N/J?QF~T #1yT36[&|rd?q=ז}N k4__ur8{• Fnwt|<|T~d8}dپgݏY _Ϻ{n>f\%scš|"WΞps.@|-GMlk|C xVCg׳lɑl^[2?}8*'}׷ݾQ@N`yur4ms{ljgu'ggYg׳x1 YiBy3`l>9{\ɴ>:?Gg׳ ߫?}8*'}81T+.V+z4ziBާj}=cu6叾h&^\8גWwR>I׶;{gT_9:O#)qqد6Fu#e^ UaM;~wYLuK/m^ UaM;~Q^6|hZ%I1M>ruֻFߤOs2ΕgJ[%5N k6|Ķ_wNƑ-Gӯnljadl2iΑkGWl7ȟϯMng<-P$'pU3,֙m֟*$sWcIFz~_#km9290&oy.cS?}iO{ST?& 9ٓvyD>Yu'^h *kus'L{!ֹ705%ŌMWُ}3^S\L?O}wdD}gfT63~]wYU).K"MgG{w p!iE;ޏ"""""""""B4EDDDDDDDD3h拈g aXo/"""""""".f,̏~]fz&oK3u%ߵgުZ[UkGMpoUI^VFko}\%g~K{jMpoUI7 U&xYL[DqgުZ[UkGMpoUI^Kw~Wُi$V՚z[UktKe~_r:s?U&$P՛ުZLishe>{緿U~[Uk{jMUI5 KGjM=#z8>V՚ުZ{l6#3Nɲ?/,m[Uk{jMUI5 H󽍌O#=H5vcI_=>V՚ުZ>d6MEr?~ XvykF?z%ܒu&kяw ԟ{O5"M\Do:=N-GĶՍ35_.[׀>^}Ƒfx5ngE2&/_g hs5Ӹo?[=O9snU:%nl`ow%{>yExU7[H^_N2W<| <_{ClsѮڴ]F˭X4>XL_H/hghTSWƋޭ:pu܎f>|8=Oi/5弧5vjjֲ3F=4}-Y;wqքȴv5S?Ɔ٭GY4GZYn7 ]62i+&M4;׆EC+?[6J`|ts[O}4_.5eM_R\gGj?0sk<:5jC}>dKN?ĵ?['54L 6Gfk&u'5ҭV=m_@_l4m=oүdGo_VC,|&{F|uHXf_LW#Koͭd<ͱdp/Wǭ|@\{ñ}Y:7i+9lM\̶Idb ZlQџ]L3?~{Rapyk$oX{^Ӹz  R_RZ8i,Uޜ̟)uh?B8'%@grtnԠ>imFȅl.^ޚ|5 hr|&Ξhe2P#%_+4'y G |R׵Whq?v{5>ch׵Ȍ|X L16Z/]#?cc4fIG6Y}ؒfB$Ϻfk]GMے2>ײ{cv<^j=IZv=ه~]7`Ck­%[ >7SccJn׻PM4Un2ZnL[Ϟe06_垯 (n槱YeͭJiBҸnקjnOZҚ}ꍉj?LH>fU3|%iMgAu׎ֈF?_5ް+sv=Tz\n526Zo˚[56Wa6B{kZ=?ovYU59m5gY2[-kM[ϵ9̭Olמ[T[Ǽ49kjdvVޖ5[O[M˵&ֶmFWLsĽS 6[emcv{3o-Sv4)?^mY\VS2Ij-kf[M˵FmJ?̿5{5Cq̚ZɿX2{1,t j<&h}3 .a)vVޖ5[OGqt[k#6۵y?F{Wٺ[ۨv8r *3]&Ƿmϳ6n?drZޖ5ҙFmmmhΨ֗|J3kܗGo4e־HxL>PAZ3kn~dr1Gޖ5ҙFmUOi5{f~}qTfYܵ| ɭz[6KgGU.9D?ڇ~<5Gݺ[ۨ/?3d,/+>b[MVcrj-kf3Mˣ۪nXQC_/h6Zv̑pVS2՘ܣZo˚fL趪%ϞڇD3^&=\*y`7_ ɭz[6KgGfcu֦@f6f/?hfیw7n?drZޖ5ҙmmmc@gǧ4XR.mg2{1,vMFZOK{ӭՔLX۲fY:ӴX-3ec0Y29ZWr7kem5%-z[6K6-~\Rݶ=:63I3Yst[kMcW>Ykܗ3ǻ7ern]^ۧg~VS2՘ܣZo˚fLsf[k#Ɠ=,˟=k]ﳎYVunڛ,3ec0Y2iw[zZY{ ]ִ['kf3Ιmm-lNr=#oYkc3Z_Yۯ[f/~MQ2i<.32}]ȧHTcz\.(l5Zy9Ye6G˚-Yge FZS~-9}s6o^Sit}֑5׶l-kOT_Znce>?ck432=ܗl^-ײv 8X?Nj_ڜUCJGȈߵ-ioY.OMl]46*[M>6Bz#e\מcǢfckǺ5K/I߯cfM|n4c8LdZ{X֎QѬ#vo\T[mMS5Mj<.=fV[GK,SIVC|ӧZ}~x5גF~T28MM43]=G2Zfm~47]Fx7|IS?K#M<_j:wyUUUKAz/م{?2E[F;Ox Qjr^INe_RY+6S}C%i4O>pycCt;|K4:-i#Pg'CZ#_4SIҼoo& `_dMU!ϳ<P6PIENDB`DdjN  C *AFigure 2bLqގQ?l Zg:nLqގQ?l Zg:PNG  IHDR/ 8sRGBgAMA a pHYs.#.#x?vNIDATx^T L@ 01k?zn|,tmY˭?í_n~}wk_K!y ?TCݺu~\Z-_oY_K[ u¯_;MVfrijx ̫-5_n5}_Waz@K?_ztN/ӭ?_t>0~r[ {Op9[SoTp)[۪p .ca>s[[72t>p.cavoݣ{paz$I$It0۩ %I$Ia$I$IfDѝJ-I$I[jíT* sK$I$߶T* sK$I$ߎ8;}_n;KClU| -m;ߗ[=H;0>Q_nx}YucĻך' x8ΝSrֿ֟e]Dw5Ol_pY;0[ۺٖ~g]Dw5Ol_pY;0K|K]Rg>n.Ki"EcĻך' x8ΝSzpkں, {w;^k4ؾb:wNma~Y:[?.~awp?@XI+6 s1__;k__,}n4tk͓Wl<@V)p~_@} e}->__6b߽, {w;^k4ؾb:wN5(_ l߳Nݯ:= r{YH/Kw ޽H#7X:MV?p>އ׺oڲ|~ݽ7۬_o/uYHqҰՍ5lGSէ7vϧk>|m>7wp?@Jϖn<`Ku>n&3k}n8- _xZ|4ҁwp?@Jϖn<`Ku> Zeix; bgKW7:Mt`4ҳaOkRxB:VYXҰՍ5lGS+S+SVN)\ix\tR<" {c۵ ]cu Z͕=N.E'#7]лh5>VN)\ix\tR<" g5nbwѸk|ΝRVN)\ix߃(S[<" g5n+6:wJt`JDqi?q՞XչS 'k5W HCY8Ċ|ΝR+R+R+R+R/ҁbKix|ŞV{2K_4&KKt`Rϊ{37dsy)[JCYqq~V&mځ,6p.>/ҁbKi?+ ηZUjM;RΥxB:Vl) gVJCYiX OH֊-!88jqVi?q6@K8z Z4[-* g5nަbc)RR66BV~WZߟu0WϊM 84ո vcc)}E o=r X_0ޯ\GϊM ixKٱvl^^sS| Q_~׮0e}QYs!xPmk657\L]~}ɮՌAzu9Y_oB~V<(6ZHY`@V榀Y0w]7 P%v~V<(6ZHCY`@V榀韰w(_Cq~ɟ.ín7  {`4?~V&@;_pU)bAOa,_ :+ gŃl4ո 6m<kkn ~x0K,}[<{`4?~V&@;_pU)Bփ= GK+}Ws!xPm7ځxzMR~0|4:k:؇48h# g5n eZ.d@[^CxPm7SX V榀 0[L}r;:؇48h# g5nh/fxzM{w^}:)46觯`ǃl40E{1kkn ~0>=?C }A>@?W=g-}o,)ڋYl,^^sSO;Cϰ|":؃~`ǃl40E{1kkn >=C[Ϫ^ry}Z}H~V& ,6U)b~> γ|{9.Y=gGj|(R57\L]f}w =3.qS׼_{.S@Xz}Y8ۘ?~V& E)6U)̩֗{}Y5_{f:؇4eƤ7_h/JxzMՌK|e}Cpui?ˊI# g5n^bc)Z.jo =̹֗ٮ/r_zi?ˊI# g5n^bc)Z.j>I%svֿ[` }>!.+6&4ո B{Qkkn `ԧߗ5 {תOiG ~ՖӃ}HCY]VmL i?qKתpq%t7˰۽2} ͤnf@ ,𳺬8ۘ?~V& E)6U)ӭ5ܯ28O?o׃{Ԁ~ϺݺRmY[9>!.+6&4KתߖT5\d߻>{-E}n{Uݯܗ-`~V<(DZKX _h/JxzML5.X+848ii[WpMix߻87v%6U)A~Yf\5}LdbRj۵X V榀>Avq>i;WpMix߻87v%6U)`em]5}LdbQҷk/,xzM+J;ʌr>i[WpMix?Ë3GixK߮Hj2̯;Ӳ{pMi?K-( g5nb"TꘛV8T} ?,7]rgn86^ה𳺴x>=)^) g5nb!TꘛVOuK}~=__2gvRV} !q>};/5!.-OO WJCY@Hj|瓶s<" {ϧ'+!M Bl,ꘛS'Ӻ瓶s<" {ϧ'+!M Bl,ꘛ&Z]C?]#׿ 9m]HޥIJi?q0E{Kx:榀]jpxIۺKӓ~V&`!6zuMPC4~}Zkj{9+ix߻x>=)^) g5nhobc)W0Y]s[ g;4]Z<{hobc)WOH xDyx =JX S7׫cn h\۞Gk<" gvY<}o,)X 174cr I?.H]V<s# {c)L^cc)WԎQ?K#~fHX SX 174[.÷G.+9h/ر׫cn hNRCnAҟ/K#~fHX SX 174iG-XKϕ xDyixk/ر׫cn hj[ʯk/;2Cr)<" gvY<p4?rŎX 1745ϭ/;P-υ4e7=@ȍ?;^cc)WԀ[뀭}yi ~k/ر׫cn x.;T]PZuVwY<p4?rŎX 17LP_X5ԯA?뀭}H#7XX{^sSr;O[4ﱑxi ~k/ر׫cn xPAߪ5|}I\Kb ol,ꘛv}]>D\[IYx?)kI#7XX{ፍ^sS@S;F]ԧ;#է][ICYx?)* {c);^xcc)W,;#of^[ICYx?)* {c);^xcc)WФ~-/m JϊIWixKٱKx:榀&(TKԥy\!xP<{k/׫cn hҎ⺔uDl% gŃyث4X{ፍ^sS@vnQ[ICYx?)* {c);^xcc)WФe[u)XIl% gŃyث4X{ፍ^sS@v#R[ICY8/hWixKٱKx:榀fߥtewixc#q^`7c76zuMMu9C|Kޥ}yA JY`76zuMMܫTKJi?qlxR^)qm|wixc#q^01^) g5n X 17lv^]HL WJCY`36zuM/í!v%`F`bRjh/׫cn .[Cm'~ ؿwqNi[WޥxPL WJCY`SI. gņ9J =JXڋ6vyU h^ck}@]]ϊ s{ OI'm_mOH 84ﱡx`7p&86R!أ4ܡ _mH]>[igV5|Ҷ=>!أ4ܡ _mԎQ_~6'm Kix9J =JX ڛXնJM5ԧ﹔Z甶y4 }o,Mpl,ej[&([?Ҷ=>!أ4ܡ _mФSu~+=*/}O(-( {c)whocc)W*4iGV.s]P|) {|B!L WJCYf66R@S;F]K_J]V' {<(۴أ4RU hS띦k}]-;yI6-( {c)7m̈sJۺ' {<(۴أ4RU hҎ2#)m `4xn`7\J{3KٿV)I;ʌ8+yǃM =JX p)ll,ej[&(3ҶI6-( {c)7m̈sJۺ' guYܦ}o,f66R@vqNi[W!.+L WJX p)Mil,ej[f9~'ܖ' guYfRRRKioJcc)W*4c;E}-;yICY]V<RڛXնJM}~W|M!X+y~Vm&+}o,46R~}_7l}@]~i?ˊD-^) g6npڛXնJͬ[jy/ guY+N{SKٿV)~U;Z 9~P]x4es37p8Mil,ej[ֲ=sk}@]~i?ˊD-^) g6npڛXնJ/\jrsZP_9Q WJ846R |wk[zx4es37p8Mil,ej[&(|v/ guY+N{SKٿV)I;ʬ8+Jes37p8Mil,ej[&(3rsJۺ84s{pڛXնJMQfT? Iۺ84s=7N{KٿV)I;ʳTy]W9ixKA_mФ{[Sq!/ pXնJMQriKۿ84s=7N{KٿV)[oup\i?ËD;{}o,816R@cp\i?ËD;{}o,816Ri[Wד𳺴xi(~ o bl,ej[׎Qti(U>|:}!.-GG[{KٿV)`o_;ۿKоVz@\Χo%ICY]Z<kp4?j16RJ5O֟>}[9X4եHC6Hkocc)W*NQxѥyay!.-84kocc)W*,;2;erGM?W.-84kocc)W*,:uٜQ­58\X^ix߻xL7A_m o->>Ƕ~.^ix߻xL7A_m\>a[˺?8aJޥgo bl,ej[kosZou+ {ZIR7mzu9ksJۺ^ix߻xL7A_m5n[.>_j8t`Wyؤأ4kobc)W*ҁ^i?Ëa`7ы_mOH {/M =JX F/6R [ ߐes[HCY^<ku}o,Cjobc)W*,;gu{R~} #Pm7B[ # {c)R{KٿV)`v__o~ݞ܀Go}_w[HCY^<ku}o,Cjobc)W*,;ƣ_ԧyEͷOWt~]Jg}{>` i?Ëo-4pH^l,ej[e_ZS5خ_U׽ܯcg |d}4\GR8F/6RJyfի?SKY/9x4pHWl,ej[4XՌ;CE}cZXɿ`wx}o,Cjobc)W*4z3KEнf\Ӿ-H//gix;x}7!7^mig|B\N]5_ q_}ۛIX xRU @$g {a?6]:'ϰ}ۛIX xRU t?Cn76/~k.gTW]f[^R}~;[v#9x4pHWl,ej[;_kjw %v&7_U߿UYj7ۛIX xRU xP 뇿p{;4O[S߷UYj7ۛI{xٱ+6RiZշG@oس4n7Ժ0cWl,ej[ ;0~;uת߳UYb ' uadXնJ/||/Aתa|{=KCY]V<_lo̯`YuUݫ}\;e{𳺬xIjxٱ+6Rp Z?뇯~4_^ajY2;Tx~̰/س4eOPȎ7^mu-i݌>Q_o|d{tk x\b ' uadXնJ'Rdu3ڋ,~; Ͱ}Z.?tϵKDa>IeOPȎ7^mKO4Nfl׿'KI>w|ˊ-x4kobc)W*/. ӺIηb^?`5k~_D:( {[}o,eXնJR vF{G? xQ#ZvfY.s}7ܗgˊ-`7cWl,ej[jx]q Ri}Y:[?emY|[XuQ.+/=JXʎ7^m˨׀uԎ1:Oۯ?O¯_k?vܟgˊ-`7cWl,ej[֟殾vIo ?_s'?t~17Af{i>ݏujGHz~84]V<_l{kobc)W*|2KY_Bːy /Ss_O}C`rgˊ-`7cWl,ej[>U԰|}iGuo,,C{f}pFix߻x( {c);xRU NoChd~V$5_?Ο}}R{N?:( {[}o,eXնJ'~F0884]V<_l{kobc)W*WOT˽KTu~P]wY|QRv񊍥_m^=˲s|0sN}b أ4X{KٿV)8T~}Ҿ.re5̯ `g;wY|qR+}o,eXնJ'r #79-۷//N x4X{KٿV)8}zo甶u!//N x4X{KٿV)}sJۺ~V'RRv_m\OeSg:x8)7c Tl,ej[2~vҶ84Ikobc)W*˭#l甶u!//N x4X{KٿV)ov+sJۺ~V'RRv_m\~l-;G {Vl<_zQWJXʎ7Pme_6K3JCY]V!v~mˊWkoCguSpz?JOn%i8+Gդ{}o,e!}Y^nui݌8+Gդ{}o,e!}Y^z/V͈sJۺ-_M GRvWٞ}L'a>Jۺ-_M GRvWٞ}L>=]Z7#)m 3;x~5)ixKٱFH_i.) {=7ۨ}.4cZvZP?~Z{}o,Q\ hkZ? }Z{}o,Q\ 'ks!- {=7ۨ}.oZi?CKp46jK_q]z[;W%# .I{ixzS@PCnw?n?9sd̑n }᭴n\1}p,ixKN=)`>_;F];ں4OgI>m]1}p,ixKN=)`[Inت_j-瓶uǔJ}o,e;}QfT|ҶwYix84lO[SS.+ {ǒcpsJۻcJY^ =7zS@ݭY}sKۼcJCY^ =7zSWM;=7 /m ) guxi?+HXv1OP?[iJy[\CzTpLi?KCYGRSy xII ) guxi?+HXv1Ot`~Vx4lOH ) guxi?+HXv1OwZ.SϯKK|w.SҁcJCY^ =7zSW|pu }ί?/F =7zSiYJR_P)sϋ%4}=7zS@ѧ}4_~׿qVyג:4GRSy ho =9% guxixx4lo Ke}}mgXג:4GRSy X:K}:ωup-i?K{}o,e;?o-;G]?~Ue0ZU 96^ג:4GRSy XYv k5 |%Χo%4}=7zSJ=nw%'m % guxix3IXv1O+evjo |v{}@gcV?~`mاa~ k?瓶u# {G84lӭԐ.S-W}G7 8+ix;4?r}o,e;#}rLi[W=wxi ~3IXv1OG?Cu9+ix?H#IRSy ~v-)m Gj7@gc>0c_Os^iW=~VG84lߪK䤝[O_p4n$ {c)۩<ܡ>]opr:{IRSy >5k# e}84lOH GJp&ixKN=)p4HC=L7zSS}-+m x4HC=L7zS@SI;3JCY^3IXv1O+J;ʌks>i[W^!/ {}o,e;_oeF9+`~V=L7zSʟҎ[5tϷ5ӷWi?Kp&ixKN=)` 5gԀ:lwxix$ {c)۩<wOs>:lwxix$ {c)۩<,,~;y-۶M/ {}o,e;4~3oPݺ>>& {=L7zS@|:yev84^3IXv1OM k稡g>__OwcXPgڍ4gcn0u@ݖXu٤!v# {}o,e;>_-۩_ֿXY84n}84lФe8*l~V=L7zS@v8ICYF3IXv1OMQHۯ& tix$ {c)۩<4iG:#m 84Lwӥ=JXv1OMQHۯ& ti?+`7zS@v8Iw7] أ4lԎǭ_na?ߪ۵c~Vӥ!=JXv1OMnn׎y,:ICYM( {c)۩<4)wzt`' g5] أ4lOH ~Vӥ!=JXv1Ot`' g5] أ4lOH 9ixߛ. gQRSy x~9t`HGixKN=)`eT뭴c-v[Wsix( {c)۩<|4ϷjPym^<' g5]=JXv1OM}AjA8+!KGixKN=)~5OsH?9m]<' g5]=JXv1O+5p~mR;Q.SkUʯ_krl}/<' g5]=JXv1O+%v_;P8_4tix( {c)۩<NQd}-V^Χ?. u84lR;Eeset ϫ?. }u84lKԧ;M~hn4OV[.,<' g5]p6ixKN=)`e})5_0í'kGsa 9i49l7zSJ}"?(_۵=~fQp6ixKN=)O䧝%ۭ.~}Mi|Xi?( }u84l ~}a}W>/ksl=~fQp6ixKN=)i(_ՠ[]]7q>i;W3W IXv1OP׺}O[}{̢49l7zSt`# gƉ}IXv1O#}KgcdGb-=*I'=& {c)۩<<ȎZz>TǓ٤}o,e;ّXKχ x~V@84>m ;kPO¿;6=& n<ȎZz>TǓ }ICd#acCixlYyzHCpm ;kPO5>! JCd#QPp4D>m ;kP\G;>! ŏJCd#uaPkY xC\W:V|KJCVe)ߒ{PkY h~o~I oI=tYi(~,VQ~IzTJPkY XI;I-HU~fG ^RJI Iϕ WIsixCײRO;J]G|x4Cl$ {phZV}'p|YU }4kY h~ /Wx4HCl$ {phZe!H,|[uw%( gFVe)+~Pܺg_v^:( gFVe)OSIz7*iX!AixCײФeFS{}^R@vqNi[WQ;=8z-KMQf9m]p&i.+ {phZ̈sJۺL0]V,4iG甶ua4kY hҎ2#)m 3IwwYixCײԎǭodܪeg;ugVe))kk}@]a4$zhkZk pYi!I~OH _" ;$I:cޯ ZaKa$IguR9ۭVWukH >/ {$^_ާ']ުKןKyix߻4$z@}>4KPT O[^,}ҰC3: >/~U8XKea$Igu@O/}k_Yωuyix?KI_뀕[}k_.ks>:4w}δsyG>N:4w}δyk9Z˭/-{תj:4w}δ,;5֚RXӷ|^!` }δNO3zG[|v }[s%`eN ?aSO|^!` }δn4O5{u ~'m >/ ҏ>gZV~vwe`_F瓶uGxD3-#GҶ`{iG9|k[?TJۻALK@|nqNi{W4H?rpM}δ|`@.Sv`{i ~i o%rs'/m % \S3-wOz[?2Ŀ<X059 5qU}kJ % \S3-t`~VpM}δ\G:Vp i?+>gZuν~U;W%4\S3-A Y?9sd\C ϙ5O;̽0?Y& {pM}δ4v۽gZV~vo=b{DDzI{gLKJN~[ֿקi_Ժ?άϙ?ow}]Z[~֣֯x5i@i XYv??;[m|MP8>gZVjx~.wI۹& M]3-+Sԥv>\_&ϙT~u}Tk<&u|M2kػ>gZV~Aj_֏n}mr>i[Wפ! s%`>av78+kҐY9O[Sػ>gZpsJۻ4{LK@ݭY}sKۼ4{LKWM;=7 /m s~f]3-P?[iJy[\CzTKY>gZ~h/|zҁ^ 9OH `{i?+LKPm=Dm+M'-GJ3-+hփ1y@߷%HY>gZV^jo9}~OSn-nO# gi XI;ɬfF~U?k:ڭ~mҞWG G9vYI[|:Ntpi?+LKJ]nfu\5旡K? ~mW{q!xT3-+Zvo]z^ |/`.s7:vgߗ߷%HCwp]}δ(l}:o {_}T?޺G 7Yn'-_ i hҎ2ka5?~v=m LK@vAM~=_~pb}գ"K+0W3-MQf5]^gQoϙ&(3ڃ V/ \}δ4iGi\^珿ַ[=-#i ~s%I;ʌ߯w ue}գ">G`>gZh/0[uuۭ4?rs9Ԏۭ ̳kVY~wuqOM}[#i ~s%yŎu8K?tg{t*>G`>gZ.fҽlgpixϙY_榺SϪVۮ~ߖ84LK/g7pk}Ooi}՞}`>gZ^5ߛ~oߺzg/Yۮ߷% {s9Bު2u~}em^ړ~ߖ84@LK -[~95H} Y̵Ҟ!>gZ>P[הO;ϣէ}ܿ&oH{ɠZ Y#a=m 3HCYd}δhN}Ӣe_A~ }^WIoKA s%YZ}v{ӭo puI#?v}-gz3!>gZViG-Y.O/iiOuA s%`UשW1{u!>gZV%bfu59+ p}δ當yϙeǨZ?6ԚGkܖL+K=A3-+ˎ kuuZ\s:r]>Ȁ+6 4p A@C\\: tW/d&E&XRdnD1c?YWBwP{`'EͿ%3sk3!㉖?sN>uE+xg&)הcv~5Yg\&9qɺ"31_^GOXeuvs?s>~uE+xg&cisf'(S]Ktu'Wj4e=YFR>n]R8~Nd] AF"tO +kwP{¾{$u4ϭ|:cu} j44K'Ml$tuԞi"%(3~|mZ} Χ8VWL#}%,W|_cu} j4xg`n`MX]y_3%u场5cu} j4\iɗ%Yl'?CTGX]y_3>a5R/Q[}xgݓ%uZlQ[}xg&)ݻ#-Y+T4?>xg&?.(#Yk8VWL#d,%].g>s>}<Օ5;=0)^%r~l^fg9pT#՞i'Ɩʒ<-|}<JG8RFIA%u-|9cu%L#d<1]:y3`~|9cu%L#d,1_X!~.{sߗp>}QT{`-3|=dOw_'pT#՞idyZ>%ݓq UWP{`˒ dSw'T]y_CFj4L~_=Q_Rwu7K8>O3E-3#%EH}#+k=P2?%~diDZp>}Pu} g&)H-r>dy4s3o'w<]ji}@\Χ#T]y_CFI);,K4%>S#T]y_CFI)ޫ5x{iiPW}Pu} g&1/3ɹKK7 xq0@Օ5ԞiIɲ9R2s|n.q>0@Օ5Ԟi\Z'?_2.wi>m~,j4Lƒ8ksr%r x@Օ5Ԟi(֮o]zYiPu} g)鯭x5>:j4\>n>9le.+k=;tk@Օ5Ԟi5j4Pu} g&Y׾{<*Ow?'T]y_CFɳI> UWP{`ے|+k=0${+k=0Oߗ/4~Zd}K7l}Pu} g̲,#s).s)Ow?'T]y_CF"tO UWP{¾{$u4ϭ|:j44K'Ml$tu@Օ5Ԟi"%(3~|mZ} ΧL#}%,W|_j4Pu} g`n`M3C7&T]yy3+|%-ɓU-ɇv:@=pŏKFy__= wsԞih I3rm}eb+9Q{XS'ɲ}<+9Q{`'K}`2?oO+kL#$O[Vd~p>κ9j4LN?޵2%:5Ow?'y3yi)Sڧ2??[3yO}κ9j4LaOw_'y3ůK'̳9Nxg]y_g,=YĬw֕5Q{v> +kL#)o}$39~Oxg]y_gniI乖 ίYWFxg]y_g`n`Mxg]y_g`n`Mxg]y_go|Y%s~\lXYWwK]RwRwr~}κ9j4%E~DÒY]Z,ܺ=%~ =|?ݓZpk6|8>OזKiƥ-%,z1ܣ7u}ss#dFiX{ٿs"uqǰVfד{GH=֤G[swӍsx1Yzxyz;+R43ODoNeI]>ϚW8'g u}ssQ[@_۵Q$rG2gcxyz;a~Я@y{gs9pO)gdv~w>#ޥw9qQ>cI cu}ssvV0οwal9 e ^_ӕ5QwG#>@kV$ e~9>߮Lz\֕5QwG#j=ۆ2`ZG9{>ߐ>gו5QwG#>48']y_\w>BGA:/9]??8╝Jz t}ss݃pN}?uS3jdՕ5QsG#t9uur |eJ*2e?99y|t8NNA_ewK?eMا+kGGsQ$߮?ov]y_w>B?:Sw_'W2?kޏY ܼu}ss݃pN}2_ңl}SO|.uy.|t8NNA_e~>Rg?k2>,w``?2?υ=)(+=aI \ #\er=s)9]??8╝rϬnv``?2?DžZna|0#4s(g*]28]~d~ k?=kPQTxߺP#Aܯ+؏o#|'y8Yc%q$>u-|`d;y@G9K?ٻ,μTψ~]~d~~ QR$e_{u?>]~d~n QPY)9;tkGaI}[g{=1+d^6`n`M()Yus XF;iv/Y|Jn_d-{.}u-3ҝ& \fg0}I-1XqkݒWc[t]S| ;)e=C,9M94C;躦P)@"T7%w^E=آC%t)akIy?U۩5[t]S|yֲ5,󳟵k-)>P>v ̼V}HL{gg||Ψ|Y2kIy>ow[߄x]ה~2.s76_4躦0uB2~~]ה/YG/s㜯?+iluM a .e|k>*E5%ۓw)?Q-)>Ȼq;+?>*E5%y2?ו->*E5%nI^̟߀o1Q-)>L^,/l4Q-)>L,y\G?dluM a#kݖGfzx`6[t]S|1}˒5 X?dluM aƌ3#2ߗdW7&s`kJ|~ͳfRK2躦@u[|w,c]]ה%@mɺYnFXf.?4nآCͳo}n!_xE~dGϽR[t]S|c 6~l{o k65E5%¿4;?k2?-viO)˯8%_|ﮞ׎C7&pef>ﮞ׎C7&peGxݹmQ¾qVmGءXS?)^2_'z~;?uu Ǘ%MJ$wԝ& )S_Yǰ%,wvW2?_4$Ku ;tkr T+Zݒ,ǒm?wҝ& )S_%ux'ݹm?u^">F];MءXS2_ΫYu?IwН& )S_,Wם& Ew$ ;MءX82I6`n`M(Sκs5(˒%s5(?;# E~\R5(}$76`n`M()%',Y-V5WO{~ں5#Jdm}iY3q $eI%s=_uIm|MwC7&,N u#>.?Jo(Ie[2q fI QwC7&,)طd)ʼlN5{ ]Rg~2av躦5-)`n`M`kJءXآv躦5-)`n`M`kJءXآv躦5-)`n`M`kJءXآv躦5-)`n`M`kJءXآv躦5-)`n`M`kJءXآv躦5-)`n`M`kJءXآv躦5-)`n`M`kJءXآv躦5-)`n`M`kJءXآv躦5-)`n`M`kJءXآv躦5-)`n`M`kJءXآv躦5-)`n`M`kJءXآv躦5-)`n`MfK~Zߦ$_~I%?)`n`MY|$~\}V2cG RR5xݹnN,cIe3=2K=,v#)s\~.>| Ә?7(fKv;tkGH9^ 쑵ynk<\wWfHt ;tkGˌ{_):y`<1;# %3o~GC"?KlsءX8Yy_eF~5wpx;tkG9Cݳ5)LJ8svr2s9~,sve~.W8*x8╽k%o6IO֝/' I8]n$_O֝/' I(!^ٻ?.$|>]wC7&'xeZuDΗv$Lҝ/' I(!^2Υ;_NءXPuCw-me>;_NءXPuC2e>KwC7&'xeZGfvpfr%?|pnWe~w,OVϕGءX8;_X+C7&pw.]RK[;WNءX8;euZj'ǔ7ve.X/;ONءX8ʻsLe{7 ^[=G`n`M(g(;G,?E~f;# %wo8/SgF~yTύGءX8K%jR̶_k1 +=2?>tYy;tkG{%~k|lW'B1T|@o\g%{gx7|x5gIQtKt3Gٝt)؇cX#o$dn8{{ިw4`n`MYRroɘ͞E|5w~zF¥ s9%>;MءX9϶uMr׷yJ8##u1i\uM ;tkgwi.YVr|fԻIް8⸎Sg:rGa/K|:5s eז|R?eu-5GQ?{zqu|C7&)nY|-eow)g$o8[Ks}sqq}t}}eIsxvOءX[)a哯QK\Z/o NެXsG9⸎eur_\zceMrdq?_z|C7&0[G պM|H\YI[,grg5=uϞ|.k_c/7m>̏CN{g[#s~`=~Էe|#̓[q]+oJxzC7&0l-S[Mz)rqPd&ţ#먟-yCfft!|5aku$Kχm-Sb8K\F7k\$#먟^;-o(zC7&0)v%]l|)]+oǔܳzMG8⸎oLrg%t%(2먷;tk2?k.UfV<;i4#JoeQovo]Nfruҳ}gB#QzC7&0l)uΰO}ט/&%m7>q\ϸLroWt%|^# U>tLE~9k ->q\ϸ̿J{3|6`n`M`_r*)L]/tE򾖿=JQhoQu(?[GءXvmR!K7rk|zޢUPzC7&0tm(Mi\f$,UW?5=k2,ɽEdgW3e~y/eQovgkןR7(H!pqqmz6`n`M`eu3>}q\G\2~of(zC7&0-|oJ{}$6z#먟^2;{P6`n`M`x22;YrkgowSm)9⸎r>ѕ[(zC7&0b?K?c |ں$) =;;⸎RUs-_GGءX^Rܦ33/)vZ/8⸎eko߸Hr[(zC7&0K?\Z$f~;u^YmoT# V)SVux[6[k8#ϛmY:m>e9q{-{o^~#먟>~np審ǜ|6`n`M`x2~x^6f4[q\G\G];ڛu5\:m>PVIRE 침NݩůYfHYGu$jCy># D79TZj)^WFw Z:O>בkQY?n!dZ>I=_`n`M([߻,xQo # eOmkw\}5)c,3'z>sءX82%{}C7&pe7K-ɶ9&`z>Q1ֹY}59Yxe(G?'k#Kd/ تC7&?%^#uIrzg`|;tkrO* [| SGءXsPRY+Kܒ%yrٵ3;tkrO+ {ݒ\csvVkϹcvVK2cos9 9(?uYoy;tkrO,%uj|`n=`zN>/?_+{FÒq>C7&pg1f<# Ye~J|8n[x\|;tkGyV?sQ[xz.>QUXJgΏK|-vK[Gcs՞i5ɛySsu]S]הC7&E5% luM ;tk[t]Sd ~YUc8]ה%<]-mIsdrqu-)>X ߗd0Hgy"躦`c{2fWYf\| ^8T[t]S|/K@pk"""""""""0(>"""""""""(EDDDDDDDD3Q拈g:|2//"""""""">LFekK{Jq5GƚѺ&xnIk󀵶D}Yǫ^xnIkgƛѺ&xYuf{Y-UcXfƧHO)G%_X%󀘬8sxnIkgƛѺ&x;?.3s2xqe9D@hX 8_O^ pfE=o4k {1֬'9|dMv/זK[DL>x!uw`Z?ϲOuf{:~m1?osm<W}=/3?׼'>]G&k R^Gp:H}qzI2@m^ΗKָkȽSIs+nK/S?ĂyL41,۬uEAlf/K'808֓d$z<ܯ3[ %\(׾Y2Eu3[Y {Ƙydk u 64Zz֞$m35yR,1$cӥxk\*LBXnuJ7V4("d1vq xcYPǐk@}MUgI2Ƈk}~wW;ֺTuе@)X b8Ҙd1vq x}Gkrmi=I^ۖsZu= X+cC]kNƜ[6k_tc/ E$ c[^:w3o׀6fr@7mz=|8LX^['Ɓ='zp[uy'ο٘Ԕ=$:iZu,'$y3 5 :ԓ'y;oM്:C=y[z1tZO\w&L.#֎ey=3o;{Nvgu'g/H)#c<Ƭ-v zovkxm8_[ż]R9:ssKB?tdcYngp/TI'@5^hs;6b~LZȭL|jvkĀ6?Y/z.m7PƒZ̯1O_ѽpԙ*k 63B3Trm>^sr <$k^;~Ok~{x) Xr鵋/`v0.m?˯9`05(ˀaqO.;7㲉]\sv.KO^OH1zm38k!cX30^d_|K@"O5d1l-c>f˭댱=:n=ep{8Wc QdvV@G)yK^,_fpIJy=3O,gNU=ޜkCc1`{r2d܎} ٜ$^<}(q!I0uF^o3IH^ձ,X&*p?α~\B%y|ǫ5C-/jzx>RHk<МW3SǛ |5{%Z38w|Ι=3࣍V{.G[;9Rϯo~2~7h2?RЯ,Q? kP̏zk)8QЯ2?3l_O}'7y >R {ǫo~Su郡?Oq_r;pã|>T'PGl$]\p2?vr%KwYcOEJ0u}>dݭ?5)[|^\ז}}Y˶gۻ~A͚Iw維EO2?WrښüPp(.% 9UWՌcJy^.VS,oK=˵tՌ_mx?׬9[=5Hq õ4W+otI1vmm)kKΣpJZ$#Uwnmcu5) 콥+fA\-/TڮUhdm;~k{89yek4JrtRk&n^>W1zɸ?VZ{uKS^3oήZ8R}keHn&ĭt.ys6L)pmr kj7T];rɭJ2!). KۓQvF;'PuoLtq̈́V9ܕn$Ep-?JKotڌ-koܚ]2+/aw|9{$ V̏n#:Z k3/zϲWW&g-Y+#J[1pm[ep~om:lk=\:5|[Ef \rӵRIx.eͶ.mfgI{<6zdu\*,fompm6/.B|st>ƵR2IWߑKJKEuiVeܷ< =6K3/@\K3˷,[6l6.78mr<̿(J$^~G.v\׎2K3-޶A?K?f{w3^i,[6lmrvs㬺tn?HJZߑK[{uܛ=%g)]2y,[-߻ͥo;toq̿6?|kdr\%[-E]nk̿T&[n-?֟? :[߲M!ݿ@qLnktdkY%{uǐ{Gf=u3^n-?֟? :[߲M9]avŵR2ULw䒭e.<ⶺGw 2&Q=׮3mk;\+%[~G.Zn)-ョrk}wǐ(me߳:/}sƥ7 JV1FߑK[J{+ecwH@9K:ϳgǽWm~uFfw׬]nn?HJZߑK[J{ul Э.YotKgg=Ag{sȬ_tIIƥcuGVJ&(ֺ\,RZ{]I~YrKǑGfý׵.]ǥ[,[6l6}돭|Wr.ӵ>ֵR2Y[]w䒭e齥e{]-.;3l.nɥxϲ-lnkחnqLnktdkYr]f'knl ͽ=6{+˺tvKolYqmPmmR{fGnkw6Li?߆[\o\3~oֳKYpz]vo.֞2fO) .euUזMӕЕkf8mefw)_\Ľ?Kl٦V_.s)gw)ul<6DO))\#gW-=_g<)7|]fx@K<^RjOcq7U߀Cz `nv>X5+=] G}.== <8Xȉ9yP:8p΍Lg kk Ѐ$t!0V87`ɀ2A. @JPA#h'@8 .: ``a!2D!UH 2 dA>P ECqB**Z:]B=h~L2  5pN:|ó@ QC !H,G6 H9R ]H/r Aw( Q(OTJCm@*QGQ-(j MF+ 6h/*t:].G7Зw7 Xa<1:L1s3bXyeb~19 vGĩp+5qy^ oó|= ?'Htv`Ba3BDxHxE$Չ"XAP44077&9$An0;T2421t.54ld+s;# V]=iY9FgM֚k&=%Ō:nc1gcbcfX.}lGv{c)LŖN퉛w/p+/<j$.$%&㒣OdxTԂԑ4i3|o~C:&S@L u[Uo3C3OfIgwdO|;W-wsz 17jl8c͉̈́3+{%lKWr[ $ llGmnacOkE&EEY׾2⫅;K,KhtiN=e²{^-_V^Oo§s]?TWީrjVQ=w}`嚢zԶiו8>k׍ E  [ly邟~_Y53rW򯎼^{7so}x>|쇊z>yz7) pHYs.#.#x?v'tEXtSoftwareAdobe Photoshop 21.0 (Windows)wSx3tIME ,g"IDATx^ ]e}@уcz<="Jԩ^x)ZE[ZJGZ%  (F &ɄHfr&s2k̞۞~/^{?k$,/G 6qP @mhE8(A 6qP @mhE8(A 6qP @mhE8(A 6qP @mhE8(A 6qP @mhE8(A 6qP @mhE8(A 6qP @mhE8(A 6qP @mhE8(A 6qP @mhE8(A 6qP @mhE8(A 6qP @mhE8(A 6qP @mhE8(A2MMMdSSSؘӦhCkii?~ڠ)ڒɞkjj:;;06Ti4g]d`mZ[[)ΚdM?~vJ2ǂvccc4IOESh;OhhfIO<)L͡|O5kjh;Ohzm[Kr6gپ(o;vUg(f*)@&S()G(51$rg|ON:zO{}ғ9N8)lߟ;"P}m F)yێu^$)t?T>)ɋfQ d?Lh'ێUkkkUSO@uJ/@QL)%Aw ىG|A9{x0ۦt9;h9E 0Lġ+8{All˶99;h9E VȮyu{??nN$߶:x{XH!;H9;h9E Ti\*d+~wy-?Ę=9;h9E T ىuz|laf"g'm hP1!;Wns.u0~G{mhrvBr6 ExхqN}U?ko\N(@NhjNBvjc{ u0g/a36Sh(@Ð{x_۾]tN(@NhanCvo|]`>xݮ[{m0 9;h9E ĭP8|_sGz`qeO??,/fvrvBr6 EToz)UNm u0g]wdSff-g'm hP 8K<>Hŧ!;q{Eѯԍ{϶)j6svBr6 Ev㥛Ȕ4m3s6Sh(@:_>|;f=<=|ىޡ<0^?ܳnG_UN(@NhnˠY>ǝ\slR*#vGy\w0ѳd0g'm hP1gn? h񩧷ݿ==x?\;wʶ E)@4moyƍO==֣gٞZ03x:8o vyN?қm3I吳6Sh((z#|_Ьǚ~臿, fπѣK6u7\+[<58鳌d$g'm hPYV?pOY5_]7x<7 u0g]iS唳6Sh(:pxߗy{}ЬG'Իl5;z|榽϶ E)@4m` { ^hٿp >Ak÷,=Zqqg%^`>~Þ}6S9;h9EFEm&Ȯx"il,iH$Ȯ[Z7r7IcpBImmmMZ[[ӇԔÝ~Z1yr﫦&0a|FGy^!NVT__-!}+Y_D`V!2XIvRZO?y 0 :r)іYF=|i,֣Ƨ~%}6ylx[/on*^9;h9EFE"Ủ\.axNL<&7쪙XO&8q =$ڮTHh;wÔT,wHIH}?7fIvRrɋQbwi-1onS0kQmɟoD@yo{ƍO{YGݟlpԿOV:x=rΎ%8evsvBr6+ymJNT]Mq'da'Eaw(6f)<W~ܐ4_Tz6OHY\ U:|Ybҳ)іYF7z?6y}}xG{ͣ6%EN(@NQyE;ؔ+=<-fNFz/3Z7E2SxriJ$Ȯ%-~]?(nsW!q%:R'E' K|Jb!%R=>k߈R(ٲG^4ặ텁R]\pG{8>_%;O7gϖ/ ^mJ*P Dv޹OrLWW$w\(g].M'"֣Φ]Zl7Ph^qmW:^k֞lR.g'm hѨc1+@bIzޑ: y a^G3}.IɽO**g׎<Gz4#2vL&u;d"ߡS*N&nE;[u˿eMt)іj?3޵m;O ov^=mѻ]AWtd1g'm hѨ23'yV֙.{GbPԚZ1Ɣ8\UA?4x0S{Kc#;u3䤟}:rY^NR~L,H#c.]g zG"LHÙ83n#G5Pڢ ܚ+zm%.gyׇDR728,q:Ͽ4^SAGax*r7il[.~⁲qusf(jG)")~ϕd'SSE{!%R=ڒgwmw}n㉧zy^o [8ztkv:w~fME섢 m Q4MD:xPǭ #ՕZxIL:k ﱸ!EOd:5$;_2kQmI3W߈( ѯ>Ak݇$*|tv zM{37彂svBr6xvW&atd ?ǭ #%$) kb:y ZðIM$NV&w1 Ikǐ?Qf#+'b<MO;̮-!E_lj;H%ɔgN;$wTG[7" "h9h֣q<w߽:xN~ۯ~w[zmf]e섢 m 4܌,iʍ{0nM$o5/mz$xsw9eۯhp@!fU|N(@NiN_M{TmO<5'X?ܜq"oS=3yfX(y2sm=ENP; ?'yyi*uL~Ev]< +ḕ"z*yHÛKTLwθoY6kQmI3W߈rֿuG/Yoڗm<׶{x=relP 9;h9EFE;{{7N0 |O${N'_r=YK7K魓-PzXYvG"&>vrf]{O||qE_>ȑby*y{*jJ$ykLCr%R=gu 'dQg 6kzXra7їm3G$g'm hшh籸Ev܃oR3^nnmmxYH#l*yv>".m}dUcJlĨ9R/`Iru-mʌS DCR(tG삠Y5s~煁l230TyUyWs_k;m hP ?<;hc?lpχ;{m͖C6Sh(PBC>os©;Tc_e_Gn}L.O#)@Nh@I ܳ{7=am6tƮH{qY^`.n޳~G_MGh9E Է~wn㉧zyW v6.KCGo_{u0ﹺeݑBe$#gEr6 E=Y5m_Boμ8>uH_l9(E)@4mC7ܱwzwiqUyup+? ȹ};d۔798E)@4mBw7-A};屷C]XO:=\?қmSq)@NhD =0[6rzзq[q+=xcww9e;~r?'Br6 ExG3l=lyO~sc_qy:bl9{m hP`,=w 'dQgᄆ>m\:Wx=rgDBΞ8E)@4m ]{k.hc`yy,x_9)/[zm!gO m 6 xvЬǚ{cpO[υ`~E 6'Kr6 ECns©;TϪM1ض7 z}]ql@r6 E*7sg2֣ͦoۙmC=CW,9pւ0^l99{jm hPZ}뷶_6xZG{p`l uuWu:t,IF'gO m 6UUyцN ŏ =}Ƒx`{E`zyfӢh9E @:t^z~Ьǚm/{ס,J6}A9_yg(OIr6 EjPm㯂f=wʣohqpϹ<|<ڛm-9{m hPl6?>֣ƧmܖmBy2]Wu#t> 9$m hPT/o: [:ݟ@l㨬=A;}ýl9tm hP<=+7x'7pjG-}GrGol%h9E @(n_54futށBC6:^뾇{m'g m 600x?Gz^w]'86Gm]A+oPB%h9E @Ԇ_z9od#uw7u8] 3Ar6 EH ܳWztJ:=tg|{vgT 9{(@Nh _6>Au6?6PU]]9)/vײݕs3Gr6 Et߹7}dqzi{_oӗmu06pšށʫrR DC CCnc Xmju0}Gzm*=m hPCݶ Xn_mѣ7v7|gSfUǭ*=m hPC_z9od :bU9h9E ,h߻Wztwdo_?#oڻmoM犢 m 6o'4֣{?}?Xۯ~w-=6U@ΞC6Sh(̂e<p)Au_o]QxO[υ`~e 6U@Ξ[6Sh(̠C?^wzIVdlmo?ߴ7#ڿk0ۦ:sNr6 EPtcۋ*h֣qּ'`<[1[.W6Sh(LY3:>wdK+ΞÃ_3# {s ۦZeKr6 E)uwmju0=ܓmSrh9E ܿHݙ,Gm]A+oP4|2h9E duও_t*8g:.y99)@Nh0)Ut]Y#u0޶6UOΎ m 6W$g?WZ*t\kn'ٱP DC`,YY$g8=9eM+E)@4m&+6>eANr}_e_GοrÃ6#gEr6 Eq^z~%ޡoyac{˶qrvtm hP(H~:ғ_݇v{gGnX@ $gW E)@4mQ,g٢2;Pmju0և{m<9z(@NhT"9{ᅱ G.kv:lyUP4kY쪢h9E P }%޲S7 u0g]s2{Zjh9E P . *v>elၳF`>[wg0UrvR DCdEs\-+?C?|ޕ2kw-{IFOήN6Sh(hُeg֞^7)vE{Cjv UKr6 E2 x?; |x=r̶azjh9E PvbS9pUK |yφ}6L]m hP*M}uSl ŃGuUGyZ,##gh9E PI Ern֕5~x9}bv)$m hP*F7}$ _88wz4l6MJr6 E2D [~譗:lJg}:9 m 6@(7xڡ͵ѣ6t;2:~kp(ۊZS'ANGήB6Sh(:S$gyInm {x v^1{Fm hP6tW?O5-x=r>{m{m(59m hPU9opC_1)/{zmr6R DCTulܹ{Kυ`~eW,d0lƢh9E yƧ+us=| ^ήlfM6Sh(:pᗜtSٽ{ܦ ^^7ۆٔE)@4mR)m.=ts`VOWu 8gvTlʄ m 6@I\rthr9{ˮOݸ7u8ّ)6Sh(ӷ߿T|~ 8zoܱ:d=SI搜MYQ DCzuPT,tw\9)]w=$#1)76Sh(Q$gw\8bko}jvlʐ m 6ٻ=[4x=r.mMyR DC= L0gg/u0gc{_ )[6Sh(S{׃Drџ?uUAWw,pd2+Iّ)g6Sh(U,glV?w:s.yC}bvlʜ m 6{u?P;x=roLVf-9h9E 0QBT|u ^w?7ۆDAr6 E`B . *v>Ervpt#zSfUmkM,m hPW4ge#ll:rɁC=bv m 68([D{^ڲ?#s7}dSfW9(@Nh38O;Qsv@G~2wkO A&:6Sh(c|ξ{Kυ`qeW,dPlbh9E 0"9S\l ;mr6R DC׿㭟 Cv:ǟz۲ujZ|:O޸]6T9x)@N5448illndtWd---mӦh }#aN9{p-tqNpͮd"DMr6TmmmŖt&655$;7o^L 0s~x̹M{_ͮLr6S U-ٵuze]]]vyC[[[W__\?s6@Hxi~(]/޺/#竷w:KΦ(@NцYSS`dnNďN7o^vy'w]E 5tѿPxio^β\`{KwKE 6Sz:1#OoJOE2"햖IE 1tW?9{p뎼A&Y,KSl* m^ڵa<[HzjQv6@ O9K u0\ezRl* mRyϮ-ugΏyiȋjbS,g?e;n竷wz|}H咳06SJ5&Fd'ښ\|E;v di/Kmju0zQl* mR陯cW$='I5<'Jl줮ngN)@:pᗜt?e ^s޷@׀sfW9h9ETzXE6]ܜ]5#d555c|jm:k?_.y2ZT*E)P`Ԕ]D.#=d7B^?1U{o;ޭ{Ql* mR3T[ZZӕJxv^?dWTݝ[ANxkwPwMeS U.X:?:=@;Y֖?QhU9g!;"9mW}N]]l* mR~2dzkbR 9|o]$Jmz+_t.]P5l mRO4"jDڱ577'+kkkˏ%֖];U6P%~ d'3G{6eSMl mRiN̛7/jֺ쪢s]M0mE{oBv:^ݱpÑT%9h9ETgggzQu޻'/N﨡!AN'g/NΦj)@N~ӆ$㯇T[[[]%͛7)Ss=}Sӹ9g ]_~NMUS DC* ]9=uVlVSl m 6PakANy R 6Sh(@%iۂβ+Sf!h9E TK֯y˂L3Z3[r6r6E)@4m`󂖝NYu" Cr6 EC _}qвY Fr6 E+K/2,:"YlM6Sh(Xsǝd> Lr6 E};W? Zv2ɕ;ؖ-0m hPYֳ]7ANfqni*#gÜP DCfSPXtEANg釯Qel+6Sh(lZANg+AV'9搢 m 60kV_xOzvg&r6-E)@4m`v-0m hPYе%hɬ?_-Pm hPO~m!gCyR DCfw_t eKr6 E( nBv:wܾ#" Lr6 E(Go^-;'flAΆ2h9E С<̠e'6ܴ"[Du)@Nh240esg-:E)@4mTkANgᙟVPl m 6P_YӹEoQl m 60}[_-;gmە- E)@4m`sd>MQl m 604e" 1R DCc9ANg? )E)@4m`V| dӧAV9h9E LMۢuxzвYܶ'[D!j6Sh(߾wo!hɬ}K}uJ'gCm hP\w-;{.1[D(@Nhh%AN'>[A2(@Nhrt]}"* Cr6 En_I/ Zv2+fhr6TE)@4m`:Y Zv2xzۯQl06Sh(D ,󃖝Ίޜ-Pym hPX!;E4f+hr6T$E)@4m`\?t{ET.9* m 6PܦV}iAN"* Lr6 E(boۮڠe'/ۺd}%gCeS DCwtlKΆh9E eᙟ Bv:o * @r6 Eݟ>,AV<9 m 60҆V;aOgj?-BP=m hP+O~MвYo[1[D(@Nh-; nQl66Sh(p _ dݗf+Pr6T!E)@4m !;E^XiLΆh9E pϺ_d?͇:|d%j)@Nhviz[ET"9 m 6{gYANgՕ-"* UNr6 EXX??,y׳T"9P DC*wW!;EP(d8r6P DCjw;Ԡe'sҵ+[Dő m 6T:UAN恧ڲET9)@Nh@u9} -;ǝf8r60 m 6T8h,lG6Sh(P~ d茋|dm hPڬnN Zv2wiIFh9E UeGV=AN&2)[De(@Nh@8uMвY)k[-@6Sh(P% ¢3. Zv:K?|E"g)@Nh@XANg/iIƥh9E `5G4Ȼ^0`w "gh9E x+̪^ձlD&Hr6 E*[׾e'S~Y "gh9E ןyΝ_l`Rm hP-y7 * L m 6TUW!;egQ)l` m hP"m_eSZv2+O~ͮer6056Sh(Py^7-;uǿd dr60e6Sh(Pa CN0h,"* L m 6T4,|'T 9&E)@4m$+t|}GzET9>E)@4mڴ)/Zv2+O~͞"* m 6TCyANf miE gh9E `h`hqAN>[DER DC 輯!;g~&[AER DCw-AN/[Dlm hP j[_-;g޶]"'g3Ar6 Eup{Ơe'ImmU Q DCH --;o?996Sh(E4!;o\R DCANg + 4E)@4mNµxzвYܶ'[Dl`(@Nh@\o߻ٯZv2k҇n_-"rr60;m hP "}K^eso""'gFr6 E"h%AN'>[Al`6)@Nh@,m1,yELf m 6DW}K̊g~"b&gOr6 E_==uANOo[6[Dl`N(@Nh@[-;_9[Dl`(@Nh@[!;E4f+ !E)@4m(g?t{EDK斢 m 6MZӂ̽yEDK朢 m 6mZANf͓_ulђrh9E e-hw-"%geBr6 E3?tlђh9E >,ANʊ m 6 7Xw(ys<~ [Dl(@Nh@س}ɯ Zv2mwm'9(C6Sh(P&sg 'E)@4m( _ dݗf+SM搢 m 6e6,: OX}ߝ 6Sh(0pϺ_d?]{g 9E)@4m[?6A>+d ?E)@4mCz՞tV]ْ-"Br6E)@4mC !;%F@,m hP`yANg* "b#gQ DC9jвoו-"6r6E)@4m}k]uҫO{ce DGr6 EfY^0/hɬ?,9 m 6̦B-;X-"6r6)E)@4mMK?|EYtE> 2Rr6/E)@4m5k[S]7G:}dl j6Sh(0;v~d_d+EDEbh9E Hgݿ7ANfqni@P DCV(qQвY+EDE* m 6̴XtlQh9E 3o/ _09$6Sh(0s큧"hɬ:Uk906Sh(0Cu-;uǟwg TE)@4m 4?t@ER DC}_Bv: g+ T*E)@4m(UW!;eg 9`6Sh(PZWlY3ʓ_{Îlʦh9E %t9hɬ;%n'[D$l)@Nh@zaвYkEDB m 6w_tS "!gUBr6 EJbۃΝ/MQl)@Nhd --;oQlE)@4mE4!;o\'g$m hP`RV| dQl m 6L\ۯ|Ӄ}z]="ʛ S DC ڿ}g>hɬ}K}u&g h9E 17 Zv:|'"ʛ P DCX4 d\#)@Nh dQlQ)@Nh@qݾz^dVoߛ-cQ DC":Y Zv2xzۢu"ʘ P m 6o~gвY՛E198E)@4m7.,:1[Aƥh9E Z doh`([D&Br6 EFt۪O:-h7ܹ?[D&Hr6 E{v>>hɬy˶.Y-\h9E -;֯,[D&Er6 Egw~-[A&Kr6 ErwANgq> Sh9E 7Xw(ys<~ [DYFr6 E{6<5ANfS^"ʒ 0e6Sh(wtV.=[DYCr6 EANg/VPliR DC-ANgK., 4%gL m 6l ;%ANfܵp#g m 6Ucc+-;O=c-"ʏ P*6Sh(TC=jZv:lQ~lR DC:-t\lG(-E)@4mвvYt B2#g m 6뗭?e'sҵ+[Df m 6UcNzUвyx쾶leF!6Sh(Tw`^вY)Y-3Gr6 E*Q(,Qflh9E @X+΢3.iIi6Sh(T5- ݿ$[D9f m 6oV=AN&rGE9`v(@NhPَtvdwʚf('r6Q DC Eg\t^ter"g&E)@4m*,Bv: _}qr"g2E)@4m*ժ _06Zvl٧h9E @Ez쾶e'Wu}4[Dِ愢 m 6k_KвYw뚗g(r6\Q DC Oes~ؕ9`)@NhPaANgaleC[6Sh(TUW!;eQl9h9E @ؾb꧞dVvd(r6@9P DC28ydu7ܓ-<eBr6p!AMMMcccvtvv&7o^솩RE^t}lA(6S577'&okkK.uvv &Oɞ @XK7|:[Ayʊ mjiή^+˓ښ0mKKKvm)(neBv:wܾ#"ʀ Pnm hC쬩I@04#i?~vyZZZA$ehm6y˃ʓ_gs{2 g!E)P?LOoJOE2AV36:~d֝pƟf(r6@yR +=@6t~`A%gP c ]d~$)̴",ӏ49!gR )D]]]msssvRQk[:AӳHY$gS t2%h0sv𪧿2h$W\HY$g0 mMhϟ??0홠h0CtvdwʚfEr6E)rniiI&;ɮtmfBPXtEANΏ^-bh9E6o޼jkkم K)3A`&, dg+Er6RMUljj btIeA(ܪ _0x:lƢh9E~-=H̟??/%hPZ^dWw}4[l(Br6dZ[[`OY96%Ե%hɬ;u˳E9m h3 rL t7NSSS}}}CCC[[[vLCcccmmm#6%h05ۖm\-;'fl3O`m Q]'nl_ j?ps Zv2N8mӭ+E<9PFuOZZZ7o^v4dm&kh`h?hE<9iRFuihhHF=Hsssv4dm&k۾tl3O`m Q]\'kG$'&*%h0)]zKYӗ-b t7QKKX jllL~LIEf()Eۺd',hۺ;[ (En0gٞ>siR;:W'U"f @ )@Nц544477g&>%h0CCK=ANgÝɒ(-E)0g&a)LĢs¿|&gPr6Sh(),zE$9h9E @q[Z~mYt BR(76S!4hrhTu7,_wK罹kl&gPm hChxnhhhmmn`)Uccƫ꧞}Ŗl&gPm hC(-N0Rnm{gYANfql&gPm hC9Fʐ P=Zv:K.fR(g6S!xLvrhT;?zUYt| (s6S!|#I^lq-;ue()9h9E P:>W-;?-lh9E Pz󂖝NY}l%%g E)PzMMMٯ()E hвY"JJ "6S_QR6@[+W|ԧA9(@NцL~f()ERn騟yM#"JG :6ݨ:MMM mmmUO2 ɏl_ PvOEвYW\Hґ t7KSSS#0Q[[]Dӓ틒R*ϑήNywf(9H)@Nwק?S--- ̛7/y}QR6@) θ(hѫE @m Q]QO<ܜ< پ()E, dg+(9)@NwN466f׎IOXMMMU#JJ$cO|jNrըeL566&?&$"m P1큧iƫ;=-Dl* t7EgggcrԳlOX94)kởe'S5/Q"r6Ar690Iٯ()E O@вӹbKLb(@Nцѵ?3 OK d?Dl* m 6@V]t[zE @Q DC#7~ANfɯٽaGR<6S4ZZZ͛D%3Jס_-;uǿd d(9h9EBd444$655e)5E RE^tu"JAR)@NцДv.ٶ9LI)ZBv: l gPm hCh:E;ݶ6LI)1jmANwħA @eS ?b=ml[qS^dZQgs{ix6S!4RSSMv]K(q9~d֝pڦ[Wf69jh9E6o޼jkkم K)3At"MJ(@NѦuvv6551$ڲtm,zۗ3?`l mL#2l .%,_e9h9E2Y,كE [[-;}[wg9jh9EQeid)e'ImmU鑳B6S ](enh`h'hl#gPm 'A(=vvrhE4!;l#gPm '(jkk_QNmr+7!;%p@@if60°@̚iK!`eX:Xz 6^.!1aҰ>w sFii4#̀ $.F^9uuy=S:ԩӗwL*CYׯ1ZvL聜 SLц[ZZJmtMwJ-;s+$z g d6l}hZvi= PLц>Gl@_)#hOBv;>f9"Et7&|VKδ҃#6RFez)dDZE=y4n)@1Y`zz:-=S7i] 0R~CלRc^-4nPhd?tE\i] 0:^[ja\j;ItKEt7&|5}tuҺ+E`DbZ ffff;655oVD_)#b͟,8v3iݒ)Et7&JÏ6ɻxtRF祐Si]Et7h^Me>s)ڿȣ-0.4І d647??.ll}hlj?Y{leqItEm SL)'<ڟ|;M+r6lJ2E E`P q|g "g@'m SP%j)dDZ4^!Em2mmooiқ4s6)@e(wo≯)0=7.MblEmE$9h68缽Բ I:9J2EQOӢ4Pl_ qWEm(?&fff DQiǾR q84-;6)PV`zzzii),ImXXXHW6555;;&Nj+++i*}h ͑}GRc3|ΟIl ]SLцZL...Eڬ8mii),I+E`8n?rRw7>Mbl腢 d6*4gh#aZL(CNԲ8z9/n#Em(NTzviqN N/m!X?Zjqzl SLцtLhzp=6Eǎ> #g@_(@hCYٴG^=;;hUA/{sJ-;KuIl h ed õKKK2h ^Uja\oGi[!g@)@hC̆tᴵ3j[nzh {o-0uΡ/L 9K2E˴֦ΨUtRa}}}Zv~_Il }hez}jj*]\\,H077imm-0-mA/BvħAvAAPLц&VVVbn433SӼ|oMm;M? g=ItLQLцffflvvWVVJ;0<͠m]K-;[ݘ&19G2EY[[[Et7h^<݅J/Bv{L耜 B2 XYY?,VD_)ݹquR'ݒ&9 djsvE_)]{/7ZvG}]&9 dlg򻔤uW6V?|jK>Pjq\It@heh/..jtEg Jتl)dDZ?H3耜 N2 `qq1-ڢ/Jؒ?v)dDZ8O씜 @2EkzZE_ й~pO\{]ߞ&9F d62#C{3Xjayi`t(@AJ1wfmN:yjWjq\$6#gHQLц&fggÏɮGQ:㝟)8V 6#gQLц&two}Dԁ}z4lA6)B_ ^mǑ?R_{HhKѤh -Ũ.w&?bJh[R㚳Ͻ$ڒ`d)@Alty.t Һ+ES'Oz{K-;>4le6nPt/Һ+EX q^4lq6nPL"R3(8v'<&њ O2 jZ1ً.Jhts^epgDkr6T d4177~LNOO/..lEߴ$RJO}]eqcλ~pDkr6T d4~L[QmJ(:]/xOeqg&њ hMOOwW/J(ZSǎO&g@(@hCs---W6@v٧^ qz{O<&т h T ;9e[i-PE6)@e(?_[ja\j;I g@E)@h&;,#ChRȎc9A!gQLцrzz:]8 N_(774~M~oD9Ə d6oIўE{m`[xkJ-;C}ōKh gXRLцiѮjkh LZvW|;i lW6)P6!]8mӢ=;;FG{m`rK!;]|A9Ƙ d6---Z-]оhkt}hb—K!;^&qn|E c@2ElM.~ d4??m`YwQ/)0=ięl{6)r19;;_ݴh? 2i}hc#7_.0z7>MLr6LEmhn~~> XZZW6,..qBZZh~[eqs^430!m S;455!I?ZjqzIɡh ,//z-vI-JEc{>rQ)dDZ4Ȧl(6)ڰhzzz~~KC=z9ƥϺ49& d6lA^x'$-eXm`,vOxUeqϿI0m SPs.y[K-;gs;$ lL6)@e(Y___=#]J(`b)@hhcfX qHIh T C_ /y[@ir6L8EmزZ8777!ۧD [U?Բ8Wz4l@2E^/,,%333kkkihKuAeqsxoir6(@h3q7S3333'h+KK>km` xŇJ-;=(M49m S8KKKMtXijAXiΎDQ1Z qi@h$a4??u\}nƒMFwm^ݦwmg gE6)LZNMMuq~L!o=??W6Pi7]&y/#7IlEm&b)aήaf4}s8H؝?7ZvG#$6@#Em&Q,ԋr[Y'nڃhȧA{aeDZil)Em&N| t#+MeG*j>_ q 6@+6)L#h?1$UOm|\d@(@]K!;ycI@[6)L# g7 T΍;WZvW<5w|4 9، d6'LZqrc+hr^Ko*0<ܣ؟&!gPLfBkqf633\@(@?|jK>Pjq\I@gm S8G`VKi+++̈́O7[h]-8V_ir61Em&N|u۝O7[hU'.8wxA&r69Em&B8==3ɬJ*ᆽ? מ4{W'iē-QLfwO >;-DVVVtRw߭\7ZvG}yE4l`m SDr\677q¦tEqNZv~4i@m SDZmjj*,loff o5E L)dDZOOḧ́Z[[4jOOOwjzk*EeJ!;H& tM2EUۏ4k쵵0w2m`dv1ZvڻxG4l6)LAG[XZZmˇC {oK-;k~ٵ>&M69葢 d6P60NrQ)dDZOh T =z9ƥϺ4ihRL*CC7|«J-;-W(M$r60m SP>:~<ѳ9i$Qh T )8vi$h T .Bvd? RF d6P6A^4ib@%(@hh]K-;OxmoJ& T d6P6У.}ѳιiĐ QL*Cz,8|4ib@(@hh?-8V_4cb@(@hh];xw~=x4i2@)@hhݹiW=ɧA^idRL*CpΟ{K-;#zɑ}idRL*CO rIw~&;9K6)@e(@zOCeq^WINƕ d6P6ʩv}ǥ8Mwr60m SPVv3?f;9o6)@e(@S>J!;Hƚ =Em2mQmǑs^eqɯwIcM& d6P6Pr-O{}eq/?]&596)@e(@ѩv轥ez4l`r(@hhE;>] q^4cDQL*C?RȎc }iIh T Dׯni{n+M_r60m SP~ÝRǜw4i|dRL*CN>xr ]jq\oIK& d6P6zJ!;o?ӌ%gL2E E&ez)dDZE=uT4l`)@hh$9Rc^-4iL6)@e(0RϿH4l@2E E&CO~oZv>4iL d6P6L7RȎc;?f)9 SL*Cц t'..8v}ir6@ d6P6Lk#ni=vo4lEm2m(w~Rc_qIHhh T y;J-;?v4lm SParJ!;l1lVm SPaB\Bv;^ l6m SPa? tcir6@{6)@e(0-W<5ơǾ}ץIcGؔ d6P6Zv&96)@e(0V_Ǯ}>;r6@m SPa蟕Bv;νp}}=M/r6@m SPa\YwQ/)0o9vOӤ"gl d6P6ۏ|/Բøq|&9`m SPag[ja=뜃}7M/r6@m SPaǮi1^l(@hhØJ!;X~ 5Em2m'W=G:ԲøY'=&U 046)@e(P 7c_Qja\[ҤꓳI2E EF{/Բ8siRCh T #S;yeqǿ&U 0|6)@e(0v볥 ͨ>9`[(@hh([oBv{·H*N.6)@e(0~}ړf$M89`)@hhh{.J-;#>ڿ"M89`{)@hhz _Rˎc'7J-;gs{Ӥ& d6P6l>XjqEiREL2E EjX}BQr6SL*Cц-9xw~=x4 lm SPs7/Բø_}Ӥ*m SPCgԲ8ھ4 l"Em2m#yޏ}%M9L2E E:W)dDZO3@H2E E6uS q}O{0Myr6%6)@e(ލ;WZvW<5w^w[4l)@hhC~eRȣ7I#O)Em2mhS;g_jq\I#OEm2mhe>[ qK3F @6)@e(ڟ|w>tD4lSL*CцF?upO\{]IM`S6)@e(Pr߭\7ZvG}yE4l:h T E|Wjqr4l:h T E;OJ!;72mr6SL*CцlE)dDZUOEm2mj;\J-;OxG4lJ2E E{oK-;k~s(Mar6]PL*Cц'Zv}i莢 d6P6t)dDZzҌ&g5Em2m&F)dDZ9y4iTB2E EI|A4iTH2E EUORǜw4iTN2E Et^Rˎ4iT d6P6iOBv;~s1Ur6h TRȎc׋{4i$ d6P6osK-;O{Ӥ$g_6)@e(Lxǁ'Բ8/ᮣiH;Em2m&CO~+8|[iHEm2m&Ϥ#I`@m SP~RȎc?A d6P6ڿȣ|exݛ&9RL*CfymW<5Ǿ↽OF )@hh3N<羣ԲXoIG`m SPoRȎco.=r6áh T~?<)g046)@e(ڌ#_ȣ^Zja\Ko469'>@?(@hh3-M? /~&9JOm SP?'=9o/8~i%M1r6çh TY](8viƈ6)@e(ڌ=RȎcǹID`(@hh3N,;򨗔Zv[},M%r6H2E Eq5?_]ja\o>PKF RL*Cf<g\eqs^4il;Em2m?Zjq i(6)@e(ڌ=AEm2mWw=Rg]@}> R`t(@hhSiԲ oGiȐ)6)@e(T{o-0uNF QL*CѦw?Zv?4id Em2m*j_(8VȨ} hRL*CѦ}ygOW4i4,Em2m*+t/0>U_4i42Em2m.巔ZvG:IA`)@hhS!|y,8޿JF SL*CѦBvOK!;م4c4T d6P6Uq~=x4iT d6P6p+K-;+շ9Mr6h T;vO=ͥƑG.KF @(@hh3> K-;J4l*G2E E?W qӌ gPE6)@e(ڌ+RȎcs~؃iv(Em2mF֍;WZvW<5w^w[lK2E Etm^]jay4iT d6P6#S;g_jq\IMm SPA;RȎcfl791h TͨYoBv{·H xPL*Cfp?RcIw~&m+9h T{.J-;k>ڿ"MVr6D2E EȧA}ǾO-IJ`(@hh3"vBvodlƏ d6P6`E)dDZ5 )g0m SPvG~yƁz;Ӥ#g0m SP^|Բø;Ҥ#g0m SPF'O<)8.Ӥ#g0m SPF;>] qxfl9h Tv3(8v='O<&m9Ih TͶw54O}=7ݕ&m9 h ToS~Բø1]r8M&r6C2E E!;]/xweDZ"M&r6E2E E![\ q4cLEm2miߧK!;]/z禎Ҥ g0m SPk}-0.p-4i;L&Em2mqɯ-0hl& d6P6CԲ8oIA`)@hh3oRȎcOӌ g0m SPK?qq)dDZsir6(@hh3PkG /{4ilm SP;'Բ8Wܰi)@hh3 'xpsQjq\/S4tr6d6)@e( ۟K3N"Em2mRȎcK>| %6)@e(ݑ]vQ/-0=M߾=)g@#Em2m +o}4\r64h TM=xy{eqK+ipЊ d6P6}:P qzӌᒳ Emj|`jjjqq1]Ekkky=RmeGqﮯIC$g@{6)0閗Z-\\YYqB%a[]U+6}qdyߑGԲørci)Emh1gOOOs\833.w`mmmW涴6mzw5?_Uja\o>uLN(@hSSSƷ/--ŕD}yEg\eqs^4il萢 d6L A㻂,,,ī[_.V\ZE f SLц_===.7 :0մٴhjLR)dDZA%6)0ڷZ-[e<߭~w\mwuNeq.x>O`m SaB-~ˑLڠ5E[hӝ[xVja^uC4,r6tA2E&\mUkIE[b;7hӅ Rf [TXNt7Uzo''l7 AXCR - tmsinnq8!I>CJa=\U AD3 <:_ ?r`>Em2IVqǜWjaxʯo3M9!+oQncWr-6}{b뜙Vy+o/>Mv*p֕^Cn)=Ab uT d6Pĺ离?5g9& ͐i!}\YYiGh7Mt'Һ6Mt[ MB]$v΍Y1G[Jζ6WlWk|S澼x6kC㹶&mG!&צx+DxۼGE;ܑvVL'E;0̉掚I{HlcnU @S6)@e(ړiܧK!;<9m1==\O`=E;|wnVM343ܛf܁ᨆ5 :/Axҿ bW5DOJE?mTS {mWm SP'F)dDZ9y4i0lE^<6׾Wrю2l:'A/hCfZja0ЕŖvSh{Z|sGqLӕlWm SP's蚳_Vja4i0lF_nmX~7Q.ڱbh4!FiEZ5k{b8ԍE;JN }KE{ۋv'_4h T=Q7y)^ja\ji`T訵x?xr ]jqHC^c]Y|iso\P7̦^omm-haa7nTQ1YZ64mղQ')@W/-Allh^9E 5okiS-F[½ k+KXmXc*{S1/ftN2E E{r?.8v`_&go9owŭs>}_l#Qrb;/ʁ/6-*$ v~3! M*64  {~'R(ΙpbߌKѳvE;3+~D>c(mYWըmU4,=^طNJqQk;?2[h T=!}j:y*M9{8Ri]ɵM'-1|g+ EMJk_'*nvz=n+jJИJ 0Е vPʠmĘ>oXپ;!]_/.޻p}om;G56Ѩ͗܍ҜwJy:FU7LhN(@hhOk}-0.4iuGKww%tYL~;P[kAUR]^ZņfZJ{ٻO}Yni-:/.hZTܽU~ōv]_נ,6DoT|#t ŗ @'m SP?_[jap4im?+߱_I[kiEўИF;۴m{YP m[nq% t}4~㋅xjn8'Ü͋e kn2x œ뢝W:]>S؟WMN*oZkL[|2gAo(5 Q/G# Em2{Rˎ羕& = ٩w,Vj=tnK,[tyAnU|fr^uvLX'oehpE;(6AӬi6n7zt-F]Zy%F>|U[)(Ax, 2PL*Cc~RȎcirىf w=q7:|ˑ`v mTZ[ҍ746S:sߋvP AA]<'W:rr >㽎JF_۷(!-jPKCcW\C-{82PL*CW#ni=;3'gSQlyvLfBhמG WeIk8/,,fӢ3$hu`ڢ+=i;2PL*C?'xpsQjq\I&gS]9fQZދv1)vnaHni+E;9 '.hg67WѮv\7tբOxi.V{޸uwd:h T=~V_RȎco.79J~_hFBmZ_I:χLдuR;7^*mpE;('v+KxϵU{%tmz:/kkkqW)Aӯ09R 6;yzd:h T=f~+ǎ|`|MB*ՕtV[c0פGt M_"]_AC]y h׭///Xq6'pj-Q6XYWe82qN=Waiљ_8/EO MW7~|:?2PL*C'GvّGԲ7@> RΦrbxmsz)ڱ?לQl[tن=4(5VӺ3ЕŐv\o3}}VGdۜ*(Qcm܍N*sSkK ZM!;f Wjjc4/tB2E E{l[~_xMOJf rywiK1yn(nqҢWVƒ*쁮/\b0z)ڥvqTj2V'L6hSpgff&,o=$\n :ӅN(@hh?wm/m9tBf2PL*C Ǯ}>+9rT4jE;O7{74}z8&zfIZͧpZwRb o70M-A)V' ܶxTKywӯVJW.>vQU#_|>2PL*C{>gǎ>&؈pg4j4iE;vq3߻qEڙo133ӦҪ2PL*CѮk#zIeq/Ҥ'1ڶ*M5/g.eKq*+Vpt+Vz/AwAW绐~[ $ 7 t(..̨^lZoUaUM<7òWeiBø<(n: M򴠘7noXTڍ6J7tB2E EnRǝN_99qr%^bˊ܌)-]1^ް7;_jpa<3aiQ؇]8v-pO/ šޖ{nXgv~(U:t⦩= Υtˮ6gӦ397pԹ)]p?MwṭWe$΍0q Ń椥kT {92RL*CѮ_+0uUj5M91#_ضfffbKj7^>uyQB'A-rËu!l7¦[u6uX $o|f.w&fhh T]9Բ UiRLn"svnmh T]-ԏ]췖ZvG:WwI}"g0VNV>ufffjjʧ5h T]!;^Rˎc& Ob]DzGT d6Pv ~ r5)[ܐ. `)@hhWš/li~& beڝlZm SP+w~eq I g@L}ZnP6)@e(ڣ.巔ZvG:I g@+kkkmr T d6P{ `eDZ|l46)@e(#n'Br6L Em2QvK+=x4gr6L&Em2u+K-;+ۏޜ&Lh T=}|seqQ/=Ҥ0m SPGçvޏ}%MꙜ N2E E{ϕBviFl@2E E{\Bv{<&FEm2r%z+J-;+;-Mꍜ D6)@e(ڣo,0<}s9m SPGĩvμԲ]&Fm SPGw}X}awߴh;v {Odjj*,\ZZJ6l t3"g`ܙWigN8OҢSv3h T= |[Ǟ'ҤP/..`?$Fl{{b؟---;ަw7P033nt2Rg`΄%Q0F LKGC'edF d6Pᮣ奖ړ]I=^$433S|r|mlnBXy|dE{zz:FVKW^[IP[YY)0pAnLuA'y+:a3aazT=Ls?NtTx]FLf)@hhon򧿡Բøs4r6X?[̰<\izbvOkee%nBRUi*DVF yv"6cjT߫rǓ2g2C2E E{=iRˎcߧr6`Uay|󊙙+wƞOZ݆MߞU!muK@W^u#rFŝQ`{xh Tvb)dDZO=$+SϵammZ(ZMt'Һ6_8>i^ۿ"4t@W^ fK/P`{x&0Em2wir64~gyZ=;;f=]=\i]LKIl~MS@W^fŝѧzx&0Em2mQ[ǜWjaxʯo3Mꖜ Ml|c>UqZRgc ݉zoiELKL>q`2n]y%XT}w'nHQL*C{nkS_Wja\s~CiRlh%oߒMmt~=r{H+fZz[^m*Zp@W^wFI7;8Rm SP䉇w=_O%gC9Um$*whmbv Iоw"hCCT| u/[ q]y%T ,*>;ǓN TQh T=d;>] qiFlh/<1ͯmŕy=1t~;b\ޝ MWUBx٪*qw>!suM Em2a|륐Ǯ䉇Ӥٴr;||wMJdKnT\[6Q|Bol(nbii)]>u=ʹ E~;ٰ|¸KAx[jVYmX30ކ*,i΄-,L7)~{x6۠q[ALWGhKdzx{?ұ 9߯VraߴhA)~WG9>Qإp۰<<.ay uM ™܉/) K?˧#3h6)@e(C엕Zv{n+MꊜM+c-r:~¿{M³/8fĸip ibM }v><3 Mw< q!(޻<Ż_|fgg'CQn~oڟQŝ JKqCQ,b~,--\Ri64(@nG٨_grcx^㜢>aڍ$: Qڟpmoa>:t}&wbw0kFݝHE~0ZΏ(@hhG;Ѝfff*N4IXJMSڐpsv ɻ|K ×OWܙVܗ 1-5ȵi*%6TzM#l8x^T䰫^ 6H t~nGiц$X\yNޙQ gEAӭ&03YQKoY‰_Map; [QL*Cw[/ҤٴqW]:~+OԳ><5M3Zv1gq|Jw&WX|3[VB@ؙtE? t\Q8|J!#(i!(damf |&ܵpw>eCyZӭăШtjoxk(e^xORzFQ.vk,NsdɏcӛǕΟoh53ůD G,~5]C&AUGfpm SP`͟,u8vf!iqoQ'4>Y O8[eSBvXs O۬jKv>.>O˷$~CJJ[!7;VciƆCYm<I:)Gŝ܆[i@Ӡ15#mz<;i G9I{ՑOtL?3~܉/Hmzػ d6Pr)űWҤjo=ߥ;߁#tu <ϖ}dP܁ѝ'Z݋6t T@|+P8nia ҃[|`14C;cU׶cOqͫ3ܯ  WZ 'ڰŴA5=ͮGgz?/L#(v{ӯӗ⸼az&03ay՗R'R>zm~mG ((@hhԵ>xM[INΦC'oiI6ޣߨɟ݁l6< u[բNlI|ߪMz.^ƎP<>At*vƻsI)xC930-mΨxLn}׆r~ ҢA~o6+z|MŃV6hs&H=nD4p4]y7z9;1;R'RO_]QL*Cj?Y{*0hur6(> OGÿs2k$3ZOB؟6{$Eᾤ+"xCc+*0hL`;T,w?(j<۴1C;s_)m/f _ KuU϶:m7浙]kFh?;<zWG>9]. L}KoT\C-{82h T= ?y,8|[iУX" 'Q׬u:)&lI|>} t(xCc+M_%]y%{G gTS6ZY,NlqC}ㆊWAzm.Oяar&wx6ڣ\VS<ȥWcw~t7&8mpgr6;Jɦ_J=HţmEGfpm SPdX q?J3NΆ͝߄FMw(&](XJQ)~;y,pm\B14 19;yQ~jxgk+s7}_j+[VE;LX4Gۭσ(^;s}grS%^ć/OM#386)@e(ڃp?9? RΆ'ɭqYttZ)b҅bu\xn߱t MC@zt(6V$drGs)$Ƣ]JOp۴J 5+ZnvG?j˙\<mdNxQ׋i(,o9ϓJDDXIDAT̺R 3]H=QL*C}sG74˞o7M"9zchggAxΙ8E1٪7M+*>d冦d̷pis0Еwxg3b皛+=&At8g`q+aJ X h moG?j˙G?a[i陊y_rSE4a/ޅ RD*awim d6PvymW<5ơǾ↽OHΆy͞v(&[;oUbcK7%tR|:7Еwb8g^pΫ vᜁyoxgϊJ  9mP<ݝ~ RΆ> O s4@ʍO&;vL_T<pfܙy&p+otpӤ3ϓpϟtv=lUP>qCA87q6gNzC(O^I~v39l FQ.6~u9y·xuM鴮 K)ЕW2h TݻA+o}r6 B60VO4iE;ˋkя:My:NN}G#^Qf&03C A_J}9^8U¾7΢xJgHGfpm SP{NԲ8iCΆ O c ODKρ8!hT3,3$9$;*_íbG9yyZy+McS{K88i|pᘄo7n d+o%ƇtM8,?,7 aiF6(ǣeCa:Vd6۠(jL~nQqO~-Σ<"_aacx҉oM`pgrwKRˉ J7 d6PvVgJ!;fl X^x27gڦ]pÍg(24(lXCt]3_(CW[*gȇ}H36톅qfb+ox! KA _#iSRN #qB030ܵp .$.osJsuӝ zPXmӹƌJc|Lngǎ>&uLΆY^^n|BF gff3OnԦ7/jrFiR <E|bS\n16E:K?Ч g j#J,*X/ĨXa!atu3ai=J3ㆲVH+aiQ3M7nҴa7֚aGdz^MhMw;WG;yG LĀ`˗RTP_*z92h Tݵ/{Q/)0.X19*$n"gT|CdDj3J0?<M'LEd2}D*QL*C~vɯ̕ZvG:пޑ&uL E{47>/H;DE;ʙQ/Hm SPj}}}-8v_4cr6@(ڣ)>.[zsp_9fx&{ 'R#Em2/Bv;^~ P- D|D333SSSvUL(Nm SPWw=Rg> RE{->Z-<@iikz=~۶|ۈܙQ/HM)@hhwC7|Zvaa*Mꌜ PEsssfh!]].,,9iDܙQ/HM)@hhwKo-0uN:#gTL}㨐XG3^[3٣L_8)@hhwb}}}+?\jqӤU|`jjJ2+++J\VKT==D2E E/B)dDZꏦ*g'2;;χ cs&{ 'Rh TCzGO,Mꀜ Em2n>PqZvۯq956)@e(mإRȣ^r͟_&u@F d6Pv+|y,8|t JF d6Pv+;X]H3: g#K2E E_Z)8NIQh TWZvW<5w|4i3r60m SPK}|seqQ/=ҤSL*C.ZԎ|ԲIJPL*C.۟+8V_4c3r6P6)@e(_N)dDZ8iR[r6P!6)@e( {(0xk4-9z8==E kkkj\xVVV"Em2o,0<}sԖ #kee%~zV1tKKKioKZ-=NيoDF2E ES;g_jq\ӤlCsss aaW+f(lzHN Rѕb(@hh{X}mP!kkk;^K{jjjfVK6Jz=QKäh TƄV)dDZy|459* [6J: 7)Ʌtff&-:-@k.ſ4ΦP6)@eLrᮣ奖Ɓ'OҤlg-yRN/ОK {H)|Z աh Tn򧿡Բøs459*â]zC`=_V @)@h1ES^RˎcߧӤlv0??m1--,,E6ESL*c2\,8V459*$tjiKC @)@h1E{E)dDZ>49M6 W-)աhPu6)@eLZѮ?W_J-;O wI-0~ DѮ"ESL*c=7ݵ+09e?Ρ49*zf{=ѷIw΋v1V˛~f.,,mk݆7"P:cx׋7^ykb_:kkk9 7 W iVZ npV7,..ͥb0 MO+n+ǀ\]c[Ω‘/yQ88wcչ>VPQߏ@h Ts.849惥3v;t[hjⴠ-6ZYY  L(&v 3K14ܩxg0-Jm57]nv,޼Q~,V;VpUnűڒ~텅q+`>"]c;@%(@h1!EOz cɯFe[ 7afӰ'جkhm{P6կTӠ8'c;@%(@h1 E9t/+0?utWԌMHҝo-ҨXkb[: } daӮz*)3qCaInC{˶]HWl$љ$5MX龴ZǪŻЗ]SN!*A2E/<_/0~y>GNf wO-|kP,ߊ[zd06}w'E LZL*m黐lc;5µZ-NJU/ʦkK.8ic;Ѓ@%(@h1E'vW*8_IٌZ'?o-T1:).;;Rm1*TZZ#c*eN^Z]nwñ4ޗ<({4m SOBv;~]ǑaRf ˍ Сt˂NRfhV׹Wh:6lEͱ\%cG21E{ߧK!;S'OI lovEkoQ~pueӔٗ uX{Vo\܁0--XMUh9iL21EosK-;˟n'Mj gkU[k[| -ʦ)/hkaZZڱNThP 6,w~RϿI lmv@62b dӔٗ WҦh_r:QŢ=@%(@h1~E'<ǁ}+Mj gÄh_zqB7*9RzCŕtXVq =V6J_U'^zpEm2ƯhK!;l@ΆѾhw6ͩ˅*in2Kqcu %zP6KѮV`E{hJPL*c̊oK!;3oir6LMvflh>55,,,l2v걺 :فVlLph T8}sG74˞o7M: ͥIv*۰i ;fiˆ:,ڽoZځ6jKr:KU hP 6)@eMѾۮxkJ-;C}ōK$gh4o7(f`{/..67azV5ImXkJN_M5-#.6 P 6)@eG>{Rˎ/|'M: X[hvAJ36v̠V/}C{u-@xZEpG„Z.oXu;SSSrAz~lA*A2E(ګRȎco.8 I7XXXHS7,~Mw1G+++ay7p(F6m  o{V'4jAXV± ˛neSwx6}hutl~pEm2ƠhWJ!;/M> RΆULe*F25}n˙鴴^Uc@$Z,Mr;n[zvTi# F5\|Za۠@U(@hQ}kyKK-;}|;&0VVVJy:cjZZNOO/..6fbClآb-> -//KDm+ 9kaNeM_nU >V 'FUPmǶ@(@hQ}/קIr6L/fKҌKbQ[woaZi[Цk-mk 9mg@(5lfffWoXTeo=Jkv2]Ll:}<8T d6P-|J-;_jz=9w7^چanKmQL2Em2[WgJ!;]4@(QL*E{GqӤlF6)@eTh_}ޣgSja\o9v449)Em2*WoRǟ'(@hQ}]+sѳ9iir6@6)@eThZv/Bt О d6P*ڻ?RȎc+?\4H9`S6)@eThyɳzҤ r6@'m SʨDѾ>J-;C7Il)@h1EKuAeqsuwA蜢 d6P#^wå)M gl d6P#^w_RȎcM36[h T(}A~&]QL*cdjW=R^u5?Nln)@h1E.巔ZvG#$96)@e`~ RˎcG;)gB2E,ڻRȎcuv!͐zh Tƨ_Z)8Nsl)@h1REWZvW<5w|8G Em2FhRȣ^zk9r6@(@h1"E{S;^RˎcǾ}h Tƈ흿RȎc'h T(+*8<'x0LN2Em/7ǾԲø≯9`m Sޢ}m^7ZvG}Á0AEm2h:yjK-;K?qq g d6PXwX}klRL*c}w>t 0h6)@elKᮣ奖Ɓ'!g d6P/Ro(09k}PEm2\O6)@e h;9eƿo__Bvr6p(@h1]OR/,8lQL*c@E'vwZvy~ 0L6)@e hs^oBvr6)@h1S˥#9S/8lSL*Ex5gۘ -m SoѾ'6ٟF d6P},?yl!;9`)@hǢ?B2E~K>U9Bm SK7y)g8Em2z/w^wO| P-6)@eXO{ps.gT d6P= PE6)@eR~+Ŝ}Uh TFE.;/T9d!g Em2+ڷ_| P]6)@etQh TFE{uvA:Em2Z޿ƀ d6P NE.JK[G:Gf4?TB593TN)T]xE/ OR`")@5x便-~͏>Ur6#;}[JKt6oxHԦ N <@)¯i)TSxoִH6P _e6Df(ڌt*oP:Em:,Df)ڌEqh3fҩAѦm SjhlF8Q'6c&mN2EN)g3mƉ8Q3TޠhSu6)@5lZoGkr6h3NmƉ͘IESL}~~g] gS6Df(ڌt*oP:EmM(ڌEqh3fҩAѦm SjhSw_9jQ'6Df̤SyM)@hЪhG:GΦZmƉ8Q3TޠhSu6)@54-7]l*Gf(ڌE1N 6Uh TCc>vK-r6Uh3NmƉ͘IESLT4ȗME)ڌEqh3fҩAѦm Sj(]Mu)ڌEqh3fҩAѦm Sj񗃩tqU%Ţ ?(gSi6Df(ڌt*oP:EmtwZ.LMM8s}\UbѾ4Eqh3NmL:7(T d6Lؠ9.I;U5U,] qT8Q'6c&mN2E&W^ 47tX.ojeӢ-gS!6Df(ڌt*oP:Em\wYXXWTWJ-gS-6Df(ڌt*oP:Em\UrA|ÏvZ׾{_O{9g'?Gf(ڌE1N 6Uh *ٴVk;y >\翺[a' o}i/R7Mlp+ N oy[PMT~HK (0ϧEgo$RUOOh0m@ц 577hf D>}0~W5=K& jvv66*COOO iQ }\U_{og>%Jц +RZtM'd}\U^~s>ow}uɓiT rE;ϽFц 533Ӿ27^YYIZ E&Ԧ zdxm'C jaa!V^kﴴ> PaB-//<77kgffҢ*hCц U[7 9Rz#> Parw i|36W5U@+6LZ_[[E&Z|KtyRX-DbsҢӶ**E&w :_,rmiUU6W+++S7:kUV)T @5(T @5(T @5(T @5(T @5(j?ajjjqq1]u}\t_'Z^O0;;a7ՙZߨz=jnn.9|NW | jWVVu0D-¤Qm~3Z<mctLq+^|7p8Ӣfggrߢpކ-uAE{ѧhC~Ϙ ^4!}\t'a;Ͽ/--ŕD~A7հ|J7nn)H%߮ax>5sssrAaC2 ^wwE{п#K*4> mī,> ӯ0*Z\>>7հp2M+``~J"g3|}<㻋4"Ư S<+e60TOrA|UHa㪠;: ÜVz?1Co,jq8|oV.U5 gw~*D'V0^qUН>^x65o6IE)_8{ii#OexB6=& Oxhr6hU> 30m <77I* MOV SSS~`{>ՙ>`Eo/SM ¯iQ }\tg8'a|zi 簶p|* MO鼶״[tXOnV233 /]6&EkJӧ?oyy9-j $9[esm}mt+sss 5oWx ?|tcB'Ji YWIVdz6yffǘp۸݄A)|}Zp|<.0oA8㭂aē=/ m`x;__vC8 SM!nRzp۸g5S:W5\N olx)(lR[O *ΠO sss2 R絍o|ʰфA)ߜ@:l1-~įO5a~}#?^E{_@U(l`㪠;> A9jzmt.ڭVIJ~a=arqmyA=ƁQhóH s> 3Г0s`px>l ݄)Wt=d^Ȁ|[Ç_3V0ų/ Zm`xg+5{#K=u}\tgp'bx$YfgiܴEaiUG B<(ڞ$Sm[Eߡ*΀N¥ZY!7U:Mi1 r M-両.p~{F U_> 0V9;u0xh4jQj鍿FOOO7]JWIc_ӷa gA 0o6S:|g8s.iQA܊7fx>ǿдh;pʵ9'& [o9bkkkהƧ[]]x|{zpln> 3? a2:UayVt~<}kyAA|7;; GXߞkJU ~>5lYs l%-|µq|A + kKa(Y606m`{W/~. j3ϴSyyy9*+OP|j1aU7Wm5{ƃ @5(T @5(T @5(T @5(T @5([H :9(h @69(h @69(h @69(h @69(h @69(h @69(h @69(h @69(h @69(h @69(h @69(h @6?ygwV:.F(bؽWyx E_r kh&6v{\mt2;~|ft RaݾuҶm4]#v8ϱsr/q\p].vەzߗqx3?ŧemf|||ԁ2c\.a0c7~*~[# '5C!wQmh0|>hm͉W#Enlo6m m-q "rpvT664~_W+irxŧө^ gEShm;!nJ/Zq%6vKb|=cĕwވ>5w//0>s/atP>*)#/h0/oZs|vZwo}m1fݸ7GյwXojp]px^’Ł QOt[4EyvZ4 \WLnW ci0-7ɺVw}o~}x)<;Ź:KX{xS=G%f?3?%Ome/aPBn꒻lz0:putاhRt^zV-)jENW{ wh0p:ת~Tڶ6(lKٗ.__h^kr/ab2~ Q5fOc!G{A=G<( {?HXh{E;̎{ Kngy1qq&D`O*|>ֹhIWB~x ݦGL\|EўΪ==qFf=(aEDelѮ_~`~}E^C=E{b8S#v1Xӣvo]e(M++Ghy/os%|E?:ly?C`ޗnIOI\.{j}ֆ}3<<{~(!οX~Oh0gx<֫$]~E^3-_XL=_O~g싊v}a0j6~C˥Π^]чBdJf-I+ڟv(ڡ',;! Ep8,ztM)߾+8|r^\>?R|'$WSEKfkjw[+\_ p8jt[{/vR>}%m.ڳyx' tƅhɼ[f[v1(ڱm81yAv]7uol7yT+&^v/=E YmXhkNNHQ`E^t<@F6hSmx!EQ)ׯl|'$ )M~|NS;_OumBx E))Pm}y)3g }+h 뼿Yh?[f9N +ͷ7e;N;]v˥R`hhۛx*B*ph"X@1" :_6]"W@A" p5\BOQB apple-converted-spaceXOaX  Char Char,CJKHOJPJQJ_HaJmH nHsH tHVOqV fontstyle01(56B*CJOJQJ\]aJo(ph:O: authors-list-itemN@N u w'a$$G$&dP 9r CJaJ\^@\ nf(Qz)a$$1$d[$d\$CJOJPJQJ^JaJKHbh[\klxmnopqrstuvwxyz{|}~ 4 5 M2 $$$A'B'd'***6-q06n:1<-BEEEtGuGGGGGiHjHvH>IIJKKeLHMMNQRUXPZb\U]^;` ggjklhmnnop qqhr%s#ttumv.w/w0w1w2w3w4w5w6w7w8wGwIwwwwwwwwwwwwwwwwwwww,x-x.x/x0x1x2x3x4x5x6x7x8x9x:x;xx?xAxxxxxxxxxxxxxxxyy!y(y/y0yy?y@yDyOyZyeyfyjyuyyyyyyyyyyyyyyyyz z z#z.z8zCzDzLzUz^zgzhz}z~zzzzzzzzzzzzzz{{{&{'{2{3{4{5{6{;{D{N{W{X{]{h{s{~{{{{{{{{{{{{{{{{{{{{{{ |||$|%|A|L|V|a|b|||||||||||||||||||||} }}!},}-}7}@}F}O}P}Z}[}\}]}^}g}r}}}}}}}}}}}}}}}}}}}}}}~~~~$~/~:~;~C~L~R~[~\~d~e~f~g~h~s~~~~~~~~~~~~~~~~~~~~~~~)45BCDEFIT]himyHIJKLMNOPQRSTUVWXYZ[ (*+,0456BCDEFJT^deit~Áāف#-678MNOPQr}ɂӂ݂ނ߂()*/9CDEJT]^_efghiǃȃɃ ()*5@JQR\]^_`kuÄ̈́؄لڄ "$%&'+1=CDSTUVWlnopqȆΆφ׆݆ *,-./MS_efntÇɇՇۇ܇$%&'(-/0127>JQRefghiӈو)+,-.9?KQR\bntuÉωՉ։%1786q{~͋΋ϋЋы17CJKSYelmɌόی!'39:?EQWX]couv{ōǍȍɍʍэ؍*12]^_`adh0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000 0 0 0 0 0 0 0 0 0  0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0 0 0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0 0 0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0 0 0 0 0 0  0 0 0 0  0 0 0 0 0 0 0 0 0  0 0 0 0  0 0 0 0 00000000000000000000 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00000 0 0 0 0 0 0 0 0 0  0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0 000 0 0 0 0 0 0 0 0 0  0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00000  Oo &$%X(o)@*1,- .B/G12I4689;j=s>@>DqEF-JMNOPS.UX[#^bceUghiPkqtuwxx{}ȀŃNȍ{  IILOPRTUVWXY[\]^_`abcdefhijklmnopqrstuvwxz{|}~3k ,uOb~q 0JpކJ]ψ>e7^lƊ"Mn~ԋ)LsΌߌ),]ѐ'ZxÑޑ0bÒAQsNn 8hȖ /9Wu˗R  * L o      0 9 : `   T    HAHbHqH{HHHHHI)ILIoIIIMQSZgy      !"#%&'()*+,-./012IN%LILbLN=ODOGOOOO+P2PPQQR-S2S5SSSST TTUUUVVVVVVVWWWXXXXXYYYIJJcKKLL,MHMNN>O u eVnMXV['%Cz%; &[()uu1-i4D7,A9+i;i @MlMrMWSVS[[|[l_jg o rN9t-7v:Kb,iE TIx7):7 =ZH5<kFS'LVq<hivO]qCi>xoxyy!y(y/y0yy?y@yDyOyZyeyfyjyuyyyyyyyyyyyyyyyyz z z#z.z8zCzDzLzUz^zgzhz}z~zzzzzzzzzzzzzz{{{&{'{2{3{4{5{6{;{D{N{W{X{]{h{s{~{{{{{{{{{{{{{{{{{{{{{{ |||$|%|A|L|V|a|b|||||||||||||||||||||} }}!},}-}7}@}F}O}P}Z}[}\}]}^}g}r}}}}}}}}}}}}}}}}}}}}}}~~~~$~/~:~;~C~L~R~[~\~d~e~f~g~h~s~~~~~~~~~~~~~~~~~~~~~~~)45BCDEFIT]himy[ (*+,0456BCDEFJT^deit~Áāف#-678MNOPQr}ɂӂ݂ނ߂()*/9CDEJT]^_efghiǃȃɃ ()*5@JQR\]^_`kuÄ̈́؄لڄ "$%&'+1=CDSTUVWlnopqȆΆφ׆݆ *,-./MS_efntÇɇՇۇ܇$%&'(-/0127>JQRefghiӈو)+,-.9?KQR\bntuÉωՉ։%1786q{~͋΋ϋЋы17CJKSYelmɌόی!'39:?EQWX]couv{ōǍȍɍʍэ؍*12dI/&I/&I/&I/&__Grammarly_42____iM__Grammarly_42___1p4H4sIAAAAAAAEAKtWckksSQxILCpxzi/NK1GyMqwFAAEhoTITAAAATH4sIAAAAAAAEAKtWcslP9kxRslIyNDYytjQ3MDA2NjW1NDM2NDRV0lEKTi0uzszPAykwrgUAVq16kywAAAA=@xxp'xxLMN5u5vfyfzfffffb@@@T@V@@@@@@@@@@ @@@,@@@@ @@Unknowny^N TN~oNybN gPlQS G:Ax Times New Roman5Symbol3& :Cx Arial;([SOSimSun7&@Calibri_ Times-RomanTimes New RomanY Times-ItalicSegoe Print[AdvOT863180fbSegoe PrintO|8I{~Arial Unicode MS  QhbCG4@"yH@"yHqZ&!),.:;?]}    & 6"0000 0 0 00000 =@\]^([{  0 0 00000;[R4 JqX)?jg2Validation of the 8th edition AJCC pathological prognostic staging system for breast cancer patients with ipsilateral supraclavicular lymph node metastasisy^N TN~oNybN gPlQSy^N TN~oNybN gPlQSOh+'08<Ht     (0Validation of the 8th edition AJCC pathological prognostic staging system for breast cancer patients with ipsilateral supraclavicular lymph node metastasis$ͬƼɷ޹˾Normal$ͬƼɷ޹˾16Microsoft Office Word@8C@̻=G@y@"y՜.+,D՜.+, X`lt| H !([cw! _PID_HLINKSKSOProductBuildVerA ! T*https://pubmed.ncbi.nlm.nih.gov/12833449/c:;Qhttps://www.ncbi.nlm.nih.gov/pubmed/?term=Locally+advanced/inflflammatory+breast+cancers+treated+with+intensive+epirubicin-based+neoadjuvant+chemotherapy:+are+there+molecular+markers+in+the+primary+tumour+that+predict+for+5-year+clinical+outcome?cxNkhttps://www.ncbi.nlm.nih.gov/pubmed/?term=Diebold-Berger%20S%5bAuthor%5d&cauthor=true&cauthor_uid=12598346c;Kehttps://www.ncbi.nlm.nih.gov/pubmed/?term=Bonnefoi%20H%5bAuthor%5d&cauthor=true&cauthor_uid=12598346c+?Hhttps://www.ncbi.nlm.nih.gov/pubmed/?term=%EF%BC%AC%EF%BD%8F%EF%BD%8E%EF%BD%87%E2%81%83%EF%BD%94%EF%BD%85%EF%BD%92%EF%BD%8D+%EF%BD%90%EF%BD%81%EF%BD%94%EF%BD%94%EF%BD%85%EF%BD%92%EF%BD%8E+%EF%BD%8F%EF%BD%86+%EF%BD%84%EF%BD%89%EF%BD%93%EF%BD%85%EF%BD%81%EF%BD%93%EF%BD%85+%EF%BD%92%EF%BD%85%EF%BD%83%EF%BD%95%EF%BD%92%EF%BD%92%EF%BD%85%EF%BD%8E%EF%BD%83%EF%BD%85+%EF%BD%81%EF%BD%8D%EF%BD%8F%EF%BD%8E%EF%BD%87+%EF%BD%90%EF%BD%81%EF%BD%94%EF%BD%89%EF%BD%85%EF%BD%8E%EF%BD%94%EF%BD%93+%EF%BD%97%EF%BD%89%EF%BD%94%EF%BDc'OEfhttps://www.ncbi.nlm.nih.gov/pubmed/?term=Johansson%20H%5bAuthor%5d&cauthor=true&cauthor_uid=18043896c)Bghttps://www.ncbi.nlm.nih.gov/pubmed/?term=Khoshnoud%20MR%5bAuthor%5d&cauthor=true&cauthor_uid=18043896cQG?https://www.ncbi.nlm.nih.gov/pubmed/?term=ER%E2%80%93/PR++subset+of+invasive+breast+carcinoma+(IBC):+a+distinct+phenotype+with+good+prognosisc0X<bhttps://www.ncbi.nlm.nih.gov/pubmed/?term=Bauer%20O%5bAuthor%5d&cauthor=true&cauthor_uid=30509058c,9ehttps://www.ncbi.nlm.nih.gov/pubmed/?term=Stolnicu%20S%5bAuthor%5d&cauthor=true&cauthor_uid=30509058cLm6ahttps://www.ncbi.nlm.nih.gov/pubmed/?term=Ryu%20JM%5bAuthor%5d&cauthor=true&cauthor_uid=29963113cu3bhttps://www.ncbi.nlm.nih.gov/pubmed/?term=Choi%20HJ%5bAuthor%5d&cauthor=true&cauthor_uid=29963113c[60`https://www.ncbi.nlm.nih.gov/pubmed/?term=Kim%20I%5bAuthor%5d&cauthor=true&cauthor_uid=29963113cor-Ghttps://pubmed.ncbi.nlm.nih.gov/?term=%22Cancer+Manag+Res%22%5Bjour%5Dc^3*`https://www.ncbi.nlm.nih.gov/pubmed/?term=Shi%20Y%5bAuthor%5d&cauthor=true&cauthor_uid=30863154c9'ahttps://www.ncbi.nlm.nih.gov/pubmed/?term=Shao%20N%5bAuthor%5d&cauthor=true&cauthor_uid=30863154c\$-https://www.ncbi.nlm.nih.gov/pubmed/30620221cQe!ahttps://www.ncbi.nlm.nih.gov/pubmed/?term=Liu%20GY%5bAuthor%5d&cauthor=true&cauthor_uid=30620221cw`https://www.ncbi.nlm.nih.gov/pubmed/?term=Yu%20TJ%5bAuthor%5d&cauthor=true&cauthor_uid=30620221cOeahttps://www.ncbi.nlm.nih.gov/pubmed/?term=Liu%20YY%5bAuthor%5d&cauthor=true&cauthor_uid=30620221cRhttps://www.ncbi.nlm.nih.gov/pubmed/?term=AJCC+8th+edition+prognostic+staging+provides+no+better+discriminatory+ability+in+prognosis+than+anatomical+staging+in+triple+negative+breast+cancerc|S_https://www.ncbi.nlm.nih.gov/pubmed/?term=Xu%20X%5bAuthor%5d&cauthor=true&cauthor_uid=31906874c;chttps://www.ncbi.nlm.nih.gov/pubmed/?term=Tsang%20JY%5bAuthor%5d&cauthor=true&cauthor_uid=31906874clQ_https://www.ncbi.nlm.nih.gov/pubmed/?term=He%20J%5bAuthor%5d&cauthor=true&cauthor_uid=31906874cbp https://www.ncbi.nlm.nih.gov/pubmed/?term=Evaluation+of+the+Prognostic+Stage+in+the+8th+Edition+of+the+American+Joint+Committee+on+Cancer+in+Patients+with+Breast+Cancer+and+Internal+Mammary+Lymph+Node+MetastasiscYr ahttps://www.ncbi.nlm.nih.gov/pubmed/?term=Son%20BH%5bAuthor%5d&cauthor=true&cauthor_uid=30194189cSoahttps://www.ncbi.nlm.nih.gov/pubmed/?term=Kim%20SS%5bAuthor%5d&cauthor=true&cauthor_uid=30194189cIrahttps://www.ncbi.nlm.nih.gov/pubmed/?term=Joo%20JH%5bAuthor%5d&cauthor=true&cauthor_uid=30194189chttps://seer.cancer.gov/c2052-11.1.0.9740  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./012346789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./12345679:;<=>?@ABCDEFGHIRRoot Entry FhTData 5E1TableȯWordDocument6hSummaryInformation(0DocumentSummaryInformation88"CompObjm  FMicrosoft Office Word ĵ MSWordDocWord.Document.89q